Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Eukaryotic cell

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424930100 - WHOLE LIVE MICRO-ORGANISM, CELL, OR VIRUS CONTAINING

424930200 - Genetically modified micro-organism, cell, or virus (e.g., transformed, fused, hybrid, etc.)

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20080317723LYMPHATIC ENDOTHELIAL CELLS MATERIALS AND METHODS - The present invention is directed to methods and compositions for isolating lymphatic endothelial cells from a mixed population of cells. More particularly, the inventors have found that certain antibodies that recognize the extracellular domain of VEGFR-3 can be used to specifically isolated lymphatic endothelial cells substantially free of other contaminating non-lymphatic endothelial cells. Methods and compositions for producing such cells and using such cells are described.12-25-2008
20090123439DIAGNOSTIC AND PROGNOSIS METHODS FOR CANCER STEM CELLS - The present invention provides methods for diagnosis and prognosis of cancer stem cells (CSC) using expression analysis of one or more groups of genes, and a combination of expression analysis from a biological sample from the subject. The methods of the invention provide a method for accuracy detecting cancer stem cells in a population of cancer cells. The invention also provides methods and kits for diagnosis and prognosis of cancer in a subject using cancer stem cell biomarker expression analysis.05-14-2009
20090123438Multivalent Vaccines Comprising Recombinant Viral Vectors - The invention relates to vaccines comprising recombinant vectors, such as recombinant adenoviruses. The vectors comprise heterologous nucleic acids encoding for at least two antigens from one or more tuberculosis-causing bacilli. The invention also relates to the use of specific protease recognition sites linking antigens through which the encoded antigens are separated upon cleavage. After cleavage, the antigens contribute to the immune response in a separate manner. The recombinant vectors may comprise a nucleic acid encoding the protease cleaving the linkers and separating the antigens. The invention furthermore relates to the use of genetic adjuvants encoded by the recombinant vectors, wherein such genetic adjuvants may also be cleaved through the presence of the cleavable linkers and the specific protease.05-14-2009
20090263364Method and constructs for delivering double stranded rna to pest organisms - The present invention relates in generally to RNAi and its use in gene silencing. In particular, the present invention relates to methods and constructs for delivering double stranded RNA (dsRNA) to pest organisms.10-22-2009
20090196860Isolated Primate Embryonic Cells and Methods of Generating and Using Same - An isolated primate embryonic cell is provided as well as cell cultures and cell lines derived therefrom. Also provided are methods of generating and using such cells.08-06-2009
20100150887Tissue Progenitor Cells That Overexpress ERG - Methods for generating a population of mesodermal progenitor cells. In some aspects pluripotent cells such as stem cells are transformed with wild-type ERG expression cassette. Mesodermal progenitor cells of the invention may be used for the treatment of cardiac damage such as myocardial infarction.06-17-2010
20100150886Method of Producing Lymphocytes - A method for preparing lymphocytes characterized in that the method comprises the step of carrying out expansion in the presence of (a) fibronectin, a fragment thereof or a mixture thereof, (b) a CD3 ligand, and (c) a CD28 ligand.06-17-2010
20080299096MODIFIED NUCLEOTIDE SEQUENCE ENCODING GLUCAGON-LIKE PEPTIDE-1 (GLP-1), NUCLEIC ACID CONSTRUCT COMPRISING SAME FOR PRODUCTION OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1), HUMAN CELLS COMPRISING SAID CONSTRUCT AND INSULIN-PRODUCING CONSTRUCTS, AND METHODS OF USE THEREOF - An isolated chimeric GLP-1 nucleic acid sequence encoding a human pro-insulin leader, a glucagon-like peptide-1 (GLP-1), and a furin cleavable site between the human pro-insulin leader sequence and the GLP-1 is provided. Also provided is an isolated modified chimeric GLP-1 nucleic acid sequence encoding a human pro-insulin leader, a glucagon-like peptide-1 (GLP-1), and a furin cleavable site between the human pro-insulin leader sequence and the GLP-1. Recombinant expression vectors comprising the chimeric GLP-1 nucleic acid sequences, which produce GLP-1 constitutively are provided, as are human cells transfected with such an expression vector in combination with an expression vector comprising a proinsulin nucleic acid sequence and an expression vector comprising a furin and a glucose-regulatable TGF-alpha promoter. Methods of producing human GLP-1 constitutively are provided as are method of producing GLP-1 and insulin or in a glucose-dependent manner using such transfected cells. Methods of treating a subject having Type II diabetes and methods of treating a subject prone to hyperglycemia or suffering from hyperglycemia are provided in which transfected cells produce human GLP-1 and insulin in a glucose-dependent manner. Also provided are methods of reducing weight in a subject by implanting into the subject transfected cells which produce human GLP-1 and insulin in a glucose-dependent manner.12-04-2008
20080260705Preventing Arrhythmias Associated with Cell Transplantation - Skeletal myoblasts are an attractive cell type for transplantation since they are autologous and resistant to ischemia. However, clinical trials of myoblasts transplantation in heart failure have been plagued by ventricular tachy-arrhythmias and sudden cardiac death. The pathogenesis of these arrhythmias is poorly understood, but may be related to the fact that skeletal muscle cells, unlike heart cells, are electrically isolated by the absence of gap junctions. An in vitro model of myoblasts transplantation into cardiomyocyte monolayers can be used to investigate the mechanisms of transplant-associated arrhythmias. Co-cultures of human skeletal myoblasts and rat cardiomyocytes result in reentrant arrhythmias (spiral waves) that reproduce the features of ventricular tachycardia seen in patients receiving myoblasts transplants. These arrhythmias can be terminated by nitrendipine, an L-type calcium channel Mocker, but not by the Na channel blocker lidocaine. Genetic modification of myoblasts to stably express the gap junction protein connexin 43 decreases arrhythmogenicity in co-cultures. It similarly can be used to increase the safety of myoblasts transplantation in patients.10-23-2008
20090191169Methods for gene transfer to mammals - To provide a transformed hair follicle and a method for transferring a gene to a mammal by means of the transformed hair follicle.07-30-2009
20090136465Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof - The present invention relates to methods and compositions for treating, ameliorating or preventing a disease or disorder in a subject by introducing into cells of the subject a therapeutic gene switch construct that controls expression of one or more therapeutic products.05-28-2009
20110189141MULTIPLE TARGET T CELL RECEPTOR - The present invention is directed to a functional T cell receptor (TCR) fusion protein (TFP) recognizing and binding to at least one MHC-presented epitope, and containing at least one amino acid sequence recognizing and binding an antigen. The present invention is further directed to an isolated nucleic acid molecule encoding the same, a T cell expressing said TFP, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen.08-04-2011
20090257990Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues - Polynucleotide expression constructs, populations of cells and methods of treating diseases caused by dysfunction in, or damage to, excitable tissues are provided.10-15-2009
20110195056COMPOSITIONS COMPRISING HEPATOCYTE-LIKE CELLS AND USES THEREOF - The invention generally features methods for generating hepatocytes from a variety of pluripotent stem cells, including adipose mesenchymal stem cells, therapeutic compositions featuring such cells, and methods of using them for the treatment of subjects.08-11-2011
20090191172Method of Controlling Administration of Cancer Antigen - The present invention is directed to mammalian bi-specific T cells and methods for using these bi-specific T cells. More specifically, the invention relates to a method of controlling administration of cancer antigen to a subject by providing bi-specific T cells that express a viral antigen T cell receptor and a cancer antigen-specific chimeric receptors and triggering their activation by also administering antigen-presenting T-cells which express viral antigen. These bi-specific T cell clones are a source of effector cells that persist in vivo in response to stimulation with viral antigen, leading to long-term function after their transfer to patients with cancer and autoimmune diseases.07-30-2009
20090191171Reprogramming of Differentiated Progenitor or Somatic Cells Using Homologous Recombination - The present invention provides methods and compositions for reprogramming somatic cells to a more primitive state, such as induced pluripotent stem cells, using homologous recombination. The induced pluripotent stem cells generated by the methods of the present invention are useful in a variety of therapeutic applications in the treatment and prevention of diseases and disorders.07-30-2009
20100158881ACTIVATED DUAL SPECIFICITY LYMPHOCYTES AND THEIR METHODS OF USE - The present invention relates to preventive, therapeutic, and diagnostic compositions and methods employing lymphocytes having T-cell receptors and chimeric receptors. In particular, the invention relates to pre-selected dual-specificity lymphocytes having endogenous T-cell receptors and chimeric T-cell receptors that recognize a strong antigen and tumor associated antigens where the pre-selected population of adoptively transferred lymphocytes is activated by in vivo immunization, thereby increasing the effectiveness of adoptive immunotherapy.06-24-2010
20090214495VASCULAR ENDOTHELIAL GROWTH FACTOR-D (VEGF)-D AND FUNCTIONALLY FRAGMENTS THEREOF FOR BONE REPAIRING - The invention refers to use of VEGF-D or fragments thereof for the preparation of a medicament for therapy and/or prevention of bone diseases, to compositions comprising the same, vectors for gene therapy, to cells expressing VEGF-D.08-27-2009
20120244132T-CELL RECEPTOR - The present invention provides a T-cell receptor (TCR) which binds to a peptide from latent membrane protein 2 (LMP-2) from the Epstein Barr Virus (EBV) having the amino acid sequence CLGGLLTMV (SEQ ID No. 1) when presented by a major histocampatability complex (MHC) molecule. The present invention also provides a nucleotide sequence encoding such a TCR, a vector comprising such a nucleotide sequence and its use to produce a EBV-specific T-cell. The present invention also provides the use of EBV-specific T-cell for cellular immunotherapy.09-27-2012
20120244131METHOD FOR MODULATING THE EFFICIENCY OF DOUBLE-STRAND BREAK-INDUCED MUTAGENESIS - A method for modulating double-strand break-induced mutagenesis at a genomic locus of interest in a cell, thereby giving new tools for genome engineering, including therapeutic applications and cell line engineering. A method for modulating double-strand break-induced mutagenesis, concerns the identification of effectors that modulate double-strand break-induced mutagenesis by use of interfering agents; these agents are capable of modulating double-strand break-induced mutagenesis through their respective direct or indirect actions on said effectors. Methods of using these effectors, interfering agents and derivatives, respectively, by introducing them into a cell in order to modulate and more particularly to increase double-strand break-induced mutagenesis. Specific derivatives of identified effectors and interfering agents, vectors encoding them, compositions and kits comprising such derivatives for modulating or increasing double-strand break-induced mutagenesis.09-27-2012
20090297486Survival, Differentiation and Structural Integration Of Human Neural Stem Cells Grafted Into the Adult Rat Spinal Cord - The present invention provides methods and compositions for treating spinal cord diseases and injuries. The methods involve transplanting neural stem cells which have been previously expanded in vitro into a patient such that the cells can ameliorate the disease or injury. The stem cells to be transplanted are derived from spinal cord tissue.12-03-2009
20130078224INDUCTION/MONITORING OF ARTERIOGENESIS USING SDF1 AND PDGFB OR INHIBITION OF PHD2 - The disclosure relates to the field of ischemia and how to increase tissue perfusion in ischemic tissue by cellular therapy. Specifically, the beneficial effects of myeloid (bone marrow-derived) cells with a particular arteriogenic gene expression profile are shown, and it is shown that increased arteriogenesis and perfusion is specifically due to the effects of combined PDGFB and SDF-1. The arteriogenic gene profile of the myeloid cells used for therapy can, for instance, be obtained by inhibition of PHD2.03-28-2013
20130078225Method for Modulating MicroRNA Content in Living Beings and the Use Thereof - The present invention relates to a method for modulating miRNA content in living beings and the use thereof, whereof the miRNAs are delivered initiatively and selectively by microparticles/MVs/exosomes to the circulatory system and target cells/tissues to perform various functions. The invention provides a novel combination of molecules that mediates the inter-cellular communication: the miRNAs secreted by cells through cellular MVs. Meanwhile, the present invention also provides a method for preparing cellular MVs entrapping certain miRNAs, and, according to the regulation and modification of gene expression in cells and tissues with the miRNA-entrapping cellular MVs, provides a novel method for modulating miRNA content in living beings, which is effective and adoptable to all cell types.03-28-2013
20120183512TCTEX-1 REGULATORY SEQUENCE AS STEM CELL MARKER - The disclosure relates to an isolated regulatory sequence for Tctex-1 that is transcriptionally active in adult neural progenitor and stem cells, including Type 1, Type 2 and Type 3 progenitors, as well as during development. The disclosure also relates to a method for selectively expressing a genetic sequence in neural progenitor cells. The disclosure of inserting and expressing a specific sequence in these cells allows marking, identification, sorting, tracking, and manipulating neural progenitor and stem cells.07-19-2012
20120183511INDUCTION OF NEURONAL DIFFERENTIATION IN NON-NEURONAL CELLS USING A NUCLEIC ACID MOLECULE - A method of transdifferentiating a non-neuronal mammalian cell into a neuronal cell including transfecting the non-neuronal non-terminally differentiated mammalian cell with a nucleic acid that promotes the transdifferentiation of the cell into a neuronal cell, wherein the nucleic acid is substantially homologous to BORG RNA.07-19-2012
20100034791Engineered Lung Tissue Construction for High Throughput Toxicity Screening and Drug Discovery - The present invention relates to compositions comprising fetal pulmonary cells and biocompatible materials. The present invention also provides an engineered three dimensional lung tissue exhibiting characteristics of a natural lung tissue. The engineered tissue is useful for the study of lung developmental biology and pathology as well as drug discovery.02-11-2010
20130034527MITOCHONDRIAL ENHANCEMENT OF CELLS - Certain embodiments disclosed herein include, but are not limited to, at least one of compositions, methods, devices, systems, kits, or products regarding rejuvenation or preservation of stem cells. Certain embodiments disclosed herein include, but are not limited to, methods of modifying stem cells, or methods of administering modified stem cells to at least one biological tissue.02-07-2013
20090257991Engineering and Delivery of Therapeutic Compositions of Freshly Isolated Cells - The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing.10-15-2009
20090087417METHODS FOR PROMOTING DOPAMINERGIC NEURONAL DEVELOPMENT BY USING NG4A-SUBFAMILY AND WNT-LIGANDS - Methods for promoting dopaminergic neuronal development and producing neural cells having a dopaminergic phenotype. Dopaminergic neural cells may be used for treating individuals having a neurodegenerative disease such as Parkinson's disease. Dopaminergic cells may be implanted into the brain of the individual, and/or dopaminergic neural development may be induced or enhanced in the brain of the individual. Methods comprise expressing a nuclear receptor of the NG4A subfamily, e.g. Nurr1, above basal levels within the cell and treating the cell with a Wnt ligand, thereby producing or enhancing proliferation, self-renewal, survival and/or dopaminergic induction, differentiation, survival or acquisition of a neuronal dopaminergic phenotype. The cell may be co-cultured with astrocytes or glial cells and may be contacted with an FGF growth factor.04-02-2009
20130039894Polypeptides and Use Thereof for Treatment of Traumatic or Degenerative Neuronal Injury - The present invention relates to polypeptides transiently activating Ras homolog gene family member A (RhoA) GTPase, polynucleotides encoding said polypeptides and pharmaceutical compositions comprising said polypeptides or said polynucleotides. The present invention further relates to the use of said polypeptides, said polynucleotides or said pharmaceutical compositions for long-term treatment of damage of the peripheral or central nervous system.02-14-2013
20130039895MIR-150 FOR THE TREATMENT OF BLOOD DISORDERS - The invention provides methods of treating certain blood related disorders, in particular, thrombocytopenia and anemia comprising increasing miR-150 expression or inhibiting miR-150 in progenitor cells respectively.02-14-2013
20090155233METHOD FOR TREATING TUMOR USING IRRADIATED TUMOR CELL EXPRESSING HUMAN HEPATITIS B SURFACE ANTIGEN AND A PHARMACEUTICAL COMPOSITION COMPRISING THE TUMOR CELL - The present invention relates to a method for treating a tumor in mammals comprising administering tumor cells in a therapeutically effective amount, in which the tumor cells lose their proliferative function by irradiation, are genetically manipulated to express hepatitis B surface antigen and are the same as the tumor to be treated, and a pharmaceutical composition for treatment of a tumor comprising the tumor cells.06-18-2009
20090155231Compositions and Methods for Treatment of Neoplastic Disease - The present invention comprises the use of sickle cells or sickle cell precursors loaded with a therapeutic agent that localizes in tumors and induces a tumoricidal response.06-18-2009
20090155229CHONDROCYTE-BASED IMPLANT FOR THE DELIVERY OF THERAPEUTIC AGENTS - The present invention relates in general to chondrocyte based explants and implants of genetically engineered chondrocytes and in particular, to the delivery of peptides, proteins and RNAi molecules to a mammalian subject using a genetically modified chondrocyte-based mass. In one embodiment the genetically modified chondrocyte-based mass is provided as a chondrocyte pellet.06-18-2009
20130045190DEGRADABLE MICROCAPSULES - The invention relates to microcapsules consisting of a polymer degradable by a polypeptide comprising a drug or other compound of interest and a genetically engineered cell expressing said polypeptide in response to a triggering compound, and to methods of directed release of the compound of interest. The preferred polymer is optionally modified cellulose sulfate/poly-diallyl-dimethyl-ammonium chloride. Such microcapsules are non-toxic, do not elicit an immunological response and have an extended half-life time in mammals. The expression system for cellulase is, for example, based on TET and doxycycline, or E.REX and erythromycin. In another example, expression of cellulase is triggered by luteinizing hormone, which can be used for artificial insemination with microcapsules carrying sperm.02-21-2013
20100143314In Vivo Production and Delivery of Erythropoietin or Insulinotropin for Gene Therapy - The present invention relates to transfected primary and secondary somatic cells of vertebrate origin, particularly mammalian origin, transfected with exogenous genetic material (DNA) which encodes erythropoietin or an insulinotropin [e.g., derivatives of glucagon-like peptide 1 (GLP-1)], methods by which primary and secondary cells are transfected to include exogenous genetic material encoding erythropoietin or an insulinotropin, methods of producing clonal cell strains or heterogenous cell strains which express erythropoietin or an insulinotropin, methods of gene therapy in which the transfected primary or secondary cells are used, and methods of producing antibodies using the transfected primary or secondary cells. The present invention also includes primary and secondary somatic cells, such as fibroblasts, keratinocytes, epithelial cells, endothelial cells, glial cells, neural cells, formed elements of the blood, muscle cells, other somatic cells, which can be cultured and somatic cell precursors, which have been transfected with exogenous DNA encoding EPO or an insulinotropin, which is stably integrated into their genomes or is expressed in the cells episomally.06-10-2010
20100034789Novel carbosilane dendrimers, preparation method thereof and use of same - Novel carbosilane dendrimers, their preparation and their uses. The dendrimers of the invention have secondary, tertiary and quaternary amino groups at their branch ends. Their possible uses include vehicles for carrying anionic-charged molecules in the blood, such as nucleic acids, among them ODN and RNAi, and other anionic drugs with which they have the capacity of interacting, protecting them from interaction with plasma protein and/or increasing their penetration rate in target cells. In the cases where the bond is long-lasting, the dendrimers of the invention can be used to fix anionic molecules to surfaces. Their uses also include their administration as active ingredients to prevent or treat diseases caused by micro-organisms with whose structure and/or life cycle they interfere.02-11-2010
20090087416B7-H3 AND B7-H4, NOVEL IMMUNOREGULATORY MOLECULES - The invention provides novel B7-H3 and B7-H4 polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides.04-02-2009
20100092437RADIATION INDUCIBLE PROMOTER - The present invention relates to a radiation inducible promoter, more particularly to a radiation inducible promoter including a base sequence represented by SEQ ID NO: 3 derived from 04-15-2010
20100330053MIXED-CELL GENE THERAPY - The subject invention is directed to a mixed cell composition to generate a therapeutic protein at a target site by providing a first population of mammalian cells transfected or transduced with a gene that is sought to be expressed, and a second population of mammalian cells that have not been transfected or transduced with the gene, wherein endogenously existing forms of the second population of mammalian cells are decreased at the target site, and wherein generation of the therapeutic protein by the first population of mammalian cells at the target site stimulates the second population cells to induce a therapeutic effect.12-30-2010
20100330051POLYPEPTIDE HAVING AN IMPROVED CYTOSINE DEAMINASE ACTIVITY - The present invention relates to a polypeptide possessing a CDase activity, characterized in that it is derived from a native CDase by addition of an amino acid sequence with the proviso that said polypeptide has no UPRtase or Thymidine Kinase activity.12-30-2010
20100330050USE OF HUMAN STEM CELLS AND/OR FACTORS THEY PRODUCE TO PROMOTE ADULT MAMMALIAN CARDIAC REPAIR THROUGH CARDIOMYOCYTE CELL DIVISION - The present invention relates to methods and compositions for stimulating the proliferation of cardiomyocytes for enhancement of cardiac repair. The invention is based on the discovery that upon contact with stem cells, or conditioned media derived from said stem cells, terminally differentiated cardiomyocytes can be stimulated to enter the cell cycle. Additionally, scaffolds capable of attracting stem cells to the area of implantation have been shown to induce cardiomyocyte proliferation. The present invention further relates to the discovery that the Wnt-5A ligand, which binds to the frizzled receptor (fz), functions to stimulate cardiomyocyte proliferation. The methods and compositions of the invention may be used in the treatment of cardiac disorders including, but not limited to, myocardial dysfunction or infarction. The invention further relates to screening assays designed to identify compounds that modulate the proliferative activity of cardiomyocytes and the use of such compounds in the treatment of cardiac disorders.12-30-2010
20130028876THYMIDINE KINASE - A polynucleotide comprising a nucleotide sequence encoding a thymidine kinase wherein at least one of the nucleotides corresponding to the splice donor site nucleotides is replaced by another nucleotide and wherein the nucleotides of the splice acceptor sites are not altered.01-31-2013
20130028875Immune Effector Cells Pre-Infected with Oncolytic Virus - Compositions and methods are provided for the treatment of cancer. An immune effector cell population is pre-infected with an oncolytic virus. The combined therapeutic is safe and highly effective, producing an enhanced anti-tumor effect compared to either therapy alone. The methods of the invention thus provide for a synergistic effect based on the combined biotherapeutics.01-31-2013
20080311094Isolated Liver Stem Cells - Isolated liver progenitor stem cells and cell populations of isolated liver progenitor stem cells are disclosed. The progenitor stem cells originate from adult liver, especially human adult liver. The isolated progenitor stem cells have uses in medicine, hepatology, inborn errors of liver metabolism transplantation, infectious diseases and liver failure. Methods of isolating these cells and their culture is described. The isolated cells are characterized before and after differentiation. Their use for transplantation and as animal models of human disease, toxicology and pharmacology is disclosed.12-18-2008
20110268711PANCREATIC STELLATE CELL SPECIFIC PROMOTER AND USES THEREOF - There is presently provided a method for effecting pancreatic stellate cell-specific gene expression comprising delivering a nucleic acid comprising a glial fibrillary acidic protein promoter operably linked to a coding sequence to a pancreatic stellate cell.11-03-2011
20090304654METHODS FOR ISOLATING ADIPOSE-DERIVED STEM CELLS AND THERAPEUTIC USE THEREOF - The application discloses adipose tissue-derived stem cells (ADSC) and related compositions and methods. ADSCs are useful for (i) production of insulin producing cells, (ii) treatment of diabetes, (iii) endothelial cell reconstitution, (iv) treatment of overactive bladder and urge incontinence, (v) prevention and treatment of bladder voiding dysfunction; (vi) treatment of neurogenic impotence such as that resulting from diabetes or after prostate cancer therapy; (vii) treatment of vasculogenic impotence, such as that resulting from hypertension, dyslipidemia, atherosclerosis and diabetes; (viii) the promotion of wound healing; (ix) reduction of skin wrinkling; and (x) hair growth.12-10-2009
20090304653METHODS TO IDENTIFY POLYNUCLEOTIDE AND POLYPEPTIDE SEQUENCES WHICH MAY BE ASSOCIATED WITH PHYSIOLOGICAL AND MEDICAL CONDITIONS - Disclosed are methods to identify an agent which may modulate resistance to HIV-1-mediated disease, comprising contacting at least one agent to be tested with a cell comprising human ICAM-1, and detecting the cell's resistance to HIV-1 viral replication, propagation, or function, wherein an agent is identified by its ability to increase the cell's resistance to HIV-1 viral replication, propagation, or function. Also disclosed are human mutant ICAM-1 polypeptides and methods to treat HIV-1 viral replication, propagation, or function in a human subject by ICAM-1 gene therapy relating to one or more of the following 10 mutations to human ICAM-1: L18Q, K29D, P45G, R49W, E171Q, wherein the mutant ICAM-1 is otherwise identical to human ICAM-1.12-10-2009
20090304651Insulin-Like Growth Factor II (IGF-II) Binding Factors - This invention relates to modified IGF-II binding domains of the Insulin-like Growth Factor 2 Receptor (IGF2R) which have enhanced binding affinity for IGF-II relative to the wild type IGF-II binding domain. Suitable IGF-II binding domains may be modified, for example, by substituting residue E1544 for a non-acidic residue. These modified domains may be useful in the sequestration of Insulin-like Growth Factor II (IGF-II), for example, in the treatment of cancer.12-10-2009
20090304650Repair of the Bone Marrow Vasculature - Stem cells repair the marrow vascular niche following bone marrow transplantation. Donor-derived vasculogenesis occurred whether whole bone marrow cells, isolated stem cells, or single stem cells were transplanted. Damaged marrow sinusoids led to hypoxia, followed by upregulation of angiogenic factors hypoxia inducible factor-1 and stromal derived factor-1.12-10-2009
20090304652IDENTIFICATION AND SELECTION OF STEM CELLS BEING COMMITTED TO DIFFERENTIATE TO A SPECIFIC TYPE FOR OBTAINING A HOMOGENEOUS POPULATION OF STEM CELLS - The stem cell (12-10-2009
20090041734USE OF CELL IMPLANTS IN BLADDER AND GUT OF NON-HUMAN ANIMALS FOR THE PRODUCTION OF PEPTIDES - Provided are means and method for the production of proteins in non-production in non-human animals. Cells producing a protein of interest is implanted in said non-human animal whereupon produced protein is harvested. In a preferred embodiment cells are implanted into a bladder or gut of said non-human animal02-12-2009
20130071365INDUCED HEPATOCYTES - An object of the present invention is to produce hepatic cells from non-hepatic cells that can be obtained less invasively and at low cost. The gene of HNF3α, HNF3β, or HNF3γ and the gene of HNF4α are transduced into non-hepatic cells. The present invention enables the production of induced hepatocytes from somatic cells that are non-hepatic cells, such as skin cells. The use of the induced hepatocytes obtained by the present invention can establish and develop, as general medical treatment, cell transplantation into the liver, artificial livers, and drug response tests, which are the areas that have not been generalized because of the difficulty of procuring hepatocytes.03-21-2013
20130071366INSULIN-LIKE GROWTH FACTOR II (IGF-II) BINDING FACTORS - This invention relates to modified IGF-II binding domains of the Insulin-like Growth Factor 2 Receptor (IGF2R) which have enhanced binding affinity for IGF-II relative to the wild type IGF-II binding domain. Suitable IGF-II binding domains may be modified, for example, by substituting residue E1544 for a non-acidic residue. These modified domains may be useful in the sequestration of Insulin-like Growth Factor II (IGF-II), for example, in the treatment of cancer.03-21-2013
20130164270POLYNUCLEOTIDES AND CONSTRUCTS ENCODING SFLT1-14 AND METHOD FOR EFFICIENT PROPAGATION AND EXPRESSION THEREOF - The present invention relates to engineered polynucleotides and constructs comprising nucleic acid sequences encoding a specific splice-variant (sFLT1-14) of the VEGFR family Flt-1, methods for efficient propagation and expression thereof and compositions and uses thereof. More particularly, the invention relates to isolated polynucleotides comprising a nucleic acid sequence coding for sFlt1-14 or any fragment thereof comprising the serine-rich C-terminus region of said sFlt1-14, wherein at least one of the TCA serine coding codons in said serine-rich C-terminus region of sFlt1-14 as encoded by the nucleic acid sequence of SEQ ID NO. 1, is replaced by any one of TCT, TCC, TCG, AGT, AGC. The invention further provides compositions and method of treating VEGF-associated medical conditions using the polynucleotides of the invention.06-27-2013
20090053185Coagulation factor x polypeptides with modified activation properties - The present invention relates to modified cDNA sequences coding for human Factor X and their derivatives with improved stability and modified activation sequences, recombinant expression vectors containing such cDNA sequences, and host cells transformed with such recombinant expression vectors. The invention also relates to recombinant factor X polypeptides and derivatives which have biological activities of the unmodified wild type protein but with improved stability and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA.02-26-2009
20090092588Cloned ungulate embryos and animals, use of cells, tissues and organs thereof for transplantation therapies including parkinson's disease - Methods and cell lines for cloning ungulate embryos and offspring, in particular bovines and porcines, are provided. The resultant fetuses, embryos or offspring are especially useful for the expression of desired heterologous DNAs, and may be used as a source of cells or tissue for transplantation therapy for the treatment of diseases such as Parkinson's disease.04-09-2009
20130058908HIGH AFFINITY NY-ESO T CELL RECEPTORS - The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC SEQ ID NO:126 peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a K03-07-2013
20090035287ATRIAL NATRIURETIC PEPTIDE (ANP) SPLICE VARIANTS AND METHODS OF USING SAME - Novel ANP polypeptides and polynucleotides encoding same are provided. Also provided are methods and pharmaceutical compositions which can be used to treat ANP-related diseases and disorders including cardiovascular disorders using the polypeptides and polynucleotides of the present invention.02-05-2009
20090269320VARIANTS OF PIGMENT EPITHELIUM DERIVED FACTOR AND USES THEREOF - The present invention provides anti-angiogenic variants of pigment epithelium derived factor (PEDF) comprising at least one altered phosphorylation site, polynucleotides encoding same and uses thereof. Particularly, the present invention provides variants of human PEDF comprising at least one amino acid substitution at serine residues (24), (114), and (227). The PEDF variants are potent anti-angiogenic factors, and thus useful in treating diseases or disorders associated with neovascularization.10-29-2009
20090238806TREATMENT OF INTERVERTEBRAL DISC DEGENERATION - The present application discloses a method for preventing or retarding degeneration of intervertebral disc at an intervertebral disc defect site, which includes injecting a mammalian connective tissue cell into the intervertebral disc defect site.09-24-2009
20090238805METHODS AND COMPOSITIONS FOR INCREASING RNA INTERFERENCE - The present invention relates to compositions containing a combination of a first active component comprising one or more sulfated polysaccharides and/or glycosaminoglycans and a second active component comprising one or more RNAi-inducing molecules, and methods for using these compositions to enhance double-stranded RNA (dsRNA)-mediated gene silencing in pest or pathogen species. The invention further relates to methods for controlling pests or pathogens, methods for preventing pest infestations or pathogen infections and methods for knocking down gene expression in pests or pathogens using the compositions and methods of the invention.09-24-2009
20090238804USE OF CELLS CONTAINING A SPECIFIC DNA MOLECULE AS CYTOPATHIC AGENTS TO INHIBIT THE PROLIFERATION OF CELLS - The present invention relates to the use of cells containing in their genome a specific DNA molecule, as cytopathic agents able to inhibit the proliferation of cells, when these proliferative cells are contacted with the cells containing the above-mentioned DNA molecule.09-24-2009
20090238807CELL LINE - The invention provides a cell line complementing HSV ICP4, ICP27, and UL55 genes.09-24-2009
20090232784ENDOTHELIAL PREDECESSOR CELL SEEDED WOUND HEALING SCAFFOLD - Compositions and processes for promoting wound healing are provided by the present invention which increase the rate and completeness of wound healing. Broadly described, an inventive composition includes a degradable scaffold of biocompatible material and a cell involved in wound healing, or a predecessor of such a cell, disposed in contact with the scaffold. In one embodiment, an albumin scaffold is provided with an endothelial cell predecessor disposed therein. Optionally, a cell involved in wound healing or a predecessor of such a cell is administered by local or systemic injection in conjunction with application of an inventive composition. Processes for promoting wound healing are provided as well as processes for producing the described compositions for promoting healing.09-17-2009
20110014165Thymidylate Kinase Mutants and Uses Thereof - The invention relates to a composition comprising a stably integrating delivery vector; and a modified mammalian thymidylate kinase (tmpk) wherein the modified mammalian tmpk increases phosphorylation of a prodrug relative to phosphorylation of the prodrug by wild-type human tmpk. The invention also relates to use of these compositions in methods of treatment of diseases such as graft versus host disease and cancer.01-20-2011
20090317369COMPOSITIONS COMPRISING CARDIAC STEM CELLS OVEREXPRESSING SPECIFIC MICRORNAS AND METHODS OF THEIR USE IN REPAIRING DAMAGED MYOCARDIUM - The invention provides compositions comprising modified stem cells containing a transgene that affects the expression of at least one gene that inhibits or promotes cardiomyogenesis. In particular, the invention discloses compositions comprising cardiac stem cells, wherein said cardiac stem cells comprise a transgene encoding a microRNA. The compositions of the invention find use in the treatment of cardiovascular disorders, such as myocardial infarction. Methods of repairing damaged myocardium in a subject using the modified stem cells are also disclosed.12-24-2009
20120114619PROTEIN WITH PROMOTING EFFECTS FOR AXONAL GROWTH OF NEURONS OF CENTRAL NERVOUS SYSTEM - This invention comprises a polypeptide, a recombinant vector, a recombinant organism as well as RNA- and DNA-sequences. Furthermore, the use of polypeptides and recombinant vectors is described. Additionally the invention comprises methods for medical treatment.05-10-2012
20090010900Embryonic Stem Cell Derivatives, and Methods of Making and Using the Same - The presently disclosed subject matter provides embryonic stem (ES) cell derivatives that can be employed in therapeutic methods. Also provided are methods for generating and using the ES cell derivatives.01-08-2009
20100086526NUCLEIC ACID CONSTRUCTS AND METHODS FOR SPECIFIC SILENCING OF H19 - The present invention is directed to recombinant constructs and methods for treating pathological conditions associated with H19 expression, such as tumors characterized by up-regulated expression of H19 RNA. Specifically, the recombinant constructs of the invention comprise at least one nucleic acid sequence encoding a small interfering RNA (siRNA) molecule directed to H19, the nucleic acid sequence being operably linked to at least one H19-specific transcription-regulating sequence. Vectors comprising these constructs, pharmaceutical compositions comprising them and therapeutic methods of using same are also provided.04-08-2010
20130183276METHODS AND COMPOSITIONS FOR TREATING HIV - The invention features nucleic acid constructs encoding chimeric immune T-cell receptors (CIRs) that are useful for treating HIV in patients. In general, the CIRs contain an extracellular domain which targets HIV or HIV infected cells (e.g., the extracellular domain of CD4), a transmembrane domain, and a cytoplasmic domain for mediating T-cell activation (e.g., CD3 zeta and/or the partial extracellular domain of CD28). The invention also features the use of host cells expressing CIRs in the treatment of HIV.07-18-2013
20080305088Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy - A novel nucleic acid construct for down-regulating angiogenesis in a tissue of a subject is provided. The nucleic acid construct includes: (a) a first polynucleotide region encoding a chimeric polypeptide including a ligand binding domain fused to an effector domain of an apoptosis signaling molecule; and (b) a second polynucleotide region encoding a cis acting regulatory element being for directing expression of the chimeric polypeptide in a specific tissue or cell; wherein the ligand binding domain is selected such that it is capable of binding a ligand present in the specific tissue or cell, whereas binding of the ligand to the ligand binding domain activates the effector domain of the apoptosis signaling molecule. Also provided are methods of utilizing this nucleic acid construct for treating diseases characterized by excessive or aberrant neo-vascularization or cell growth.12-11-2008
20100278790MESENCHYMAL STEM CELLS, COMPOSITIONS, AND METHODS FOR TREATMENT OF CARDIAC TISSUE DAMAGE - The present invention provides compositions comprising mesenchymal stem cells (MSCs), and methods for their novel use in the repair of cardiac damage and treatment of inflammatory diseases. The invention also provides methods for using TSG-6 protein that is secreted by MSCs under certain conditions, for repair of cardiac damage and inflammatory disease. The compositions of the invention may be particularly useful in restoring cardiac function following cardiac damage, including, but not limited to, myocardial infarction, as well as in reducing symptoms of inflammatory disease.11-04-2010
20110280846OLFACTORY EPITHELIAL-DERIVED STEM CELLS AND METHODS OF USE THEREFOR - The presently disclosed subject matter provides recombinant dopaminergic neurons and/or recombinant progenitors thereof that include one or more transgenes encoding a nurr-1 polypeptide, a pitx3 polypeptide, an Imxi a polypeptide, a biologically active fragment thereof, a biologically active derivative thereof, and/or any combination thereof. Also provided are methods for producing a recombinant dopaminergic neuron or recombinant progenitor thereof, methods for producing lineage primed cells, methods for ameliorating at least one symptom associated with a neurological disorder, methods for transplantation, methods for inducing growth, repair, and/or regeneration of a neuron, for delivering a cytokine or a growth factor to the central nervous system, methods for providing a dopaminergic neuron function, and cell cultures that include recombinant olfactory epithelial-derived stem cells and/or a differentiated derivatives thereof.11-17-2011
20110280845TREATMENT OF RHEUMATOID ARTHRITIS USING PLACENTAL STEM CELLS - Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.11-17-2011
20110280844HEPATOCYTE PRODUCTION BY FORWARD PROGRAMMING - The invention generally features methods for providing hepatocytes from a variety of cell sources, particularly pluripotent stem cells, therapeutic compositions featuring such cells, and methods of using them for the treatment of subjects.11-17-2011
20100150889Polycistronic Vector For Human Induced Pluripotent Stem Cell Production - Methods of producing induced pluripotent stem (iPS) cells are provided. For example, a method of producing an iPS cell from a differentiated cell, which includes transforming the differentiated cell with a first vector comprising a nucleic acid sequence comprising a nucleic acid sequence encoding an Oct4, a nucleic acid sequence encoding a Sox2, and a nucleic acid sequence encoding a Klf4. Each of the nucleic acid sequences are separated from each other by a first and second viral 2A sequence. The method described can further comprise culturing the transformed cell under conditions that allow for the production of an iPS cell and isolating the cultured iPS cell.06-17-2010
20110027239ADIPOSE-DERIVED STROMAL CELLS (ASC) AS DELIVERY TOOL FOR TREATMENT OF CANCER - The present invention generally relates to use of adult Adipose-derived stromal cells (ASC) and genetically engineered ASC for the treatment of cancer. In particular, the present invention generally relates, in part to a method for treating a subject with cancer comprising administering to the subject a composition comprising engineered ASCs which have been modified to express a gene encoding at least one anti-cancer agent. In some embodiments, an anti-cancer agent is a pro-apoptotic agent. In some embodiments an anti-cancer agent is an agent which inhibits the expression of an oncogene.02-03-2011
20090311225Compositions of and Methods of Using Stabilized PSMA Dimers - The invention includes cysteine-modified PSMA polypeptides and disulfide-bond-stabilized dimers thereof, compositions and kits containing the cysteine-modified PSMA polypeptides, including dimers thereof, as well as methods of producing and using these compositions. Such methods include methods for eliciting or enhancing an immune response to cells expressing PSMA, methods of producing antibodies to PSMA, including dimeric PSMA, as well as methods of treating cancer, such as prostate cancer.12-17-2009
20100008892QUALITY ASSAYS FOR ANTIGEN PRESENTING CELLS - The present invention provides methods for evaluating the quality of a preparation of antigen presenting cells, such as dendritic cells. Assays for antigen-independent co-stimulation of T cells and for presentation of predetermined antigen by APCs are provided.01-14-2010
20120107286PLURIPOTENT STEM CELLS - Methods and compositions for the generation and use of footprint-free human induced pluripotent stem cells are provided.05-03-2012
20110286982GLUCAGON ANALOGUES - The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metablic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.11-24-2011
20110286980METHODS FOR INDUCING SELECTIVE APOPTOSIS - Provided herein are methods for cell therapy by modifying transfused cells to express an inducible caspase 9 protein, so that the cells may be selectively killed if the patient experiences dangerous side effects. Provided also within relates in part to methods for preventing or treating Graft versus Host Disease by modifying T cells before administration to a patient, so that they may be selectively killed if GvHD develops in the patient.11-24-2011
20110286985METHOD OF TREATMENT USING ORGANOTYPICALLY CULTURED SKIN TISSUE COMPRISING NIKS CELLS THAT EXPRESS EXOGENOUS HIF-1A - The present invention relates to in vitro cultured skin tissue, and in particular to cultured skin tissue comprising exogenous genes encoding angiogenic growth factors. In some embodiments, the keratinocytes express exogenous angiopoietin-1, HIF-1α, or a member of the VEGF family, preferably VEGF-A. In particularly preferred embodiments, the keratinocytes are incorporated into cultured skin tissue.11-24-2011
20110286983LONG LASTING DRUG FORMULATIONS - The present invention is directed to long-lasting erythropoietin therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes erythropoietin.11-24-2011
20110286981GLUCAGON ANALOGUES - The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.11-24-2011
20110286979CHEMOSENSITIZATION BY BI-FUNCTIONAL SMALL HAIRPIN RNA (bi-shRNA) - Compositions and methods of augmenting the anti-tumor activities of docetaxel and other taxanes by combination with a bi-functional small hairpin RNA (bi-shRNA) is described herein. The instant invention describes the interactive outcome of STMN1 knockdown with docetaxel. In vitro docetaxel (DOC) dose response assessments with or without co-treatment with bi-shRNA11-24-2011
20110286978Genetically Intact Induced Pluripotent Cells Or Transdifferentiated Cells And Methods For The Production Thereof - The present disclosure relates to methods for dedifferentiating and transdifferentiating recipient cells, preferably human somatic cells. These methods minimize the risk of undesired genome sequence alteration. These methods employ reprogramming factors, which may be used alone or in certain combinations with one another. These methods have application especially in the context of cell-based therapies, establishment of cell lines, and the production of genetically modified cells.11-24-2011
20110110902MEANS AND METHODS FOR COUNTERACTING, DELAYING AND/OR PREVENTING HEART DISEASE - The invention relates to the fields of molecular biology and medicine, more specifically to treatment and prevention of heart disease. The invention provides alternative methods for counteracting, diminishing, treating, delaying and/or preventing heart disease.05-12-2011
20110293587GLUCAGON ANALOGUES - The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.12-01-2011
20110293585COMPOSITIONS AND METHODS FOR TREATMENT OF LYSOSOMAL STORAGE DISORDERS - Compositions and methods for treating lysosomal storage diseases are disclosed. Lysosomal dysfunction is usually the result of deficiency of a single enzyme necessary for the metabolism of lipids, glycoproteins (sugar containing proteins) or mucopolysaccharides which are fated for breakdown or recycling. The compositions contain triplex-forming molecules which can be used to induce site-specific homologous recombination in mammalian cells when combined with donor DNA molecules, by stimulating cellular DNA synthesis, recombination, and repair mechanisms. The methods are particular useful for correcting point mutations in genes associated with lysosomal storage diseases such as Gaucher's disease, Fabry disease, and Hurler syndrome. Methods for determining the frequency of target gene repair and assessing the restoration of the enzymatic activity of corrected polypeptides are also disclosed. Ex vivo and in vivo methods of gene correction in patients are also provided.12-01-2011
20110293586GLUCAGON ANALOGUES - The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metablic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.12-01-2011
20080311096Combinations of Cry1Ab and Cry1Fa as an insect resistance management tool - Compositions for controlling lepidopteran insects use Cry1Fa and Cry1Ab core toxin containing proteins in combination to delay or prevent development of resistance.12-18-2008
20110286984GENE ENCODING HUMAN GLUCOKINASE MUTANT, ENZYME ENCODED BY THE SAME, RECOMBINANT VECTORS AND HOSTS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF, METHODS FOR TREATING AND PREVENTING DISEASES - Gene encoding human glucokinase mutant is provided. The gene has the nucleotide sequence chosen from the nucleotide sequence listed as SEQ ID NO:2 and the nucleotide sequence wherein the ORF region encodes the same amino acid sequence as the one encoded by ORF region (position 487 to 1884) of SEQ ID NO:2 and the rest of the region is same as the non-ORF region of SEQ ID NO:2. Human glucokinase mutant encoded by the gene, the recombinant vectors carrying the gene, the hosts comprising the vectors, pharmaceutical compositions thereof, uses thereof, and methods for treating and preventing diseases by using the same are provided. The human glucokinase mutant encoded by the gene has higher activity than that of the wild type human glucokinase, and thus provides a new way of controlling blood glucose and/or preventing and/or treating disturbance of carbohydrate metabolism, especially preventing and treating diabetes.11-24-2011
20110300116Method for Generating a Recombinant Clonal Cell Line and Novel Reagents for Use in the Method - A method for generating a recombinant clonal cell line expressing a target cell surface receptor at a specific level of expression from a cell population comprising cells transfected with a plasmid encoding the cDNA sequence of the target receptor and expressing the target cell surface receptor, the method comprising (c) incubating the cell population with a receptor specific fluorescent ligand (d) selecting single cells from step (c) expressing the target cell surface receptor by monitoring the specific binding of the fluorescent ligand using flow cytometry; and novel fluorescent ligands.12-08-2011
20110300114METHOD OF CELL CULTURE AND METHOD OF TREATMENT COMPRISING A vEPO PROTEIN VARIANT - In one aspect the present invention is concerned with a method of cell culture, comprising the steps of (i) obtaining a stem or progenitor cell sample, (ii) culturing the stem or progenitor cell sample in media and under closed conditions appropriate to cause proliferation or differentiation of the stem or progenitor cells, wherein the media comprises a vEPO protein variant, (iii) purifying the stem or progenitor cells ex vivo. The invention relates to a method of increasing the number and survival of stem and progenitor cells in vitro and in vivo using a vEPO protein variant. The invention also relates to improved differentiation of stem and progenitor cells in vitro and in vivo using a vEPO protein variant.12-08-2011
20110300115USE OF INDUCTOR AGENTS GSE24.2 FOR PRODUCING PHARMACEUTICAL COMPOSITIONS FOR TREATING ILLNESSES RELATING TO CELLULAR SENESCENCE - This invention describes the use of an inductor or activator compound GSE24.2 for producing a medicament or pharmaceutical composition for treating a preferably human illness or pathological situation caused by a senescence process. Said pharmaceutical composition can be useful for a treatment of tissue regeneration, for example of epithelial tissues or haematopoietic cells, and also for the immortalisation of eukaryote cells for use of same in biotechnological research or processes.12-08-2011
20110300113Death Receptor CD95 Controls Neurogenesis of Adult Neural Stem Cells in Vivo and in Vitro - The present invention relates to the activation of the CD95L/CD95 system for inducing neuronal differentiation in vitro and in vivo and the use of CD95L compositions to effect differentiation.12-08-2011
20120189596NUCLEAR RECEPTOR AND MUTANT THEREOF AND THE USE OF THE SAME IN THE REPROGRAMMING OF CELLS - According to the invention there is provided methods for inducing pluripotent stem cells in vitro, comprising introducing a gene or polypeptide of a nuclear receptor and one or more gene or polypeptide selected from the group consisting of Sox, Krüppel-like factor or the myc family, to cells in vitro. The present invention also provides vectors and compositions for producing the same and methods for using the induced pluripotent stem cell for treating a patient in need of a pluripotent stem cell treatment.07-26-2012
20090123440Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases - The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or its variant into a segment of a blood vessel ex vivo using a gutless adenovirus vector. Another aspect of the present invention is to provide a gutless adenovirus vector carrying a transgene, such as a gene encoding TM protein or its variant.05-14-2009
20110217274METHODS FOR PRODUCTION AND USES OF MULTIPOTENT ,PLURIPOTENT, DIFFERENTIATED AND DISEASE-RESISTANT CELL POPULATIONS - The claimed invention is directed towards the generation of pluripotent, multipotent, and/or self-renewing cells which are capable of beginning to differentiate in culture into a variety of cell types and capable of further differentiation in vivo. The claimed invention is also directed towards the generation of desirable, differentiating cell populations transplantable to patients, genetic modification of endogenous cells, and the treatment of patients suffering from diseases that may be ameliorated by these methods. This invention also provides methods for preventing, treating, or retarding disease related to immunodeficiency virus (e.g. HIV-1, HIV-2, SIV, FIV, etc.) infection.09-08-2011
20090130071Soybean Plant And Seed Corresponding To Transgenic Event MON87701 And Methods For Detection Thereof - The present invention provides a transgenic soybean event MON87701, and cells, seeds, and plants comprising DNA diagnostic for the soybean event. The invention also provides compositions comprising nucleotide sequences that are diagnostic for said soybean event in a biological sample, probes and primers for use in detecting nucleotide sequences that are diagnostic for the presence of said soybean event in a biological sample, and methods for detecting the presence of said soybean event nucleotide sequences in a biological sample. The invention further provides methods of growing the seeds of such soybean event into soybean plants, and methods of breeding to produce soybean plants comprising DNA diagnostic for the soybean event.05-21-2009
20100111912COMPOSITIONS AND METHODS FOR TARGETED ABLATION OF MUTATIONAL ESCAPE OF TARGETED THERAPIES FOR CANCER - Provided herein are compositions and methods for targeted ablation of mutational escape in the face of cancer therapeutic agents. Compositions comprising the yeast-based vehicles are used in combination with other cancer therapeutic agents.05-06-2010
20090311224THERAPEUTIC AGENT COMPRISING LIPOCALIN 2 AGAINST CANCER METASTASIS, AND METHODS OF EARLY DIAGNOSIS AND INHIBITION OF CANCER METASTASIS USING LIPOCALIN 2 - The present invention relates to a pharmaceutical composition for the inhibition of cancer metastasis, more precisely, a novel pharmaceutical composition against cancer metastasis comprising lipocalin 2 protein, a gene encoding the protein, an expression vector containing the gene or cells transfected with the expression vector as an effective ingredient, a method for the inhibition of cancer metastasis using the composition, a diagnostic kit for the prediction of cancer metastasis, a method for the selection of a metastasis risk group using the kit, a novel pharmaceutical composition for the inhibition of cancer growth and a method for the inhibition of cancer growth using the same. The pharmaceutical composition of the present invention specifically inhibits cancer metastasis, so that it can improve the effect of cancer treatment dramatically. And, the diagnostic kit and the method for the selection of a metastasis risk group using the kit enable the selection of a metastasis risk group by measuring the level of lipocalin 2 in tumor tissues or in body fluid. Therefore, the kit and the method can contribute to the effective clinical control of a cancer patient. Further, the composition of the invention can be effectively used for the treatment of liver cancer owing to its liver cancer growth inhibitory effect.12-17-2009
20090074733THYMIDYLATE KINASE MUTANTS AND USES THEREOF - The invention relates to a composition comprising: 03-19-2009
20100119496ADIPOSE TISSUE DERIVED STROMAL CELLS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS - The present invention relates to a treatment of neural injury and neurodegenerative diseases. Also included in the present invention is the use of adipose tissue derived stromal cells for the treatment of neural injury (stroke, traumatic brain injury, spinal cord injury) and neurodegeneration (i.e. Parkinson's disease).05-13-2010
20120189595INDUCED PLURIPOTENT STEM CELLS AND METHODS OF USE - The invention relates to the field of stem cells and, specially, to the reprogramming of adult somatic cells; to obtain pluripotent cells by the transfection of specific genes. Thus, the invention provides induced pluripotent stem cells (iPS) and methods of obtaining and using them.07-26-2012
20090311226COMPOSITION AND METHOD FOR TREATING ESOPHAGEAL DYSPLASIA - Enhancing the immune response to esophageal tumor cells reduces the incidence of esophageal cancer developing, recurring, or metastasizing. Esophageal cancer cells are modified to render them more immunogenic and proliferation compromised. They are used in an antigenic preparation to raise a T cell response in the recipient.12-17-2009
20090202502HEPATIC STELLATE CELL SPECIFIC PROMOTER AND USES THEREOF - Methods and reagents for effecting transgene expression in Hepatic Stellate Cells (HSC) comprising a 2.2 kb fragment of the promoter region of the Glial Fibrillary Acidic Protein (GFAP) gene, said construct being up-regulated by pro-fÊbronetic cytokines such as TGF-beta 1 in a dose and time dependent manner, and uses thereof.08-13-2009
20120107285Mitochondrial enhancement of cells - Certain embodiments disclosed herein include, but are not limited to, at least one of compositions, methods, devices, systems, kits, or products regarding rejuvenation or preservation of stem cells. Certain embodiments disclosed herein include, but are not limited to, methods of modifying stem cells, or methods of administering modified stem cells to at least one biological tissue.05-03-2012
20120107284Stem cells for transplantation and methods for production thereof - A medicament for cell differentiation to alleviate cell and cell-related deficiencies in a mammal is described. The medicament comprises in two or more parts in vitro produced non-activated inducible gene construct(s) capable of expressing transcription factor(s), and optionally additional suppressor(s) or activator(s) of expression of said transcription factor(s), in a cell for transfection, such as a stem cell, and separate exogenous inducer(s) for in vivo expression, such as tetracycline, streptogramin and macrolide. Examples of the cell and cell-related deficiencies are traumatic injuries to the brain and spinal cord, neurodegenerative disorders, stroke, demyelinating disorders, neuropathic pain disorders, diabetes, myocardial infarction, skeletal muscle disorders. Further, a delivery system for delivery of the medicament to a mammal as well as a method of treating cell and cell-related deficiencies in a mammal, are described.05-03-2012
20090263365Methods and compositions for transforming dendritic cells and activating cells - Recombinant dendritic cells are made by transforming a stem cell and differentiating the stem cell into a dendritic cell. The resulting dendritic cell is an antigen presenting cell which activates T cells against MHC class I-antigen targets. Kits, assays and therapeutics are based upon the activation of T cells by the recombinant dendritic cell. Cancer, viral infections and parasitic infections are all ameliorated by the recombinant dendritic cells, or corresponding activated T cells. Therapeutic compositions and pharmaceutical compositions are provided.10-22-2009
20090047262Expression of class II transactivator fusion proteins for control of tumor growth - The present invention relates to tumor immunotherapy. In particular, the present invention provides methods and compositions for converting cancer cells into antigen presenting cells. Thus the present invention provides immunogenic compositions for the treatment and prevention of cancer.02-19-2009
20090274671VECTOR ENCODING HUMAN GLOBIN GENE AND USE THEREOF IN TREATMENT OF HEMOGLOBINOPATHIES - Recombinant lentiviral vectors having a region encoding a functional β-globin gene; and large portions of the β-globin locus control regions which include DNase I hypersensitive sites HS2, HS3 and HS4 provides expression of β-globin when introduced into a mammal, for example a human, in vivo. Optionally, the vector further includes a region encoding a dihydrofolate reductase. The vector may be used in treatment of hemoglobinopathies, including β-thalessemia and sickle-cell disease. For example, hematopoietic progenitor or stem cells may be transformed ex vivo and then restored to the patient. Selection processes may be used to increase the percentage of transformed cells in the returned population. For example, a selection marker which makes transformed cells more drug resistant than untransformed cells allows selection by treatment of the cells with the corresponding drug.11-05-2009
20110171185Genetically intact induced pluripotent cells or transdifferentiated cells and methods for the production thereof - The present disclosure relates to methods for dedifferentiating and transdifferentiating recipient cells, preferably human somatic cells. These methods minimize the risk of undesired genome sequence alteration. These methods employ reprogramming factors, which may be used alone or in certain combinations with one another. These methods have application especially in the context of cell-based therapies, establishment of cell lines, and the production of genetically modified cells.07-14-2011
20090285789METHODS FOR ENHANCING INNATE AND ADAPTIVE IMMUNITY AND ANTIGEN IMMUNOGENICITY - The present invention is related to a method for enhancing innate and adaptive immunity by activating dendritic cells (DCs) and macrophages, comprising administering a subject LZ-8 protein. The present invention is also related to a composition for enhancing innate and adaptive immunity, comprising LZ-8 protein.11-19-2009
20090285788RANDOM RNAi LIBRARIES, METHODS OF GENERATING SAME, AND SCREENING METHODS UTILIZING SAME - This invention provides expression vectors for a ribonucleic acid (RNA) molecule comprising a double-stranded region of random sequence, sets and libraries of same, methods of generating same, and methods for identifying an RNA therapeutic or RNA molecule that has an ability to affect a biological parameter, for identifying a drug target for a disease or disorder of interest, and for identifying a variant of an RNA molecule that has an altered ability to affect a biological parameter of interest.11-19-2009
20080241115Use Of Mesenchymal Stem Cells Genetically Modified To Express A Suicide Gene For Treating A Cancer - Mesenchymal stem cells expressing a suicide gene show excellent and highly selective anticancer effects against cancer tissues through the selective conversion of a prodrug of an anticancer agent to the anticancer agent at around the cancer. Also disclosed herein are a pharmaceutical composition for treating a cancer comprising the mesenchymal stem cell; a kit for treating a cancer comprising an expression vector comprising the suicide gene, the mesenchymal stem cell and the prodrug; and a method for treating a cancer patient, which comprises successively administering the mesenchymal stem cell and the prodrug to the patient.10-02-2008
20110171186CHONDROCYTE THERAPEUTIC DELIVERY SYSTEM - Systems and methods for modifying the environment of target cell using genetically altered chondrocytes are provided. The genetically engineered chondrocytes can be used to express a therapeutic agent in a subject, including in an environment typically associated with chondrocytes and in an environment not typically associated with chondrocytes.07-14-2011
20110171184Method for Introducing a Pna Molecule Conjugated to a Positively Charged Peptide into the Cytosol and/or the Nucleus by Photochemical Internalisation (Pci) - The present application relates to a method for introducing a PNA molecule into the cytosol, preferably the nucleus of a cell, comprising contacting said cell with a PNA molecule and a photosensitising agent, and irradiating the cell with light of a wavelength effective to activate the photosensitising agent, wherein said PNA molecule is conjugated to a positively charged peptide. Compositions comprising such conjugated PNA molecules, cells made using the method and uses of the method are also described.07-14-2011
20090274670DPH2 GENE DELETION MUTANT AND USES THEREOF - Diphtheria and 11-05-2009
20080311095Methods and compositions for increased transgene expression - Described herein are methods of expressing nucleic acids in T cells pre-exposed to a co-stimulatory signal and then transduced with adenoviral vectors. In some embodiments, the co-stimulation is provided by anti-CD3 and anti-CD28 antibodies and the adenoviral vector is pseudotyped for T-cell entry. The invention also relates to compositions for carrying out these methods, provided as kits or pharmaceutical compositions that can be used to treat diseases including immunological conditions and hematological malignancies.12-18-2008
20090104166STIMULATING NEURITE OUTGROWTH USING TCTEX-1-RELATED POLYPEPTIDES - A method of stimulating neurite outgrowth in a subject may include administering to the subject a formulation that includes a tctex-1-related polypeptide that stimulates neurite outgrowth in vitro.04-23-2009
20090104165TRANSGENIC STRAINS OF TRICHODERMA AND THEIR USE IN BIOCONTROL - The present invention relates to a transgenic 04-23-2009
20100278791ADENO-ASSOCIATED VIRUS SEROTYPE I NUCLEIC ACID SEQUENCES, VECTORS AND HOST CELLS CONTAINING SAME - The nucleic acid sequences of adeno-associated virus (AAV) serotype 1 are provided, as are vectors and host cells containing these sequences and functional fragments thereof. Also provided are methods of delivering genes via AAV-1 derived vectors.11-04-2010
20100278792METHOD OF ENHANCING PROLIFERATION AND/OR HEMATOPOIETIC DIFFERENTIATION OF STEM CELLS - The present invention provides a method for enhancing the proliferation and/or hematopoietic differentiation and/or maintenance of mammalian stem cells. The method is useful for generating expanded populations of hematopoietic stem cells (HSCs) and thus mature blood cell lineages. This is desirable where a mammal has suffered a decrease in hematopoietic or mature blood cells as a consequence of disease, radiation or chemotherapy. The method of the present invention comprises increasing the intracellular level of a cdx in stem cells, including hematopoietic stem cells, in culture, either by providing an exogenous cdx protein to the cell, or by introduction into the cell of a genetic construct encoding a cdx. The cdx is selected from the cdx family and includes cdx1, cdx2, or cdx4. The cdx may be a wild type protein appropriate for the species from which the cells are derived, or a mutant form of the protein.11-04-2010
20090291068Modulation of bio-electrical rhythms via a novel engineering approach - The present invention relates to novel compositions and methods to induce, and/or modulate bio-electrical rhythms (e.g. in cardiac, neuronal and pancreatic cells) by fine-tuning the activity of HCN-encoded pacemaker channels via a novel protein- and genetic-engineering approach to augment or attenuate the associated physiological responses (e.g. heart beat, neuronal firing, insulin secretion, etc) for achieving various therapeutic purposes (e.g. sick sinus syndrome, epilepsy, neuropathic pain, diabetes, etc).11-26-2009
20110200567METHODS AND COMPOSITIONS FOR THE TREATMENT OF LUNG DISEASES AND DISORDERS - A method of treating injured or diseased alveolar epithelial tissue in the lung of a mammal comprising transplanting into the lung a population of differentiated transgenic stem cells, or progeny thereof, which have an alveolar type II phenotype, effective to repair at least a portion of the injured or diseased alveolar epithelial tissue; an expression vector for transgenically modifying stem cells, comprising a DNA sequence encoding human surfactant protein C promoter operably linked to a DNA sequence encoding at least one drug-resistance gene; transgenic stem cells comprising such expression vector; and a method of preparing such transgenic stem cells and progeny thereof, a high percentage of which have an alveolar type II phenotype.08-18-2011
20090041735CD34 Stem cell-related methods and compositions - This invention provides novel stem cell-based methods for treating a number of conditions. These methods employ CD3402-12-2009
20110200568INDUCED PLURIPOTENT STEM CELLS - This document provides methods and materials related to induced pluripotent stem cells. For example, induced pluripotent stem cells, compositions containing induced pluripotent stem cells, methods for obtaining induced pluripotent stem cells, and methods for using induced pluripotent stem cells are provided. In addition, methods and materials for using induced pluripotent stem cells to repair tissue (e.g., cardiovascular tissue) in vivo as well as methods and materials for using induced pluripotent stem cells to assess their therapeutic potential in appropriate animal models are provided.08-18-2011
20080213233Method of Delivering Nucleic Acid Molecules Into Embryonic Stem Cells Using Baculoviral Vectors - There is provided a method of delivering a nucleic acid molecule to an embryonic stem cell, including a human embryonic stem cell, by infecting the embryonic stem cell with a baculoviral vector comprising the nucleic acid molecule. Embryonic stem cells transduced by this method are useful for treating a disease or disorder in a subject.09-04-2008
20120294838Regulation of endogenous gene expression in cells using zinc finger proteins - The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.11-22-2012
20110268713Variants of Ancestral Uricases and Uses Thereof - The present invention provides uricases and methods of their production and use in reducing the amount of uric acid in a subject. The present invention further provides methods employing a uricase of this invention in the treatment and/or prevention of hyperuricemia, gout, tumor lysis syndrome and/or hypertension in a subject.11-03-2011
20100291048Modification of CXCR4 using engineered zinc finger proteins - Disclosed herein are methods and compositions for modulating activity of CXCR4 genes, for example using zinc finger transcription factors (ZF-TFs) or zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding ZF-TFs or ZFNs, vectors comprising polynucleotides encoding ZF-TFs or ZFNs and cells comprising polynucleotides encoding ZF-TFs or ZFNs and/or cells comprising ZF-TF or ZFNs are also provided.11-18-2010
20090169529COMPOSITIONS AND METHODS FOR IMMUNOSTIMULATORY RNA OLIGONUCLEOTIDES - The present invention provides 4-nucleotide (4mer) RNA motifs that confer immunostimulatory activity, in particular, IFN-α-inducing activity to a RNA oligonucleotide. The present invention also provides RNA oligonucleotides, including siRNA, with high or low immunostimulatory activity. The present invention further provides the use of the RNA oligonucleotides of the invention for therapeutic purposes.07-02-2009
20090297487METHOD FOR INTRODUCING SIRNA INTO CELLS BY PHOTOCHEMICAL INTERNALISATION - The present invention relates to a method for introducing an siRNA molecule into the cytosol of a cell, said method comprising i) contacting said cell with an siRNA molecule, a carrier and a photosensiting agent, and ii) irradiating the cell with light of a wavelength effective to activate the photosensitising agent, wherein said carrier comprises a cationic polyamine such as a lipopolyamine in a non-liposomal formulation, polyethyleneimine (PEI), a betacyclodextrin amine polymer, an amine group containing dendrimer, and a cationic peptide. Cells or a population of cells obtainable by the method, a composition containing an siRNA molecule and the carrier molecule, kits and therapeutic uses of the above are also provided.12-03-2009
20080233090Method of Treatment by Administration of Rna - A method of effecting a treatment response in a target tissue of a subject, comprising: administering to the subject isolated RNA comprising an RNA sequence extractable or extracted from a source tissue such that said treatment response is effected; wherein the RNA is isolated polyA positive RNA in substantially pure form.09-25-2008
20080233089Modified Cells Expressing a Protein That Modulates Activity of Bhlh Proteins, and Uses Thereof - The present invention relates to modified cells carrying a heterologous gene sequence encoding a protein, such as an Inhibitor of differentiation (Id) gene sequence that binds a basic helix-loop-helix (bHLH) protein to inhibit cell growth, differentiation and/or tumorigenesis of the modified cells. The modified cells are differentiated, proliferate and do not become tumorigenic when grafted into a recipient subject. Additionally, the modified cells produce a factor or factors that enhance the viability of co-grafted organs, tissues or cells. Thus, the modified cells are useful for testing agents for effects on the cells, for co-grafting with transplant organs, tissues or cells. The modified cells are also useful for enhancing the viability of thawing cells that have been cryo-preserved. In one embodiment, the modified cells are modified Sertoli cells.09-25-2008
20120058093METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS - Cells present in adipose tissue are used to treat patients, including patients with PVD and related diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit.03-08-2012
20100129332METHODS AND PHARMACEUTICAL COMPOSITIONS FOR HEALING WOUNDS - A pharmaceutical composition and method for inducing or accelerating a healing process of a skin wound are described. The pharmaceutical composition contains, as an active ingredient, a therapeutically effective amount of at least one agent for modulating PKC production and/or activation, and a pharmaceutically acceptable carrier. The method is effected by administering the composition to a wound.05-27-2010
20080274092Erythrocytes Containing Arginine Deiminase - Use of erythrocytes containing arginine deirainase for the preparation of a medicinal product for lowering the plasma concentration of arginine in vivo. Said use relates in particular to the treatment of arginine-dependent tumors, such as hepatocarcinoma and malignant melanoma, or inhibition of the synthesis of nitric oxide, and the prevention and/or treatment of septic shock.11-06-2008
20080274091Autologous T Cell Manufacturing Processes - The invention provides novel processes for manufacturing autologous T cells, transducing T cells and expanding the transduced T cell population.11-06-2008
20080286247METHOD FOR SELECTIVELY TRANSDUCING PATHOLOGIC MAMMALIAN CELLS USING A TUMOR SUPPRESSOR GENE - A method for transducing a pathologic hyperproliferative mammalian cell is provided by this invention. This method requires contacting the cell with a suitable retroviral vector containing a nucleic acid encoding a gene product having a tumor suppressive function. Also provided by this invention is a method for treating a pathology in a subject caused by the absence of, or the presence of a pathologically mutated tumor suppressor gene.11-20-2008
20080311091Engineered Dopamine Neurons and Uses Thereof - The invention relates to dopamine neuron determinants, the use of these determinants in differentiating cells to dopamine neurons, cells produced by the over-expression of these determinants, and uses of these cells.12-18-2008
20080311093STEM CELL SECRETIONS AND RELATED METHODS - Stem cell secretions are derived from epithelial cells conditioned media. The stem cell secretions are then applied topically, orally, or rectally, etc., to derive health benefits from the growth factors and other molecules comprising the stem cell secretion. The stem cell secretion may optionally be modified by covalently bonding fatty acids to protect the molecules through the delivery process and to make them more readily available to cells.12-18-2008
20080286248Hiv Vif Mutants - A polynucleotide comprising a nucleotide sequence encoding Vif, wherein each of the amino acids corresponding to positions 127, 128, 130, 131, 132 and 142 of the amino acid sequence in FIG. 11-20-2008
20110142811MEASLES VIRUS FOR THE ELIMINATION OF UNWANTED CELL POPULATIONS - The present invention concerns recombinant measles virus as a therapeutic, in particular a recombinant measles virus comprising a suicide gene in its genome, a mutated viral hemagglutinin, and a specificity domain specifically recognizing a cancer antigen. Furthermore, it relates to a polynucleotide coding for such a recombinant measles virus and a vector comprising said polynucleotide. The current invention also relates to a method for the manufacture of and a medicament comprising said recombinant measles virus, as well as a method for treating a solid tumor using said recombinant measles virus.06-16-2011
20090191170Nucleic acid compositions and methods of introducing nucleic acids into cells - The invention relates to a bifunctional nucleic acid which includes a first nucleic acid which comprises an aptamer bonded to a second nucleic acid that possesses a biological activity (herein referred to as a “biological effector sequence”) and which is not a nucleic acid ligand.07-30-2009
20080248009REGULATION OF ACHERON EXPRESSION - The invention relates to novel apoptosis-associated nucleic acids and polypeptides and methods for use thereof, including methods of treatment of disorders associated with aberrant cellular proliferation, differentiation, or degeneration. Included are methods of enhancing the success of cell transplantation and cell-based genetic therapy procedures.10-09-2008
20090092589METHODS FOR ENHANCED VIRUS-MEDIATED DNA TRANSFER USING MOLECULES WITH VIRUS- AND CELL-BINDING DOMAINS - A method to increase the efficiency of transduction of hematopoietic and other cells by retroviruses includes infecting the cells in the presence of fibronectin or fibronectin fragments. The fibronectin and fibronectin fragments significantly enhance retroviral-mediated gene transfer into the cells, particularly hematopoietic cells including committed progenitors and primitive hematopoietic stem cells. The invention also provides improved methods for somatic gene therapy capitalizing on enhanced gene transfer, hematopoietic cellular populations, and novel constructs for enhancing retroviral-mediated DNA transfer into cells and their use.04-09-2009
20100143315Method for Improving the Specific Effector Function of Single-Chain Antigen-Recognizing Genetic Constructs (SCARC) Through Murinization Thereof - The present invention relates to a method for producing a cell line expressing a stabilized functional single chain-antigen-recognizing genetic construct (scARC), comprising a genetic construct of the human scARC to be expressed, comprising the domains huV06-10-2010
20110206648Gene-enhanced tissue engineering - Provided are mammalian cells comprising a recombinant sonic hedgehog (SHH) gene such that a recombinant SHH protein can be expressed by the cell. Also provided are matrices suitable for applying to a tissue defect. Additionally provided are tissue regeneration compositions. Methods of regenerating tissue at the site of a tissue defect in a mammal are also provided.08-25-2011
20110268712Stem Cells Suitable for Transplantation, Their Preparation and Pharmaceutical Compositions Comprising Them - The present invention relates to stem cells suitable for transplantation and to methods for their preparation.11-03-2011
20090162333PHARMACEUTICAL COMPOSITION COMPRISING APOLIPOPROTEINS FOR THE TREATMENT OF HUMAN DISEASES - A pharmaceutical composition has an adequate pharmaceutical carrier or diluent and an element selected from a pharmaceutical composition having an adequate pharmaceutical carrier or diluent and an element selected from: —apolipoprotein apoL-III; —a pharmaceutically active fragment of this apolipoprotein apoL-III; —a nucleotide sequence encoding this apolipoprotein apoL-III or the fragment; —a vector having the nucleotide sequence; —a cell transformed by the nucleotide sequence or the vector; —an inhibitor or activator directed against the apolipoprotein apoL-III, its fragment or its nucleotide sequence, —an anti-inhibitor or anti-activator directed against the inhibitor or activator or its encoding nucleotide sequence.06-25-2009
20090162331COMPOSITIONS CONTAINING SERTOLI CELLS AND MYOID CELLS AND USE THEREOF IN CELLULAR TRANSPLANTS - The present invention relates to the use of Sertoli cells and myoid cells for creating an immunologically privileged site in a mammalian subject, thereby facilitating the transplantation of cells that produce a biological factor in the treatment of a disease that results from a deficiency of such biological factor. Pharmaceutical compositions containing Sertoli cells and myoid cells, as well as therapeutic methods relating to the use of these cells are provided by the present invention.06-25-2009
20090028837Methods for Altering the Reactivity of Plant Cell Walls - Methods and means are provided for the modification of the reactivity of plant cell walls, particularly as they can be found in natural fibers of fiber producing plants by inclusion of positively charged oligosaccharides or polysaccharides into the cell wall. This can be conveniently achieved by expressing a chimeric gene encoding an N-acetylglucosamine transferase, particularly an N-acetylglucosamine transferase, capable of being targeted to the membranes of the Golgi apparatus in cells of a plant.01-29-2009
20090186007USE OF CELLS DERIVED FROM ADIPOSE TISSUE FOR THE PREPARATION OF AN ANTI-TUMOR MEDICAMENT - Use of cells isolated from extramedullary white adipose tissue, selected from the group consisting of the stromal-vascular fraction and a subpopulation of said stromal-vascular fraction consisting of adherent cells, for the preparation of an anti-tumor medicament.07-23-2009
20090162332METHODS AND COMPOSITIONS FOR TREATING BRAIN DISEASES - The present disclosure provides targeting peptides and vectors containing a sequence that encodes targeting peptides that deliver agents to the brain.06-25-2009
20120070419METHOD OF ALTERING THE DIFFERENTIATIVE STATE OF A CELL AND COMPOSITIONS THEREOF - The present invention provides a method of altering the differentiative state of cells utilizing innovative protein expression constructs encoding transcription factors. The methods and compositions described herein may be used to generate induced pluripotent stem (iPS) cells, as well as differentiate, transdifferentiate or dedifferentiate cells of various epigenetic status. The method includes introduction of a nucleic acid construct, or expression product thereof, into a cell, and culture of the cell under culture conditions that efficiently converts the cell into a pluripotent cell, enhances the retention of the pluripotent state or efficiently converts the cell into a cell of a cell lineage corresponding to endoderm, mesoderm or ectoderm.03-22-2012
20090136466METHODS FOR MAKING SKIN CELL DERIVED STEM CELLS - The present invention relates to methods of deriving a stem cell from a skin cell.05-28-2009
20090136464Methods and compositions for cell therapy - Improved methods of cell therapy are provided using cells and tissues that are histocompatible with a human or non-human transplant recipient. The cells and tissues for transplant produced by the present invention exhibit a youthful state and can be committed to specific cell lineages to better infiltrate and proliferate at a desired target, e.g., a tissue, or organ in need of cell replacement therapy. For providing cells and tissues for transplant to a non-human mammal, the cells and tissues can be isolated from a gastrulating embryo produced by same-species nuclear transfer. Histocompatible cells and tissues for transplant to a human can be isolated from a gastrulating embryo that (i) is genetically modified to be in capable of developing beyond an early stage, or (ii) is produced by cross-species nuclear transfer between a human nuclear donor cell and an enucleated recipient cell, e.g., an oocyte, of a non-human mammal, or (iii) is produced by androgenesis or gynogenesis, or from pluripotent stem cells generated from such an embryo. Methods for producing histocompatible cells and tissues for transplant to a human can also be used to produce such cells or tissues for transplant to non-human mammals. The present invention also provides model embryonic systems having defined genetic makeup that are useful for developing and testing methods for cell and tissue therapy, and for studying genetic imprinting, reprogramming, rejuvenation, and other biochemical, metabolic, and physiological phenomena associated with embryogenesis.05-28-2009
20080317722Methods and Compositions Involving Developmental Decision Promoter Regions - The present invention concerns s-SHIP promoter and developmental decision promoter compositions and methods of using the promoter. It includes polynucleotides, vectors, host cells, and transgenic animal including a developmental decision promoter, for example, an s-SHIP promoter, controlling the expression of a heterologous nucleic acid. Methods of the invention concern methods of expressing a heterologous nucleic acid is a tissue-specific, developmental-specific, or temporally controlled manner. Other methods includes screening methods and therapeutic methods.12-25-2008
20090252715IMMORTALIZATION OF MAMMALIAN CELLS - Genomic instability in T antigen expressing cells can be overcome by modifying the gene expressing T antigen so that it lacks Bub1 binding. Stable cell lines can be produced by incorporation of the modified T antigen gene, preferably together with the catalytic sub-unit of the telomerase construct.10-08-2009
20090252714Autoantigenes for Improved Diagnosis, Prognosis and Treatment of Inflammatory Neurological Diseases - According to the invention, autoantibodies, the appearance of which is characteristic of neurological autoimmune diseases, especially multiple sclerosis, are detected and the respective autoantigens identified. It can further be shown that many of these autoantigens are expressed specifically in the brain. The identification of the autoantigens and autoantibodies is useful for diagnosis and treatment. A brain-specific expression of the autoantigens further emphasizes an important role of the antigens and antibodies in the origin and development of neurological autoimmune diseases.10-08-2009
20090053184COMPOSITIONS COMPRISING T CELL RECEPTORS AND METHODS OF USE THEREOF - Nucleic acids encoding antitumor TCRs recognizing MART-1, NY-ESO-1, and melanoma gp100 peptides; vectors and cells comprising the same; and methods of using the foregoing.02-26-2009
20110223144Creation of a Biological Atrioventricular Bypass to Compensate for Atrioventricular Block - A method of creating an atrioventricular bypass tract for a heart comprises growing mesenchymal stem cells into a strip with two ends, attaching one end of the strip onto the atrium of the heart, and attaching the other end of the strip to the ventricle of the heart, to create a tract connecting the atrium to the ventricle to provide a path for electrical signals generated by the sinus node to propagate across the tract and excite the ventricle.09-15-2011
20090081171Cell system for alleviating syndromes of Parkinson's disease in a mammal - A cell system for treating neurodegenerative disorders in a mammal is provided. The cell system includes a population of neurons differentiated from umbilical mesenchymal stem cells for expressing at least one of tyrosine hydroxylase (TH), dopamine-β-hydroxylase (DBH), glutamate decarboxylase (GAD), aromatic L-amino acid decarboxylase (AADC) and dopaminergic transporter (DAT) in a cell culture. A method for treating neurodegenerative disorders in a mammal is also provided. The method comprises the steps of differentiating umbilical mesenchymal stem cells into a population of neurons that express at least one of TH, DBH, GAD, AADC and DAT in a cell culture, and transplanting the population of neurons into the brain of the mammal.03-26-2009
20090202505Rescue of Photoreceptors by Intravitreal Administration of an Expression Vector Encoding a Therapeutic Protein - The invention provides methods for treating ocular diseases using a recombinant vehicle to express a protein useful in the treatment of ocular disease, with particular preference for use of neurotrophin-4 (NT4) for targeting subpopulations of cells in the retina. A genetically engineered gene transfer vector containing sequences encoding a growth factor such as neurotrophin-4 (NT4) is used to transduce cells of the retinal ganglion cell (RGC) layer, in situ, via administration of the vector intravitreally. Accordingly, methods are disclosed for treating subjects in need thereof by therapeutic protein delivery via a recombinant expression vector, including rescue of photoreceptors by targeting the RGC layer subpopulation of retinal cells.08-13-2009
20110229445METHOD FOR HEALING BONE FRACTURE USING TRANSFECTED CHONDROCYTES - The application discloses a method for making bone at a bone defect site for a person suffering from low bone mass which includes inserting a gene encoding a protein having bone regenerating function into a connective tissue cell operably linked to a promoter, and transplanting the mammalian cell into the bone defect site, and allowing the bone defect site to make the bone.09-22-2011
20090148424Reversibly immortalized mammalian liver cells and use thereof - The present invention provides a reversibly immortalized mammalian liver cell line, especially CYNK-1 (deposited with International Patent Organism Depository, National Institute of Advanced Industrial Science and Technology, address: AIST Tsukuba Central 6, 1-1, Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, 305-8566 Japan, deposited date: Mar. 10, 2004, accession number: FERM BP-08657) comprising an immortalizing gene interposed between a pair of site-specific recombination sequences and a suicide gene in the outside of the pair of site-specific recombination sequences, characterized in that the suicide gene can exhibit its function after excision of the pair of site-specific recombination sequences, or passage cell line thereof; a mammalian liver cell obtained by excising the immortalizing gene from the reversibly immortalized mammalian liver cell line or passage cell line thereof; and use of these cells. By utilizing the reversibly immortalized mammalian liver cell line of the present invention enables the obtainment of the number of the liver cells and utilization as materials for artificial liver reactors and cell preparations.06-11-2009
20090148425THERAPEUTIC METHOD FOR BLOOD COAGULATION DISORDER - The present invention provides agents for treating blood coagulation abnormalities, which contain as an active ingredient a lentiviral vector carrying a blood coagulation factor gene operably linked to a promoter which induces platelet-specific expression. Agents for treating hemophilia A or hemophilia B are provided by application of the gene encoding Factor VIII or Factor IX. Blood coagulation abnormalities can be treated by gene therapy by infecting hematopoietic stem cells or such with the therapeutic agents of the present invention.06-11-2009
20090004162Hecgf-1 Related Polymorphisms and Applications Thereof - The invention identifies tumor-associated antigens that may be used for immunotherapy of malignancies in patients having undergone an allogeneic stem cell transplantation, whereby the therapy is mediated by induction of a graft versus tumor immune response. The invention discloses minor histocompatibility antigens encoded by polymorphisms in reading frames present in the hECGF-1 gene. The invention provides peptides comprising polymorphic minor histocompatibility binding peptides or fragments, which may be in the context of an MHC molecule. The invention also provides T cell receptors and T lymphocytes capable of binding to these minor histocompatibility antigens, preferably in the context of MHC molecules. The molecules and cells of the invention can be used for treatment of subjects and manufacture of medicaments for the treatment of subjects suffering from malignancies expressing the hECGF-1 protein.01-01-2009
20090004163METHOD OF ENHANCING PROLIFERATION AND/OR HEMATOPOIETIC DIFFERENTIATION OF STEM CELLS - The present invention provides a method for enhancing the proliferation and/or hematopoietic differentiation and/or maintenance of mammalian stem cells. The method is useful for generating expanded populations of hematopoietic stem cells (HSCs) and thus mature blood cell lineages. This is desirable where a mammal has suffered a decrease in hematopoietic or mature blood cells as a consequence of disease, radiation or chemotherapy. The method of the present invention comprises increasing the intracellular level of a cdx in stem cells, including hematopoietic stem cells, in culture, either by providing an exogenous cdx protein to the cell, or by introduction into the cell of a genetic construct encoding a cdx. The cdx is selected from the cdx family and includes cdx1, cdx2, or cdx4. The cdx may be a wild type protein appropriate for the species from which the cells are derived, or a mutant form of the protein.01-01-2009
20090202504METHODS FOR THE DETECTION AND PROGNOSIS OF BREAST TUMORS - This invention relates to the production of specific antibodies for the detection of human tumor associated urokinase-type plasminogen activator receptor (uPAR) deletion variants in biological samples as well as to their diagnostic and therapeutic application.08-13-2009
20090220469PEPTIDES AGAINST AUTOANTIBODIES ASSOCIATED WITH GLAUCOMA AND USE OF THESE PEPTIDES - The invention relates to nucleic acid molecules encoding peptides which interact with autoantibodies associated with glaucoma, to the peptides themselves, to a pharmaceutical composition comprising said nucleic acid molecules and peptides, and to the use of said peptides—especially in apheresis—for the treatment of glaucoma.09-03-2009
20090220467USE OF TYPE II PNEUMOCYTES IN THE TREATMENT OF PULMONARY DISEASES ASSOCIATED WITH PULMONARY FIBROSIS - It describes the use of type II pneumocytes as inhibitory agents of fibroblast proliferation, for which reason they can be used in the preparation of a drug for the treatment of lung diseases which present with pulmonary fibrosis.09-03-2009
20080292602T Cell Receptors Which Specifically Bind to Vygfvracl-Hla-A24 - The present invention provides isolated T cell receptors (TCRs) having the property of specifically binding to the VYGFVRACL-HLA-A24 peptide-MHC. Such TCRs are useful, either alone or associated with a therapeutic agent, for targeting cancerous cells presenting the complex.11-27-2008
20090246183eNOS mutations useful for gene therapy and therapeutic screening - The present invention relates to new NOS variants or mutants which contain structural alterations in the site of Akt dependent phosphorylation. The altered NOS proteins or peptides, especially the human eNOS proteins or peptides, Akt proteins or polypeptides and their encoding nucleic acid molecules are useful as gene therapy agents for the treatment of diseases including post angioplasty restenosis, hypertension, atherosclerosis, heart failure, diabetes and diseases with defective angiogenesis. NOS proteins and peptides are also useful in methods of screening for agents which modulate NOS activity.10-01-2009
20100015108Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA - Disclosed are cells and methods for treating or preventing tumor formation or infections with pathogens in a patient. The cells of the invention are antigen-presenting cells (e.g., dendritic cells or macrophage) that have been loaded with RNA derived from tumors or pathogens. By administering the RNA-loaded antigen-presenting cells to a patient, tumor formation or pathogen infections can be treated or prevented. Alternatively, the RNA-loaded cells can be used as stimulator cells in the ex vivo expansion of CTL. Such CTL can then be used in a variation of conventional adoptive immunotherapy techniques.01-21-2010
20100003226Methods and Compositions for Treating Disease - The present invention relates to methods and compositions for treating a subject comprising destroying diseased cells in the subject. The methods comprise obtaining a population of cells from a subject and determining the activity of at least one disease marker gene within the population of the obtained cells. A polynucleotide molecule that encodes a polypeptide that is lethal to the cells is then introduced into the cells, where the expression of the lethal polypeptide is controlled by the promoter of at least one of the disease marker genes previously identified. After introduction of the polynucleotide, the cells are treated with conditions to induce expression of the lethal polypeptide to destroy the cells that are expressing the disease marker gene(s). After destruction of the diseased cells, the remaining live cells, which did not express the lethal polypeptide to an extent necessary to kill the cells, are separated from the dead cells, and the live cells are restored to the subject.01-07-2010
20100150888CELLS FOR JOINT FLUID - Disclosed are methods of enhancing recovery from joint surgery, comprising administering to the joint during surgery a composition comprising stem or progenitor cells in an amount effective to enhance recovery, and a pharmaceutically acceptable carrier.06-17-2010
20100150885METHODS AND COMPOSITIONS FOR INDUCING BROWN ADIPOGENESIS - Methods and compositions for treating obesity and related disorders. The methods include the use of stem cells treated with BMP-2, -4, -5, -6 and/or -7.06-17-2010
20100150884Anticancer Agent to Be Combined with Telomelysin - The present invention relates to providing a pharmaceutical composition with a still more enhanced anticancer activity. Specifically, the present invention relates to a pharmaceutical composition for combination therapy for tumors, comprising a recombinant virus comprising a polynucleotide containing a promoter for human telomerase, an E1A gene, an IRES sequence and an E1B gene in this order, and a substance having an antitumor effect.06-17-2010
20100178280USE OF SIRT7 FOR TREATING AGE-RELATED DISEASES - The present invention relates to a pharmaceutical composition comprising (i) a nucleic acid molecule encoding a protein having Sirt7 function wherein said nucleic acid molecule (a) has the sequence of SEQ ID NO: 1, 3, 5 or 7; (b) encodes a protein having the sequence of SEQ ID NO: 2, 4, 6 or 8; (c) hybridizes under stringent conditions to the molecule of (a) or (b); or (d) has an identity on the nucleic acid level of at least 80% with the molecule of (a), (b) or (c); (ii) a vector comprising the nucleic acid molecule of (i); (iii) a host cell comprising the vector of (ii); or (iv) a protein encoded by the nucleic acid molecule of (i). The pharmaceutical composition is used for example in the treatment of age-related diseases. Furthermore, the invention relates to screening methods for the identification of compounds useful in the treatment of age-related diseases.07-15-2010
20100183572CELL CAPABLE OF EXPRESSING LACRITIN AT HIGH LEVEL - The present invention relates to a means that allows supplying lacritin stably and in large amounts, and provides a vector containing polynucleotide that encodes lacritin, wherein said nucleotide is operatively linked to a cytomegalovirus immediate early enhancer/promoter and an SV40 late polyA signal, a lacritin-expressing cell prepared by introducing the vector into a cell, a method of producing recombinant lacritin, including the step of culturing the lacritin-expressing cell in a medium, and the step of isolating lacritin in the culture supernatant, and an agent for treating ocular disease containing the lacritin-expressing cell.07-22-2010
20100189701METHODS AND COMPOSITIONS TO TREAT ARRHYTHMIAS - The present invention provides compositions and methods of treatment for atrial fibrillation and ventricular tachycardia. The compositions are useful for modifying the conducting properties of heart tissues in which impulses are generating and/or are useful for altering refractoriness without prolonging repolarization.07-29-2010
20100260731PROPAGATION OF PRIMARY CELLS AND THE USE THEREOF - The invention relates to a method for propagating or concentrating primary cells without tumorous characteristics and to the subsequent use thereof.10-14-2010
20100260732ROLE FOR SRY IN PARKINSON'S DISEASE - The present invention relates to a method for treating or preventing Parkinson's disease in a patient, the method comprising administering to the patient a therapeutically effective population of neuronal cells transformed with a nucleic acid molecule encoding SRY, wherein the transformed cells express SRY.10-14-2010
20110129450METHOD OF PROMOTING NEUROGENESIS BY MODULATING SECRETASE ACTIVITIES - This invention provides methods and reagents for promoting neurogenesis, by modulating neural stem cell proliferation and differentiation. Particularly, this invention provides methods and reagents for promoting neurogenesis in a patient's central nervous system where the patient suffers from an aging-related neurodegenerative disease. Specifically, the invention provides methods for promoting neurogenesis comprising modulating the α and/or γ-secretase activities.06-02-2011
20110104129T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE - The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a cancer antigen, e.g., a renal cell carcinoma antigen, wherein the TCR recognizes the cancer antigen in a major histocompatibility complex (MHC)-independent manner. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials.05-05-2011
20100226898COMPOSITIONS AND METHODS FOR ENGRAFTMENT AND INCREASING SURVIVAL OF ADULT MUSCLE STEM CELLS - Embodiments herein relate to compositions and methods for engraftment of and increasing survival of muscle cells in a subject in need thereof. In certain embodiments, compositions including myofibers and/or satellite stem cells may be administered to a subject. Other embodiments relate to compositions and methods for introducing one or more compounds to a subject using cell compositions disclosed herein. Still other embodiments relate to uses of these compositions in kits for portable applications and methods.09-09-2010
20120195865TRANSPLANTATION OF BONE MARROW STROMAL CELLS FOR TREATMENT OF NEURODEGENERATIVE DISEASES - The present invention relates to a treatment of an autoimmune demyelinating disease/disorder. Also included in the present invention is the use of bone marrow stromal cells for the treatment of multiple sclerosis (MS).08-02-2012
20120195864CELLS GENETICALLY MODIFIED TO COMPRISE PANCREATIC ISLET GLUCOKINASE AND USES THEREOF - The present invention relates generally to a population of cells genetically modified to comprise pancreatic islet glucokinase and capable of producing insulin in a glucose responsive manner and uses thereof. More particularly, the present invention relates to a population of cells so genetically modified capable of producing insulin in response to physiologically relevant levels of glucose and uses thereof. The cells of the present invention are useful in a wide variety of applications, in particular in the context of therapeutic and prophylactic regimes directed to the treatment of diabetes and/or the amelioration of symptoms associated with diabetes, based on the transplantation of the cells of the present invention into mammals requiring treatment. Also facilitated is the design of in vitro based screening systems for testing the therapeutic effectiveness and/or toxicity of potential adjunctive treatment regimes.08-02-2012
20110059057KERATINOCYTES EXPRESSING EXOGENOUS ANGIOGENIC GROWTH FACTORS - The present invention relates to in vitro cultured skin tissue, and in particular to cultured skin tissue comprising exogenous genes encoding angiogenic growth factors. In some embodiments, the keratinocytes express exogenous angiopoietin-1, HIF-1α, or a member of the VEGF family, preferably VEGF-A. In particularly preferred embodiments, the keratinocytes are incorporated into cultured skin tissue.03-10-2011
20110059056Method for the Generation of Genetically Modified Vertebrate Precursor Lymphocytes and Use Thereof for the Production of Heterologous Binding Proteins - The present invention generally relates to the fields of genetic engineering and antibody production. In particular, it relates to the generation of genetically modified vertebrate precursor lymphocytes that have the potential to differentiate into more mature lymphoid lineage cells, and to the use thereof for the production of any heterologous antibody or binding protein.03-10-2011
20130216509CHIMERIC RECEPTORS WITH 4-1BB STIMULATORY SIGNALING DOMAIN - The present invention relates to a chimeric receptor capable of signaling both a primary and a co-stimulatory pathway, thus allowing activation of the co-stimulatory pathway without binding to the natural ligand. The cytoplasmic domain of the receptor contains a portion of the 4-1BB signaling domain. Embodiments of the invention relate to polynucleotides that encode the receptor, vectors and host cells encoding a chimeric receptor, particularly including T cells and natural killer (NK) cells and methods of use.08-22-2013
20100239546BACTERIAL MEDIATED TNF ALPHA GENE SILENCING - Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating an inflammatory disease or disorder. The bacterium includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells.09-23-2010
20110129449COMPENSATING FOR ATRIOVENTRICULAR BLOCK USING A NUCLEIC ACID ENCODING A SODIUM CHANNEL OR GAP JUNCTION PROTEIN - A method of increasing the velocity of AV conduction in a mammal that may be in heart block or at risk of heart block by causing, in an AV node and/or His bundle having less than normal conduction speed, the expression of a sodium channel or gap junction protein, such as the SkM-1 channel, Cx43 or Cx32, so as to increase the velocity of conduction by the AV node.06-02-2011
20120141440FOAMYVIRUS VECTORS AND METHODS OF USE - The disclosure of the present application provides foamyvirus vectors, as well as methods and kits involving the same. In at least one embodiment, a plurality of recombinant vectors comprises an expression sequence encoding at least one component of a foamyvirus particle, wherein at least one codon of the expression sequence is optimized for expression in 06-07-2012
20090252713CIRCULAR DNA MOLECULE HAVING A CONDITIONAL ORIGIN OF REPLICATION, PROCESS FOR THEIR PREPARATION AND THEIR USE IN GENE THERAPY - A circular DNA molecule, useful for gene therapy, comprising at least one nucleic acid sequence of interest, characterised in that the region allowing the replication thereof has an origin of replication with a functionality in a host cell that requires the presence of at least one specific protein foreign to said host cell. A method for preparing same, cells incorporating said DNA molecules and uses thereof in gene therapy are also described.10-08-2009
20120141442MEANS AND METHODS FOR COUNTERACTING, DELAYING AND/OR PREVENTING ADVERSE ENERGY METABOLISM SWITCHES IN HEART DISEASE - The invention relates to the fields of molecular biology and medicine, more specifically to treatment and prevention of heart disease. The invention provides alternative methods for counteracting, diminishing, treating, delaying and/or preventing heart disease.06-07-2012
20120141441Methods and Compositions for Treatment of Muscular Dystrophy - The present disclosure provides methods for introducing a gene encoding a muscle membrane protein into a cell isolated from a subject to generate a genetically modified cell. The genetically modified cell may be introduced back, e.g., engrafted into the subject. The isolated cell may be additionally modified by introducing into the isolated cell a gene encoding one or more reprogramming transcription factors that induce the cell to form an induced pluripotent stem cell. The genetically modified cell may be differentiated in vitro to form muscle cell precursors before engrafting into the subject. Also provided are compositions comprising autologous cells isolated from a subject which cells comprise a muscle membrane protein gene integrated into a genome attachment site in the genome of the cell. The autologous cell may be an induced pluripotent cell or a mesenchymal stem cell, such as an adipose-derived mesenchymal stem cell (AD-MSC).06-07-2012
20100221232COMPOSITION AND METHODS FOR OSTEOGENIC GENE THERAPY - The present disclosure provides compositions and methods for increasing bone growth and/or enhancing wound healing, for example, fracture repair. The disclosure provides recombinant nucleic acids useful for promoting bone growth. For example, the disclosure provides recombinant nucleic acids that encode a fibroblast growth factor-2 (FGF-2) analog. The disclosure also provides vectors and cells incorporating these nucleic acids, as well as FGF-2 analogs encode by them. The disclosure also provides a mouse system of bone marrow transplantation and methods for producing as well as methods for using the system. Methods for inducing division and/or inducing differentiation of a hematopoietic stem cell are also provided, as are methods for enhancing bone growth and/or wound repair (for example, fracture repair).09-02-2010
20090074734MICROBIAL INTESTINAL DELIVERY OF OBESITY RELATED PEPTIDES - Microbial delivery of obesity related peptides is disclosed. Genetically modified yeasts and/or lactic acid bacteria are described for the delivery of neuropeptides and/or peptide hormones that play a role in stimulation or inhibition of food intake and/or energy homeostasis.03-19-2009
20120034197HIV-RESISTANT STEM CELLS AND USES THEREOF - Disclosed are recombinant stem cells that are resistant to HIV infection. Also disclosed are their uses in treating AIDS.02-09-2012
20120195866PKD Ligands and Polynucleotides Encoding PKD Ligands - The invention relates to kinase ligands and polyligands. In particular, the invention relates to ligands, homopolyligands, and heteropolyligands that modulate protein kinase D (PKD) activity. The ligands and polyligands are utilized as research tools or as therapeutics. The invention includes linkage of the ligands and polyligands to cellular localization signals, epitope tags and/or reporters. The invention also includes polynucleotides encoding the ligands and polyligands.08-02-2012
20090220468Specific CD4+CD25+ Regulatory T Cells for Haematopoietic Cell Transplantation and Immune Tolerance - A pharmaceutical composition comprising CD4+ CD25+ regulatory T cells specific for at least one minor histocompatibility antigen, and stem cells, advantageously haematopoietic, carrying at least the antigen can be used as a medicament for increasing the immune tolerance of a histocompatible host.09-03-2009
20110027241Intraperitoneal Delivery of Genetically Engineered Mesenchymal Stem Cells - A method of expressing at least one protein in an animal by intraperitoneal administration of mesenchymal stem cells genetically engineered with at least one polynucleotide encoding the at least one protein. The method may be employed in treating lysosomal storage disorders, such as Fabry Disease, or arthritic disorders, or hemophilia, for example.02-03-2011
20090130070METHOD OF TREATMENT - The present invention discloses the use of fetuin and fetuin producing agents in methods and compositions for treating burn injuries in animals.05-21-2009
20080292603TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES USING GENE THERAPY - Provided herein are compositions and methods for treating and/or preventing neurodegenerative disease, such as Alzheimer's disease. In particular aspects, compositions administered herein encode a cellular immune response element. The compositions may be prepared and administered in such a manner that the cellular immune response element coding sequence is expressed in the subject to which the composition is administered. The compositions include expression systems, delivery systems, and certain cellular immune response element genes.11-27-2008
20080286249USE OF MESENCHYMAL STEM CELLS FOR TREATING GENETIC DISEASES AND DISORDERS - A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal.11-20-2008
20080274093METHOD OF DIMINISHING THE SYMPTOMS OF NEURODEGENERATIVE DISEASE - A method of diminishing the symptoms of neurodegenerative disease in a patient is disclosed. In one embodiment, the method comprises the steps of: (a) identifying a patient with a neurodegenerative disease, (b) producing a cell culture, wherein the cell culture comprises cells with induced antioxidant response element (ARE) mediated transcription, and (c) transplanting at least a portion of the cell culture into the brain of the patient, wherein symptoms of neurodegenerative disease are diminished.11-06-2008
20100303776Methods and compositions for regulated expression of multiple nucleic acids - The present invention provides a cell comprising a first heterologous nucleic acid construct and a second heterologous nucleic acid construct, wherein each of said first and second heterologous nucleic acid constructs comprises: A. a first nucleotide sequence encoding a nucleotide sequence of interest (NOI); and B. a second intronic nucleotide sequence comprising: i) a first set of splice elements defining a first intron that is removed by splicing to produce a first RNA molecule encoded by said first nucleotide sequence in the absence of activity at a second set of splice elements; and ii) the second set of splice elements defining a second intron different from said first intron, wherein said second intron is removed by splicing to produce no RNA molecule and/or to produce a second RNA molecule that is not encoded by said first nucleotide sequence, wherein each said first nucleotide sequence of each of said first and second heterologous nucleic acid constructs is different from one another and wherein each said second intronic nucleotide sequence of each of said first and second heterologous nucleic acid constructs is different from one another.12-02-2010
20100303775Generation of Genetically Corrected Disease-free Induced Pluripotent Stem Cells - Methods and compositions for the generation and use of genetically corrected induced pluripotent stem cells are provided.12-02-2010
20090214496BMX/ETK TYROSINE KINASE GENE THERAPY MATERIALS AND METHODS - The present invention relates to materials and methods for the treatment of arterial diseases having impaired arteriogenesis and angiogenesis. More particularly, the invention provides materials and methods for treating arterial disease using a gene therapy vector expressing Bmx tyrosine kinase.08-27-2009
20090214494Cancer Vaccines and Therapeutic Methods - Compositions and methods of producing improved cancer vaccines are described. In addition, methods of identifying tumor associated antigens are also described.08-27-2009
20110110903CELL FUSION PROMOTER AND UTILIZATION OF THE SAME - It is intended to provide a regeneration promoter for regenerating a tissue with the use of somatic stem cells. It is also intended to provide a cell fusion promoter safely usable in vivo. Namely, it is intended to provide a cell fusion promoter comprising ATP or its metabolite. A cell fusion promoter comprising ATP or its metabolite and a method of producing fused cells in the presence of ATP or its metabolite. A medicinal composition for regenerating or improving the function of a tissue or an organ, which suffers from dysfunction or hypofunction due to injury or denaturation, by using stem cells. This composition comprises ATP or its metabolite and a pharmaceutically acceptable carrier.05-12-2011
20110008302Compositions and methods for immortalizing cells and screening for anti-cancer agents - An embodiment of the invention provides methods and compositions for immortalizing cells, and in another embodiment for reversing immortalization of cells. Methods for screening for anti-cancer agents by identifying compounds that bind to and inhibit activity of an Ndy protein are also provided. Novel cancer diagnostic and prognostic methods using Ndy1, Ezh2 and miR-101 are shown with samples of tissue or cell lines from cancers of lung, colon, ovary, bladder and transitional cell carcinoma.01-13-2011
20090068159Insecticidal Compositions and Methods for Making Insect-Resistant Transgenic Plants - The present invention provides isolated polynucleotide sequences encoding ET37, TIC810 and TIC812 proteins from 03-12-2009
20090068158THYMIDYLATE KINASE MUTANTS AND USES THEREOF - The invention relates to a composition comprising: a stably integrating delivery vector; a modified mammalian thymidylate kinase (tmpk) wherein the modified mammalian tmpk increases phosphorylation of a prodrug relative to phosphorylation of the prodrug by wild-type human tmpk. The invention also relates to use of these compositions in methods of treatment of diseaseuuius such as graft versus host disease and cancer.03-12-2009
20110243904RNA INTERFERENCE TARGET FOR TREATING AIDS - The present invention relates to RNA interference target sequence targeting HIV for the treatment of AIDS. Based on the target sequence, recombinant expression vectors, packaging vectors and cells were constructed, which express a siRNA and/or a miRNA and/or a ribozyme and/or an antisense oligonucleotide targeting HIV. Also provided is the use of the recombinant expression vectors, packaging vectors and recombinant cells in the manufacture of a medicament for the treatment of AIDS.10-06-2011
20110033429Inducible Gene Expression - The invention relates to vector constructs for an HIV-specific gene therapy. The expression of transgenes is coupled with an infection of the cell with HIV while the transcription of the transgene is controlled by a transcription control region derived from HIV. In addition, the transgene is improved with regard to RNA stability and expression efficiency by modifying the nucleotide sequence.02-10-2011
20110033430METHODS FOR THE INDUCTION OF A CELL TO ENTER THE ISLET 1+ LINEAGE AND A METHOD FOR THE EXPANSION THEREOF - The present invention relates to methods for the induction and a cell to enter the Islet 102-10-2011
20110117067Glucanases, Nucleic Acids Encoding Them and Methods for Making and Using Them - The invention relates to polypeptides having glucanase, e.g., endoglucanase, mannanase, xylanase activity or a combination of these activities, and polynucleotides encoding them. In one aspect, the glucanase activity is an endoglucanase activity (e.g., endo-1,4-beta-D-glucan 4-glucano hydrolase activity) and comprises hydrolysis of 1,4-beta-D-glycosidic linkages in cellulose, cellulose derivatives (e.g., carboxy methyl cellulose and hydroxy ethyl cellulose) lichenin, beta-1,4 bonds in mixed beta-1,3 glucans, such as cereal beta-D-glucans or xyloglucans and other plant material containing cellulosic parts. In addition, methods of designing new enzymes and methods of use thereof are also provided. In alternative aspects, the new glucanases e.g., endoglucanases, mannanases, xylanases have increased activity and stability, including thermotolerance or thermostability, at increased or decreased pHs and temperatures.05-19-2011
20100135970Methods for Reprogramming Adult Somatic Cells and Uses Thereof - As described below, the present invention features methods for reprogramming somatic cells and related therapeutic compositions and methods.06-03-2010
20100111910Treatment of excessive neovascularization - The present invention relates to methods of treating or preventing angiogenesis-related diseases by the administration of stem cells and/or progeny cells thereof.05-06-2010
20100034790Use of materials for treatment of central nervous system lesions - Disclosed are methods and materials for treatment of central nervous system lesions. Preferred methods and materials comprise neuronal precursor cells and/or marrow adherent stem cell-derived neuronal cells.02-11-2010
20100034788Method for diagnosing and treating bone-related diseases - The present invention relates to the field of molecular biology and medicine. The present invention relates to the use of polynucleotides encoding a mammalian PLEKHM1 polypeptide and the polypeptides encoded by these polynucleotides for regulating bone homeostasis and for diagnostic and/or therapeutic applications. The present invention further relates to vectors, host cells, antibodies, diagnostic and therapeutic methods for detecting and treating diseases, in particular bone-related diseases.02-11-2010
20100040589Novel Compositions and Uses Thereof - The present invention provides a cellular vaccine for therapeutic or prophylactic treatment of a pathological condition, the vaccine comprising or consisting of a population of CD 402-18-2010
20100055080BIOADHESIVE DIRECTED SOMATIC CELL THERAPY - The subject invention is related to a cell-mediated gene therapy treatment using a cell composition that includes bioadhesive material. The bioadhesive material allows targeted and localized delivery of therapeutic somatic cells to the site of interest.03-04-2010
20110081327TRANSIENT EXPRESSION OF IMMUNOMODULATORY POLYPEPTIDES FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE DISEASE, ALLERGY AND TRANSPLANT REJECTION - A method is provided for treating or preventing an undesired immune response in a patient, comprising: administering to said patient, cells that transiently express, and/or that are transfected with mRNA encoding, one or more polypeptides selected from the group consisting of an IL-4 receptor agonist, an IFN-γ receptor antagonist, an IFN-α receptor antagonist, an IL-12 receptor antagonist, an IL-23 receptor antagonist, and a TNF antagonist. Preferably, the cells selectively accumulate in one or more secondary lymphoid tissues at or proximate to the site of the undesired immune response. Related compositions are provided. The methods and compositions are useful for the treatment or prevention of undesired immune responses including, but not limited to, transplant rejection, autoimmune disease, allergy and immune responses directed against therapeutic compositions.04-07-2011
20110104130THYMIDYLATE KINASE FUSIONS AND USES THEREOF - The application relates to a composition comprising: a stably integrating delivery vector; a modified mammalian thymidylate kinase (tmpk) wherein the modified mammalian tmpk increases phosphorylation of a prodrug relative to phosophorylation of the prodrug by wild-type human tmpk; and a detection cassette fused to tmpk. The application also relates to use of these compositions in methods of treatment of diseases such as graft versus host disease and cancer.05-05-2011
20110104128Device and Method for Transfecting Cells for Therapeutic Use - This invention generally relates to devices and methods for transfection of living cells using electroporation, in particular high throughput microfluidic electroporation, and to therapeutic uses of the transfected cells.05-05-2011
20110150849Tumor-associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules - The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.06-23-2011
20110150850REDUCED COLONIZATION OF MICROBES AT THE MUCOSA - The invention is in the field of use of engineered microbes for the delivery and administration of therapeutic peptides or proteins to humans or animals suffering from a disease, or the use of engineered microbes for the delivery of antigens such as for vaccination purposes. More in particular, the invention relates to a recombinant microbe that has reduced capacity of colonizing the mucosa in comparison to its wild type ancestor, in particular when residing in the alimentary tract as part of a treatment or vaccination of a human or animal. In particular, the recombinant microbe contains an inactive thymidylate synthase gene that causes the reduced capability for the microbe to colonize in the alimentary tract. The invention also covers the use of said recombinant microbes comprising nucleic acids or vectors for expressing heterologous or homologous proteins; and also for delivery, especially therapeutic delivery, of the said proteins to animals or humans.06-23-2011
20130164271TAILORED RECOMBINASE FOR RECOMBINING ASYMMETRIC TARGET SITES IN A PLURALITY OF RETROVIRUS STRAINS - The present invention relates to a method for preparing an expression vector encoding a tailored recombinase, which tailored recombinase is capable of recombining asymmetric target sequences within the long terminal repeat (LTR) of proviral DNA of a plurality of retrovirus strains inserted into the genome of a host cell, as well as to the obtained expression vector, cells transfected with this, expressed recombinase and pharmaceutical compositions comprising the expression vector, cells and/or recombinase. Pharmaceutical compositions are useful, e.g., in treatment and/or prevention of retrovirus infection. In particular, asymmetric target sequences present in a plurality of HIV strains are disclosed, as well as tailored recombinases capable of combining these sequences (Tre 3.0 and 4.0) and expression vectors encoding them.06-27-2013
20100310532GENE TARGETS IN ANTI-AGING THERAPY AND TISSUE REPAIR - Novel gene and protein targets are described for treatment of cardiac disorders, anti-aging therapies and tissue repair. Identified biomarkers are prognostic of long term survival of patients suffering from heart diseases and related disorders.12-09-2010
20100297090HEMATOPOIETIC CELL CULTURE NUTRIENT SUPPLEMENT - The present invention provides a serum-free supplement which supports the growth of hematopoietic cells in culture. Also provided are a medium comprising a basal medium supplemented with the serum-free supplement of the present invention. The present invention also provides methods for culturing and for differentiating hematopoietic cells.11-25-2010
20100111913METHOD OF ENHANCING MIGRATION OF NEURAL PRECURSOR CELLS - There is provided methods relating to enhancing migration of a neural precursor cell by augmenting levels of TMEM18 protein in the neural precursor cell. Such methods may be used in the treatment of disorders, including treatment of a glioma or a neurodegenerative disorder.05-06-2010
20110250186METHODS FOR PROMOTING WOUND HEALING AND MUSCLE REGENERATION WITH THE CELL SIGNALING PROTEIN NELL1 - The present invention provides methods for promoting wound healing and treating muscle atrophy in a mammal in need. The method comprises administering to the mammal a Nell1 protein or a Nell1 nucleic acid molecule.10-13-2011
20120201794DUAL VECTOR FOR INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS - The present invention provides an expression vector for preventing or inhibiting HIV entry, fusion or replication in mammalian cells. In particular, the invention provides a recombinant retroviral vector that encodes an inhibitor of a HIV co-receptor, such as CCR5 or CXCR4, and a protein that inhibits HIV fusion to target cells and/or HIV replication. Pharmaceutical compositions comprising such constructs and methods of use thereof to prevent or treat HIV infection in a patient are also disclosed.08-09-2012
20090022699Method Of Genotypically Modifying Cells By Administration Of RNA - A method of inducing genotypic modification in a cell, which comprises providing isolated RNA comprising RNA extractable from source tissue to the cell under conditions whereby the desired induction of genotypic modification is achieved, wherein the RNA is isolated polyA positive RNA in substantially pure form.01-22-2009
20080248010Compositions and methods of using apoptosis signaling kinase related kinase (ASKRK) - The invention provides apoptosis signaling kinase related kinase (ASKRK) nucleic acid and polypeptide sequences and methods of using such sequences to identify modulators of ASKRK. Such modulators can be used for the treatment of diabetes or for delaying the onset of diabetes. The invention also provides methods of diagnosing diabetes or pre-diabetes and methods of making a prognosis based on the detection of ASKRK nucleic acids and proteins.10-09-2008
20090324562Defensin Proteins - This invention relates to the novel proteins, termed INSP108 and INSP109, herein identified as members of the defensin family of proteins and to the use of these proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease.12-31-2009
20090317368B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE - The invention provides novel polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides.12-24-2009
20120201793DERMAL MICRO-ORGANS, METHODS AND APPARATUSES FOR PRODUCING AND USING THE SAME - Embodiments of the present invention provide Dermal Micro-organs (DMOs), methods and apparatuses for producing the same. Some embodiments of the invention provide a DMO including a plurality of dermal components, which substantially retain the micro-architecture and three dimensional structure of the dermal tissue from which they are derived, having dimensions selected so as to allow passive diffusion of adequate nutrients and gases to cells of the DMO and diffusion of cellular waste out of the cells so as to minimize cellular toxicity and concomitant death due to insufficient nutrition and accumulation of waste in the DMO. Some embodiments of the invention provide methods and apparatuses for harvesting the DMO. An apparatus for harvesting the DMO may include, according to some exemplary embodiments, a support configuration to support a skin-related tissue structure from which the DMO is to be harvested, and a cutting tool able to separate the DMO from the skin-related tissue structure. Other embodiments are described and claimed.08-09-2012
20120201792METHODS AND PRODUCTS FOR MANIPULATING HEMATOPOIETIC STEM CELLS - The invention relates to methods for manipulating hematopoietic stem cells and related products. In one aspect the invention relates to the use of stem cell G-protein coupled receptor (SC-GPR) related compositions to identify bone marrow derived hematopoietic stem cells, to enhance mobilization of hematopoietic stem cells, to improve the efficiency of targeting cells to the bone marrow and/or to modulate hematopoietic cell function.08-09-2012
20090010901PRIMARY CULTURED ADIPOCYTES FOR GENE THERAPY - The present invention relates to primary cultured adipocytes for gene therapy, where the adipocytes stably maintain a foreign gene encoding a protein that is secreted outside of cells. This invention provides cells suitable for gene therapy, which can replace bone marrow cells and liver cells used for conventional ex vivo gene therapy. The present invention established methods for transferring foreign genes into primary cultured adipocytes, which are suitable for ex vivo gene therapy; can be easily collected and implanted; and can be removed after implantation. Specifically, the present invention established these methods that use retroviral vectors. The present invention also established primary cultured adipocytes for gene therapy, where the adipocytes stably maintain a foreign gene encoding a protein that is secreted outside of cells.01-08-2009
20080279831METHODS AND COMPOSITIONS FOR IDENTIFYING PROSTATE CANCER OR A HUMORAL IMMUNE RESPONSE AGAINST PROSTATE CANCER - The present invention relates to prostate cancer markers, compositions comprising such markers, immunoglobulins specific for such markers, and methods of using such markers and/or immunoglobulins to assess an immune response against prostate cancer. An immune response against the markers correlates with an immune response, in particular a humoral immune response, against prostate cancer cells which immune response is preferably associated with prophylaxis of prostate cancer, treatment of prostate cancer, and/or amelioration of at least one symptom associated with prostate cancer.11-13-2008
20080279832OSTEOGENIC DIFFERENTIATION OF PREOSTEOBLASTIC CELLS - The application discloses a method for making bone at a bone defect site which includes generating a member of a transforming growth factor superfamily of proteins; generating a population of cultured connective tissue cells that may contain a vector encoding a gene, or a population of cultured connective tissue cells that do not contain any vector encoding a gene; and transferring the protein and the connective tissue cells of to the bone defect site, and allowing the bone defect site to make the bone.11-13-2008
20110177043METHOD OF IMPROVING DIFFERENTIATION OF CHONDROGENIC PROGENITOR CELLS - We disclose a method of promoting cartilage, bone or ligament repair or inducing repair or regeneration of chondral tissue, the method comprising enhancing the expression or activity of ZNF145 or a fragment, homologue, variant or derivative thereof in an chondrogenic progenitor cell, for example a mesenchymal stem cell. We also provide for a chondrogenic progenitor cell, for example a mesenchymal stem cell (MSC) engineered to increase expression or activity of ZNF145 or a fragment, homologue, variant or derivative thereof.07-21-2011
20080267930Biological Materials and Uses Thereof - A method of producing a reprogrammed cell or reprogrammed cell nucleus, comprising exposing a differentiated cell, or the nucleus of a differentiated cell to a cell or cell extract thereof derived from an oocyte, egg, ovary or early embryo of a cold blooded vertebrate, wherein the cold blooded vertebrate has one or more of the following properties: (i) a primitive vertebrate body plan including laterally projecting ribs and/or spinal projections; (ii) germ cells which do not contain germ plasm; and/or (iii) the oocyte, egg, ovary or early embryo cell or cell from which the cell extract is derived, expresses a highly conserved form of Oct-4 and/or nanog. There is also provided uses of the reprogrammed cells.10-30-2008
20080267931Compositions for Silencing the Expression of Vdac1 and Uses Thereof - The present invention relates generally to the down regulation of mitochondrial protein, voltage-dependent anion channel (VDAC1), expression by RNAi or antisense therapy. In particular, the present invention is directed to VDAC1 silencing molecules useful in regulating cell proliferation and to pharmaceutical compositions comprising same useful in the treatment of diseases associated with aberrant cell proliferation.10-30-2008
20080267929Use of stem cells to generate inner ear cells - This invention relates generally to methods and compositions for inducing stem cell or progenitor cell differentiation, and more particularly to methods and compositions for inducing differentiation of stem cells and/or progenitor cells into cells that function within the inner ear.10-30-2008
20080267928Compositions and Methods for Making Insulin-Producing Cells - An insulin-producing cell made by delivering a combination of at least two transcription factors, such as Pdx-1 and Pax4, to a liver cell. Cells according to the invention can be used to reduce an insulin insufficiency in a diabetic subject.10-30-2008
20080219959Support Having Nanostructured Titanium Dioxide Film And Uses Thereof - The present invention relates to supports for bioassays and the use thereof in cell culturing and in cell-based methods and assays. More precisely, the invention provides solid materials coated with films of nanostructured titanium dioxide suitable for the immobilisation of viruses and for cell-adhesion. The nanostructured TiO2 film-coated support of the invention is particularly useful for the preparation of microarrays for genetic and phenotypic analysis.09-11-2008
20080241114Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or T cell subset activity by modulation of XBP-1 activity - The invention demonstrates that the transcription factor XBP-1 is a regulator of hepatocyte growth, plasma cell differentiation and T cell subset activity. Methods for identifying modulators of hepatocyte growth, plasma cell differentiation and/or T cell subset activity, using XBP-1-containing indicator compositions or XBP-1-deficient cells, are provided. Methods of modulating hepatocyte growth, plasma cell differentiation and/or T cell subset activity (e.g., Th2 cytokine production) using agents that modulate the activity of XBP-1 are also provided. Methods for diagnosing disorders associated with aberrant hepatocyte growth, plasma cell differentiation and/or T cell subset activity, by assessing a change in XBP-1 expression, are also provided. XBP-1 deficient cells, animals and embryos, as well as kits for the methods of the invention, are also provided by the invention.10-02-2008
20080213234USE OF OSTEOPONTIN FOR THE TREATMENT AND/OR PREVENTION OF NEUROLOGIC DISEASES - The invention relates to the use of osteopontin, or of an agonist of osteopontin activity, for treatment or prevention of a neurologic diseases.09-04-2008
20110165133METHOD OF DE-DIFFERENTIATING AND RE-DIFFERENTIATING SOMATIC CELLS USING RNA - RNA prepared by in vitro transcription using a polymerase chain reaction (PCR)-generated template can be introduced into a cell to modulate cell activity. This method is useful in de-differentiating somatic cells to pluripotent, multipotent, or unipotent cells; re-differentiating stem cells into differentiated cells; or reprogramming of somatic cells to modulate cell activities such as metabolism. Cells can also be transfected with inhibitory RNAs, such as small interfering RNA (siRNA) or micro RNA (miRNA), or combinations thereof to induce reprogramming of somatic cells. For example, target cells are isolated from a donor, contacted with one or more RNA's causing the cells to be de-differentiated, re-differentiated, or reprogrammed in vitro, and administered to a patient in need thereof. The resulting cells are useful for treating one or more symptoms of a variety of diseases and disorders, for organ regeneration, and for restoration of the immune system.07-07-2011
20110020300COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF GLUCOCORTICOID RECEPTOR (GCR) GENES - This invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a GCR gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a GCR gene using said pharmaceutical composition; and methods for inhibiting the expression of GCR in a cell.01-27-2011
20110020301USE OF S-ADENOSYLMETHIONINE (SAM) AND SUPEROXIDE DISMUTASE (SOD) FOR THE PREPARATION OF MEDICAMENTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE - The use of S-adcnosylmcthioninc (SAM) in combination with supcmxidc dismutase (SOD) for the preparation of medicaments for the treatment of Alzheimer's disease.01-27-2011
20110027240SECRETABLE HIV ENTRY INHIBITORY PEPTIDES FOR THERAPY OF HIV INFECTION - The invention relates to gene therapy of HIV infection by providing to a patient a nucleic acid for the expression of in vivo secretable peptides that prevent entry of the virus into the cell. The invention makes available nucleic acids and vectors containing the same that code for a fusion protein which contains two HIV entry inhibitory peptides which are connected by a cleavable linker, wherein the peptides are preferably derived from the second (C) heptad repeat of the gp41 protein of HIV.02-03-2011
20110027242METHOD FOR PRODUCTION OF TRANSFECTED CELL - Disclosed is a method for producing a cell population into which a desired gene is introduced, which is characterized by comprising the following steps (1) and (2): (1) culturing a cell population containing a T-cell and/or a progenitor cell of a T-cell in a vessel containing fibronectin or a fragment thereof and a CD3 ligand; and (2) adding a vector carrying the desired gene to the vessel of the step (1). By carrying out both the steps (1) and (2) in the same vessel, the gene transfer can be achieved with high efficiency.02-03-2011
20100284978CULTURES, PRODUCTS AND METHODS USING UMBILICAL CORD MATRIX CELLS - Stem cells from human sources can have a variety of useful applications in disease treatment and biotechnology. More particularly the umbilical cord matrix cell cultures of the invention have a variety of totipotent, pluripotent, or multipotent cells for a variety of end uses from a non-controversial, universally available, species-specific source. The technology can have application to any amniotic animal, including agricultural and laboratory animals and humans. The invention relates to isolating the stem cells, culturing the stem cells, maintaining the stem cells, transforming the stem cells into useful cell types using genetic or other transformation technologies, stem cell and tissue banking and using untransformed or transformed cells in disease treatment.11-11-2010
20100330052Use of Mesenchymal Stem Cells for Treating Genetic Diseases and Disorders - A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal.12-30-2010
20110135612COMPOSITIONS TO EFFECT NEURONAL GROWTH - Compositions containing neurogenic agents for inhibition of neuron death and inducing proliferation of neural cells are disclosed.06-09-2011
20110135613METHODS FOR TREATING APOLIPOPROTEIN E4-ASSOCIATED DISORDERS - The present disclosure provides a method of increasing the functionality of a GABAergic interneuron in the hilus of the hippocampus of an individual having at least one apolipoprotein E4 (apoE4) allele. The method generally involves reducing tau levels in the interneuron.06-09-2011
20120148551MARROW STEM CELL AND PANCREATIC BETA CELL FUSION CELL USEFUL FOR THE TREATMENT OF DIABETES - Methods described include methods of treating T1DM, the method comprising delivering a therapeutic amount of β-MSC to a subject in need thereof. Further disclosed are fusion cells comprising and MSC and a second cell wherein the nuclei of the MSC and the second cell are not fused in the fusion cell.06-14-2012
20110256114T-CELL RECEPTOR AND NUCLEIC ACID ENCODING THE RECEPTOR - A polypeptide comprising a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 5 of Sequence Listing or a polypeptide consisting of an amino acid sequence having deletion, addition, insertion or substitution of one to several amino acid residues in the sequence, the polypeptide being capable of constituting an HLA-A24-restricted, MAGE-A410-20-2011
20110256113METHOD FOR PREVENTING AND TREATING DIABETES USING NEURTURIN - The present invention relates generally to methods for preventing and/or treating pancreatic disorders, particularly those related to diabetes, by administering a neurturin protein product.10-20-2011
20100158880REGENERATION AND REPAIR OF NEURAL TISSUE FOLLOWING INJURY - Methods, pharmaceutical compositions and kits for regenerating or repairing neural tissue, decreasing apoptosis and improving neurological function following injury are disclosed.06-24-2010
20120121560METHODS OF EXPANDING AND REDIFFERENTIATING ISLET BETA CELLS - A method of ex-vivo increasing insulin content in progenitor cells which express SLUG is provided. The method comprises downregulating an amount or activity of SLUG in the progenitor cells. Cell populations generated thereby and uses thereof are also provided.05-17-2012
20100196338COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE - A fusion protein for treating cardiovascular disease includes a transcription factor (TF) and a cell-penetrating peptide (CPP). The fusion protein can be expressed from a cell that is delivered to the tissue being treated.08-05-2010
20100196339Microparticle-Based Transfection and Activation of Dendritic Cells - The present invention provides an effective method for the transfection of dendritic cells by non-viral methods. The present invention provides this benefit by incubating dendritic cells and a specified transfection agent. The transfection agent comprises a polynucleotide and microparticles, with the microparticles being comprised of biodegradable polymer and cationic detergent. The dendritic cells and transfection agent are incubated for a time sufficient to transfect the dendritic cells with the polynucleotide.08-05-2010
20100196337METHODS AND COMPOSITIONS FOR STEM CELL SELF-RENEWAL - The present invention relates to methods for expanding a stem cell population. More particularly, the invention relates, inter alia, to methods and compositions for expanding a stem cell population, particularly a hematopoietic stem cell population.08-05-2010
20100196335Methods and Compositions for Regulated Expressions of Nucleic Acid at Post-Transcriptional Level - The present invention provides an isolated nucleic acid comprising: a) at least one first nucleotide sequence encoding a heterologous nucleotide sequence of interest; and b) at least two second heterologous nucleotide sequences, wherein each second heterologous nucleotide sequences comprises: i) a first set of splice elements defining a first intron that is removed by splicing to produce a first RNA molecule that imparts a biological function in the absence of activity at a second set of splice elements; and ii) the second set of splice elements defining one or more introns different from said first intron, wherein said one or more introns different from said first intron are removed by splicing to produce no RNA molecule and/or a second RNA molecule that docs not impart a biological function, when said second set of splice elements is active. Further provided are methods of using the nucleic acid of this invention to regulate transgene expression.08-05-2010
20110262408FURIN-KNOCKDOWN AND GM-CSF-AUGMENTED (FANG) CANCER VACCINE - Compositions and methods for cancer treatment are discloses herein. More specifically the present invention describes an autologous cancer vaccine genetically modified for Furin knockdown and GM-CSF expression. The vaccine described herein attenuates the immunosuppressive activity of TGF-β through the use of bi-functional shRNAs to knock down the expression of furin in cancer cells, and to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene.10-27-2011
20090297488METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS - Cells present in adipose tissue are used to treat patients, including patients with PVD and related diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit.12-03-2009
20080260707Isolated homozygous stem cells, differentiated cells derived therefrom and materials and methods for making and using same - The present invention discloses and describes pluripotent homozygous stem (HS) cells, and methods and materials for making same. The present invention also provides methods for differentiation of HS cells into progenitor (multipotent) cells or other desired cells, groups of cells or tissues. Further, the applications of the HS cells disclosed herein, include (but are not limited to) the diagnosis and treatment of various diseases (for example, genetic diseases, neurodegenerative diseases, endocrine-related disorders and cancer), traumatic injuries, cosmetic or therapeutic transplantation, gene therapy and cell replacement therapy.10-23-2008
20110189142Senescene Cells and Methods For Its Production - The present invention relates to a method for the generation of immortalized transduced cell lines susceptible to senescence whereby the senescence is exogenously inducible and said cells can switch severalfold between the senescent stage and the immortalized stage. In particular, the present invention relates to a method for the generation of immortalized transduced cell lines susceptible to senescence wherein two or more different immortalizing gene sequences have been incorporated whereby said immortalizing gene sequences are regulated by regulators controlled via exogenous means. In a further aspect, the present invention relates to immortalized transduced cell lines obtainable with said method. In addition, methods for screening molecules influencing senescence of cells are provided as well as kits for conducting the same.08-04-2011
20110135614MODIFIED GROWTH HORMONE - The invention provides, a nucleic acid molecule encoding a growth hormone (GH) in which the RSP sorting signal has been mutated, such that the GH can be constitutively secreted by the nonregulated secretory pathway (NRSP) in a mammalian cell. The invention also provides a nucleic acid molecule encoding a GH in which the three-dimensional conformation of the RSP sorting signal has been altered such that the GH can be constitutively secreted by the NRSP in a mammalian cell.06-09-2011
20100028312Stably transformed bone marrow-derived cells and uses thereof - The invention provides compositions comprising genetically modified bone marrow cells and related therapeutic and diagnostic methods. Transduced bone marrow cells can be therapeutically administered to a subject, such as a human patient to provide for the expression of an encoded protein in the subject in need thereof.02-04-2010
20100021443METHOD OF PREPARING LUNG ALVEOLAR EPITHELIAL TYPE II CELLS DERIVED FROM EMBRYONIC STEM CELLS - A method of preparing a population of in vitro cultured cells of alveolar epithelial type II (ATII) cell lineage derived from at least one embryonic stem cell is disclosed which comprises (a) culturing said at least one embryonic stem cell in vitro in a medium comprising Matrigel®, to produce differentiated cells without formation of an embryonic body, wherein at least some of the differentiated cells are of ATII cell phenotype; (b) identifying the differentiated cells of ATII cell phenotype by detecting expression of at least one biomarker of ATII cells; (c) isolating the differentiated cells having ATII cell phenotype; and (d) cloning the isolated cells to produce a population of cells having ATII cell phenotype. The resulting cells are preferably >99% pure ATII phenotype lineage and are potentially useful therapeutically for treating lung injury and disease.01-28-2010
20120308537Use Of Collagen Type VII For Maintaining And Re-Inducing Osteogenic Abilities Of Mesenchymal Stem Cells - This invention provides methods of inducing and maintaining osteogenic potential in mesenchymal stem cells and compositions for doing the same. The compositions this invention comprise collagen 7 (C7), the NC1 domain of C7, or the 27 kD fragment of C7. Also provided are methods for treating bone diseases and correcting bone defects by applying compositions of this invention or by first priming ex vivo mesenchymal stem cells with compositions of this invention and then applying the primed mesenchymal stem cells to the patient. The invention further provides a mesenchymal stem cell osteogenesis induction kit.12-06-2012
20120308538PREVENTING SPOILAGE IN ALCOHOL FERMENTATIONS - The invention relates to the prevention of bacterial spoilage during fermentation. In particular it relates to the prevention of beer and wine spoilage, but also the spoilage of bioethanol or biogas. This is accomplished by modifying the fermentation yeast to produce an antimicrobial peptide known as a defensin. One such defensin is the human β-defensin-3 (HBD-3) although many others can be used.12-06-2012
20090220470UBIQUITIN BINDING POLYPEPTIDES - The invention relates to Tandem Ubiquitin Affinity Entities (TUBES) which are fusion polypeptides comprising at least two ubiquitin binding domains connected to each other by non-naturally occurring spacer regions. The TUBES are capable of binding with high affinity to ubiquitin and to ubiquitylated polypeptides and are therefore suitable for the purification of ubiquitylated polypeptides from cellular extracts as well as for the identification of new ubiquitylated polypeptides.09-03-2009
20100111911MITOCHONDRIAL NUCLEIC ACID DELIVERY SYSTEMS - Nucleic acid mitochondrial delivery systems are provided. These systems are important for delivery of genetic information to a mitochondrion and for treatment of mitochondrial related diseases.05-06-2010
20120148550METHODS, SYSTEMS, AND COMPOSITIONS FOR NEURONAL DIFFERENTIATION OF MULTIPOTENT STROMAL CELLS - Some embodiments of the invention comprise methods, systems, and compositions to selectively induce, whether in vitro or in vivo, the neuronal differentiation of multipotent stromal cells through the application of microRNAs, including but not limited to miRNA-124, miRNA-137 and/or miRNA-9* expression products of those miRNAs, and molecules and compositions containing functional elements of those miRNAs. Some embodiments of the invention also comprise the therapeutic administration and use of such induced cells to treat mammalian injuries and diseases, including but not limited to, nervous system injuries or diseases that may otherwise result in decreased cell or system function.06-14-2012
20100297091COMPOSITIONS AND METHODS FOR TREATMENT OF MELANOMAS - In certain embodiments, an expression construct is provided that contains a tissue-specific promoter such as tyrosinase linked to one or more cytotoxin genes. The cytotoxin genes may be saporin genes. In certain embodiments, a vector is provided that contains an expression construct as discussed above. The vector may be an adeno-associated virus or an adenovirus. Further, neural stem cells may be provided that contain and/or produce a vector, which in turn contains an expression construct containing a tissue-specific promoter linked to one or more cytotoxin genes. In certain embodiments, methods of using the neural stem cells provided herein for production and delivery of an animal virus vector are provided. Methods for treating melanomas in a subject in need thereof are also provided by delivering an expression construct that contains a tissue-specific promoter linked to one or more cytotoxins. In certain embodiments, the melanoma is metastatic, and in certain embodiments the melanoma is a brain melanoma.11-25-2010
20080311092Murine Stem Cells and Applications Thereof - The invention relates to animal solid tumour models which comprise a transgenic non-human mammal containing in its genome a DNA construct that comprises a gene created and/or activated by a genetic anomaly associated with human cancer operatively bound to a promoter that directs the expression of the gene in Sca1+ cells. The invention also relates to stem cells capable of specifically expressing in stem cells human genetic anomalies associated with human pathologies. Applications of these models and stem cells, such as diagnostic, therapeutic and prophylactic applications for human diseases, and products and methods are provided.12-18-2008
20110070208HBV EPITOPE REACTIVE EXOGENOUS T CELL RECEPTOR (TCR) AND USES THEREOF - There is provided at least one isolated cell comprising at least one HBV epitope-reactive exogenous T cell receptor and/or fragment thereof, and methods for producing them. In particular, there is provided polynucleotides, constructs and vectors encoding at least one HBV epitope-reactive exogenous T cell receptor for use in the treatment of Hepatitis B Virus (HBV) and Hepatocellular Carcinoma (HCC). The invention further provides kits and methods of detection of HBV and HCC.03-24-2011
20090068157Derivation of unlimited quantities of neutrophils on monocyte/dendritic cells - A method to generate unlimited numbers of macrophage/dendritic cells or neutrophils from mice, using conditional Hox oncoproteins is disclosed. The invention further includes the establishment of a system to investigate immune responses to microorganisms or diseases involving chronic inflammation.03-12-2009
20110091430MESENCHYMAL STEM CELLS AND METHODS OF USE THEREOF - The invention provides compositions and methods of enhancing the viability of primary stem cells and enhancing the engraftment of transplanted stem cells into a mammalian recipient. Accordingly, the invention includes a method of regenerating a mesenchymally-derived tissue by contacting the tissue with a composition containing an isolated adult mesenchymal stem cell, which are apoptosis-resistant. The mesenchymal stem cell is an adult cell obtained from an adult bone marrow.04-21-2011
20090047263Nuclear reprogramming factor and induced pluripotent stem cells - The present invention relates to a nuclear reprogramming factor having an action of reprogramming a differentiated somatic cell to derive an induced pluripotent stem (iPS) cell. The present invention also relates to the aforementioned iPS cells, methods of generating and maintaining iPS cells, and methods of using iPS cells, including screening and testing methods as well as methods of stem cell therapy. The present invention also relates to somatic cells derived by inducing differentiation of the aforementioned iPS cells.02-19-2009
20100158879EXPRESSION CASSETTE AND VECTOR FOR TRANSIENT OR STABLE EXPRESSION OF EXOGENOUS MOLECULES - The disclosure provides an expression cassette and a vector comprising the cassette for expression of a polynucleotide. The expression cassette includes a promoter/enhancer, an intervening region, and a polyadenylation signal domain. Expression systems and methods of using the expression cassette and vector are also provided.06-24-2010
20110104131HEMATOPOIETIC STEM CELLS AND METHODS OF TREATMENT OF NEOVASCULAR EYE DISEASES THEREWITH - Isolated, mammalian, adult bone marrow-derived, lineage negative hematopoietic stem cell populations (Lin05-05-2011
20090155230Novel genes and markers in essential arterial hypertension - The present invention relates to previously unknown disease associations between various genes, loci and biomarkers and essential hypertension. The detection of these biomarkers provides novel in vitro methods and test kits which can be used as an aid when making risk assessment, molecular diagnosis or prognosis of HT or a HT related condition. The disclosed methods and test kits do not require interaction with the body of a subject during the biomarker detection. Instead the methods and test kits are for in vitro use (e.g. in a clinical laboratory) and typically biological samples for the biomarker analyses using a method or a test kit of this invention have been collected earlier in a different place. In addition the biomarkers provide methods and systems for identifying novel agents for preventing, treating and/or reducing risk of HT or a HT related condition. The HT associated genes can be used to develop novel therapies for prevention and/or treatment of essential hypertension.06-18-2009
20100003225HSP60, HSP60 PEPTIDES AND T CELL VACCINES FOR IMMUNOMODULATION - The present invention provides novel uses for peptide p277—positions 437-460 of human heat shock protein 60 (HSP60)—in modulation of immune responses and inflammatory diseases. The invention further provides novel uses for HSP60 and p277 in the treatment or prevention of hepatic disorders. The invention discloses methods for treating, preventing or ameliorating the symptoms of T cell mediated inflammatory and autoimmune disorders, including hepatic disorders, which comprise administering to a subject in need thereof a composition comprising as an active ingredient an effective quantity of a molecule selected from: HSP60, p277, fragments, analogs, homologs and derivatives thereof, and nucleic acids encoding same. Also disclosed are T cell vaccination methods for treating or preventing T cell mediated disorders.01-07-2010
20090028838HEMATOPOIETIC CELL CULTURE NUTRIENT SUPPLEMENT - The present invention provides a serum-free supplement which supports the growth of hematopoietic cells in culture. Also provided are a medium comprising a basal medium supplemented with the serum-free supplement of the present invention. The present invention also provides methods for culturing and for differentiating hematopoietic cells.01-29-2009
20080260706Transient Transfection with RNA - A method of mRNA production for use in transfection is provided, that involves in vitro transcription of PCR generated templates with specially designed primers, followed by polyA addition, to produce a construct containing 3′ and 5′ untranslated sequence (“UTR”), a 5′ cap and/or Internal Ribosome Entry Site (IRES), the gene to be expressed, and a polyA tail, typically 10-23-2008
20090155232Neonatal human hepatocytes immortalized using tert and methods of their use - The present invention relates to the discovery of immortalized neonatal human hepatocytes that exhibit phenotypic features of human hepatic progenitor cells. The invention is also directed to a method of obtaining telomerase-immortalized neonatal human hepatocytes that exhibit phenotypic features of human hepatic progenitor cells. Furthermore, the instant invention describes methods of using the immortalized neonatal human hepatocytes in cellular therapies, toxicological studies, pharmacokinetic studies, metabolic studies, therapeutic gene delivery and for the production of fully differentiated hepatocytes.06-18-2009
20120148549METHOD TO ISOLATE, IDENTIFY, AND USE EMBRYONIC STEM CELLS DIRECTED TO FOREBRAIN INTERNEURON FATE - The present invention relates to methods of isolating a purified or enriched population of cortical or striatal immature interneuron progenitor cells and the isolated purified or enriched population of immature interneuron progenitor cells. Methods of treating a condition mediated by a loss or deficiency of interneuron function using the purified or enriched population of immature interneuron progenitor cells are also disclosed.06-14-2012
20120156183SORCS1-LIKE AGENT FOR USE IN THE TREATMENT OF INSULIN RESISTANCE AND DISEASES RELATED THERETO - The present invention relates to SorCS1-like agents, including SorCS1, nucleic acid molecule encoding expression of SorCS1 and fragments thereof, as well as vectors containing said nucleic acid and to cells expressing SorCS1 and said fragments, for use in the treatment of insulin resistance.06-21-2012
20090130069Thymidine Kinase - A polynucleotide comprising a nucleotide sequence encoding a thymidine kinase wherein at least one of the nucleotides corresponding to the splice donor site nucleotides is replaced by another nucleotide and wherein the nucleotides of the splice acceptor sites are not altered.05-21-2009
20110318318ANTI-APOPTOTIC FUSION PROTEINS - The present invention relates to a fusion protein comprising a protein transduction domain capable of introducing the fusion protein into a mammalian cell and an anti-apoptotic protein comprising the amino acid of the sequence of SEQ ID NO:1 or an anti-apoptotically active variant or fragment thereof. The invention also relates to a pharmaceutical composition comprising such a fusion protein, in particular for blocking apoptosis in a patient in need thereof. The invention also provides a polynucleotide encoding such a fusion protein, an expression vector comprising the polynucleotide and a host cell comprising the expression vector. In a further aspect, the invention relates to the use of any of theses materials for the preparation of a medicament for blocking apoptosis in a patient in need thereof.12-29-2011
20110318317CHINESE HAMSTER APOPTOSIS-RELATED GENES - Provided is an isolated polypeptide comprising a 12-29-2011
20120301449RNA INTERFERENCE TARGET FOR TREATING AIDS - The RNAi target sequences, which could be used for treating AIDS through targeting HIV. Based on the target sequences, recombinant expression vectors, packaging vectors and cells were constructed, which express siRNA and/or miRNA and/or ribozyme and/or antisense oligonucleotide for targeting HIV. And the applications of said recombinant expression vectors, packaging vectors and cells in preparing medicament for treating AIDS.11-29-2012
20120301448TH1-ASSOCIATED MICRORNAS AND THEIR USE FOR TUMOR IMMUNOTHERAPY - Described herein is the identification of miRNAs (miRs) that are up-regulated in Th1 cells compared to Th2 cells (referred to herein as Th1-associated miRs). In particular, the miR-17-92 gene cluster was found to exhibit significantly greater expression in Th1 cells. Over-expression of miR-17-92 in T cells promotes the Th1 phenotype. Thus, the use of Th1-associated miRs for cancer immunotherapy is described. Provided herein are isolated T cells containing a heterologous nucleic acid molecule encoding a Th1-associated miR, such as the miR17-92 gene cluster, or a portion thereof. Further provided is a method of treating cancer in a subject by administering to the subject an isolated T cell as disclosed herein. Also provided is a method of treating a subject with cancer by transfecting isolated T cells obtained from the subject with a heterologous nucleic acid molecule encoding a Th1-associated miR and administering the transfected T cells to the subject.11-29-2012
20120301447TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRANSDUCED T CELL SELECTION - A non-immunogenic selection epitope may be generated by removing certain amino acid sequences of the protein. For example, a gene encoding a truncated human epidermal growth factor receptor polypeptide (EGFRt) that lacks the membrane distal EGF-binding domain and the cytoplasmic signaling tail, but retains an extracellular epitope recognized by an anti-EGFR antibody is provided. Cells may be genetically modified to express EGFRt and then purified without the immunoactivity that would accompany the use of full-length EGFR immunoactivity. Through flow cytometric analysis, EGFRt was successfully utilized as an in vivo tracking marker for genetically modified human T cell engraftment in mice. Furthermore, EGFRt was demonstrated to have cellular depletion potential through cetuximab mediated antibody dependent cellular cytotoxicity (ADCC) pathways. Thus, EGFRt may be used as a non-immunogenic selection tool, tracking marker, a depletion tool or a suicide gene for genetically modified cells having therapeutic potential.11-29-2012
20120114620Engineered Dendritic Cells and Uses for the Treatment of Cancer - This invention provides the field of therapeutics. Most specifically present invention provides methods of generating in vitro engineered dendritic cells conditionally expressing interleukin-12 (IL-12) under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals including human.05-10-2012
20120003195IN VITRO MICRO-ORGANS, AND USES RELATED THERETO - Micro-organ cultures which include isolated populations of cells having specific characteristics are described. Salient features of the subject micro-organ cultures include the ability to be maintained in culture for relatively long periods of time, as well as the preservation of an organ microarchitecture which facilitates, for example, cell-cell and cell-matrix interactions analogous to those occurring in the source organ. The micro-organ cultures of the invention can be used in methods for delivering gene products to recipient subjects, for identifying cell proliferative and cell differentiating agents, and identification and isolation of progenitor and stem cells. In addition, the micro-organ cultures of the to present invention can be used in methods for identifying inhibitors of cell proliferation, cell differentiation and viral infectivity. In other embodiments, the micro-organ cultures can be used for transplantation.01-05-2012
20120064050Tissue Engineering of Lung - The present invention relates to compositions comprising a decellularized tissue. The present invention also provides an engineered three dimensional lung tissue exhibiting characteristics of a natural lung tissue. The engineered tissue is useful for the study of lung developmental biology and pathology as well as drug discovery.03-15-2012
20120003196LONG LASTING DRUG FORMULATIONS - The present invention is directed to long-lasting therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes a therapeutic polypeptide, such as erythropoietin or interferon alpha.01-05-2012
20100111914STEM CELLS FROM URINE AND METHODS FOR USING THE SAME - Provided herein are stem cells and methods for producing a culture of stem cells from urine. The stem cells may be differentiated into an osteogenic, chondrogenic, adipogenic, endothelial, neurogenic or myogenic lineage. Methods of use of the cells are provided, including methods of treating a subject in need of a cell based therapy.05-06-2010
20120207722Use Of Adipose Tissue Cells For Initiating The Formation Of A Functional Vascular Network - This invention relates to the use of cells of a medullary or extra-medullary white adipose tissue, in particular of an extra-medullary stromal vascular fraction (SVF) and/or mature dedifferentiated adipocytes of any origin for initiating the formation of a functional vascularisation.08-16-2012
20120207723COMPOSITIONS AND METHODS FOR GENERATING INDUCED PLURIPOTENT STEM CELLS - The present disclosure provides a method of generating an induced pluripotent stem cell; as well as nucleic acids and genetically modified host cells useful in generating iPSCs. The present disclosure provides iPSCs, and methods of use of same.08-16-2012
20120207721SORCS1 FOR THE TREATMENT OF OBESITY - The present invention relates to SorCS1-like agents, including SorCS1, nucleic acid molecule encoding expression of SorCS1 and fragments thereof, as well as vectors containing said nucleic acid and to cells expressing SorCS1 and said fragments, for the treatment of obesity.08-16-2012
20120009161THERAPEUTIC RETROVIRAL VECTORS FOR GENE THERAPY - Retroviral gene therapy vectors that are optimized for erythroid specific expression and treatment of hemoglobinopathic conditions are disclosed.01-12-2012
20120009162T CELL RECEPTOR AND NUCLEIC ACID ENCODING THE RECEPTOR - Disclosed are: polypeptides for TCR α-chain and β-chain which are restricted to HLA-A*0201 for Aur-A and are derived from a CTL; and nucleic acids encoding the polypeptides. The nucleic acids can impart a cytotoxic activity against a cell capable of presenting an HLA-A*0201 molecule and an Aur-A01-12-2012
20120009160CELLS FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS - There is provided a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of a Notch gene. Specifically, the invention provides a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells in vitro, which method comprises introducing a Notch gene and/or a Notch signaling related gene into the cells, wherein the finally obtained differentiated cells are the result of cell division of the bone marrow stromal cells into which the Notch gene and/or Notch signaling related gene have been introduced. The invention also provides a method of inducing further differentiation of the differentiation-induced neural cells to dopaminergic neurons or acetylcholinergic neurons. The invention yet further provides a treatment method for neurodegenerative and skeletal muscle degenerative diseases which employs neural precursor cells, neural cells or skeletal muscle cells produced by the method of the invention.01-12-2012
20120058092PROCESS FOR THE PREPARATION OF A COMPOSITION OF GENETICALLY MODIFIED HEMATOPOIETIC PROGENITOR CELLS - Described are compositions and methods relating to gene therapy, particularly as applied to hematopoietic progenitor (HP) cells, to transduced cells and methods of obtaining them, and to methods of using them to provide prolonged engraftment of modified hematopoietic cells in human subjects. The invention particularly relates to ex vivo gene therapy of HP cells for treatment or prevention of HIV infection.03-08-2012
20120014932Methods for treating disorders of amino acid metabolism - The invention is directed to methods for treating disorders of amino acid metabolism, in particular, phenylketonuria (PKU). Such methods utilize novel compositions including Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) alone or in combination with other agents or treatment modalities.01-19-2012
20100203024Sickled Erythrocytes, Nucleated Precursors & Erythroleukemia Cells for Targeted Delivery of Oncolytic Viruses, Anti-tumor Proteins, Plasmids, Toxins, Hemolysins & Chemotherapy - The present invention provides erythrocytes or nucleated erythrocyte precursors from animals or patients with SS or SA hemoglobin or erythroleukemia cells stably transfected with BCAM/Lu which are capable of selectively localizing in tumor vasculature promoting ischemia and occlusion and carrying oncolytic viruses, antitumor proteins, plasmids, toxins and chemotherapy into the tumor milieu. Nucleated erythroid precursors containing SS or SA hemoglobin and transfected with nucleic acids encoding a hypoxia-responsive element and containing nucleic acids encoding expression of oncolytic viruses, superantigens, toxins, viruses, antitumor proteins and chemotherapy are also useful in inducing a potent and specific tumoricidal response. An especially favored carrier is an SS nucleated erythroid precursor transfected with a replication competent oncolytic adenovirus or self-replicating alphavirus expressing a fusogenic membrane glycoprotein or a tumoricidal polypeptide.08-12-2010
20120058091DIAGNOSTIC AND THERAPEUTIC TREATMENTS RELATED TO MITOCHONDRIAL DISORDERS - The invention is based in part on the discovery that chromosomal disorders such as Down Syndrome can be diagnosed by assessing maternal mitochondrial status. Thus the invention relates to diagnostic and therapeutic methods and related products for chromosomal disorders such as Downs Syndrome, for example, for identifying a risk of fetal Downs Syndrome and methods of mitigating that risk. The methods also are useful for other therapies where it is desirable to manipulate mitochondria such as tissue generation.03-08-2012
20090028836STEM AND PROGENITOR CELL EXPANSION BY EVI, EVI-LIKE GENES AND SETBP1 - A method of increasing cell proliferation by modulating levels of EVI and related genes. Activation of EVI-1, PRDM16, or SETBP1 can increase the proliferation rate, self renewal and/or in vitro and/or in vivo survival and/or engraftment of human cells, either in vitro or in vivo. The gene modulation can be performed by various means, including traditional cloning methods and retroviral-based gene activation methods. The method can also be used to more efficiently deliver gene-corrected cells to a patient in need of treatment.01-29-2009
20120207724Compositions for Improving Migration Potential of Stem Cells - The present invention relates to a composition for improving the migration potential of a stem cell, a method for evaluating the migration potential of a stem cell and a method for screening an adjuvant of cell therapy improving the migration potential of a stem cell. The present invention may be effectively used for enhancing the efficacy of neurological disease-treatment by inducing therapeutic stem cells to migrate efficiently to the lesion site.08-16-2012
20120207725MESENCHYMAL STEM CELL INCORPORATING A NUCLEOTIDE SEQUENCE CODING TGFB, AND USES THEREOF - One or more specific examples of the present invention relate to a mesenchymal stem cell incorporating a nucleotide sequence coding TGFβ, and to the uses thereof.08-16-2012
20120156182Autogenic Living Scaffolds and Living Tissue Matrices: Methods and Uses Thereof - The present invention is drawn to a 3-dimensional cell-produced scaffold construct comprising cells and the extracellular matrix that has been produced and arranged by these cells.06-21-2012
20110076257Modified Nucleotide Sequence Encoding Glucagon-Like Peptide-1 (GLP-1), Nucleic Acid Construct Comprising Same for Production of Glucagon-Like Peptide-1 (GLP-1), Human Cells Comprising Said Construct and Insulin-Producing Constructs, and Method of Use Thereof - An isolated chimeric GLP-1 nucleic acid sequence encoding a human pro-insulin leader, a glucagon-like peptide-1 (GLP-1), and a furin cleavable site between the human pro-insulin leader sequence and the GLP-1 is provided. Also provided is an isolated modified chimeric GLP-1 nucleic acid sequence encoding a human pro-insulin leader, a glucagon-like peptide-1 (GLP-1), and a furin cleavable site between the human pro-insulin leader sequence and the GLP-1. Recombinant expression vectors comprising the chimeric GLP-1 nucleic acid sequences, which produce GLP-1 constitutively are provided, as are human cells transfected with such an expression vector in combination with an expression vector comprising a proinsulin nucleic acid sequence and an expression vector comprising a furin and a glucose-regulatable TGF-alpha promoter. Methods of producing human GLP-1 constitutively are provided as are method of producing GLP-1 and insulin or in a glucose-dependent manner using such transfected cells. Methods of treating a subject having Type II diabetes and methods of treating a subject prone to hyperglycemia or suffering from hyperglycemia are provided in which transfected cells produce human GLP-1 and insulin in a glucose-dependent manner. Also provided are methods of reducing weight in a subject by implanting into the subject transfected cells which produce human GLP-1 and insulin in a glucose-dependent manner.03-31-2011
20090136467APOLIPOPROTEIN ANALOGUES - The invention relates to a pharmaceutical composition comprising an apolipoprotein construct, to an apolipoprotein construct, a nucleic acid sequence encoding the apolipoprotein construct, a vector comprising the nucleic acid sequence, a method for producing the apolipoprotein construct, and a method of treatment comprising administering the apolipoprotein construct. The presented data document that the constructs according to the invention are capable of binding lipids, are capable of binding cubilin, which is a strong Apo AI receptor, stronger than native Apo A-I and that the plasma half life of the constructs is at least tripled compared to native Apo A-I. Together these data document that the constructs according to the invention are strong candidates for treatment of cardiovascular diseases.05-28-2009
20110104127mRNA-TRANSFECTION OF ADULT PROGENITOR CELLS FOR SPECIFIC TISSUE REGENERATION - The present invention relates to progenitor cells, medicaments containing progenitor cells and also uses thereof for specific tissue regeneration. Such processes are required in all medical sectors, in particular in the treatment of cardiovascular, haematological, nephrological, neurological, dermatological, gastroenterological or orthopaedic disorders. The progenitor cells are characterized in that they are transfected with mRNA which codes for a protein which promotes colonization of the progenitor cells in a target tissue and/or the differentiation of the progenitor cells in target cells or target tissue cells.05-05-2011
20110104133METHODS AND COMPOSITIONS FOR INDUCING BROWN ADIPOGENESIS - Methods and compositions for treating obesity and related disorders. The methods include the use of Sca-1+ progenitor cells treated with BMP-2, -4, -5, -6, and/or -7.05-05-2011
20110104132FGF-9 AND ITS USE RELATING TO BLOOD VESSELS - There is provided a composition for controlling formation and/or stabilization of a blood vessel comprising a first isolated nucleic acid molecule that encodes a FGF-9 polypeptide and optionally one or more isolated nucleic acid molecule that encodes another angiogenic polypeptide. There is provided a composition for controlling formation and/or stabilization of a blood vessel comprising an isolated. The compositions provided herein may be useful for controlling angiogenesis and/or vasculogenesis.05-05-2011
20120121558COMPOSITIONS AND METHODS FOR TREATING PLASMA PROTEIN DEFICIENCY DISORDERS - The disclosure of the present application provides compositions and methods for treating a blood disorder. In at least one embodiment of a method for treating a patient with a plasma protein deficiency disorder, the method comprises the steps of administering a cell-based composition to a patient with a plasma protein deficiency disorder to treat the plasma protein deficiency disorder, where the cell-based composition comprises a mammalian adipose stromal cell that is capable of effectuating the production of a plasma protein within the patient.05-17-2012
20120121559TREATMENT AND PREVENTION OF PATHOLOGICAL CONDITIONS USING IDUNA RELATED TECHNIQUES AND COMPOSITIONS - Research into neuroprotective mechanisms has at its heart the goal of developing new therapeutic strategies to treat patients. For example, the compositions and induction strategies disclosed herein have use for acute injuries such as stroke or trauma, and would be extremely useful in treating patients undergoing cardiac bypass surgery, neurosurgery or other surgical cohorts where ischemia is a risk. Further, patients with subarachnoid hemorrhage, transient ischemic attacks, soldiers at risk for blast injury or patients suffering from chronic neurodegenerative diseases would also benefit from enhanced neuronal survival based upon the techniques and compositions disclosed herein. In addition, protecting against cell death by, for example, interfering with PAR polymer signaling via the compositions and processes disclosed herein, offers new therapeutic strategies for the treatment of neurologic disorders.05-17-2012
20080206210Drugs for the Prevention or Treatment of Immunodeficiencies, Autoimmune Diseases or for the Induction of Immune Tolerance - The invention relates to the use of viral vectors able to stably integrate into the genome of thymic stromal cells, or of intrathymic lymphocytes or lymphocytes precursors, for the manufacture of a medicine intended for intrathymic administration in the frame of the prevention or treatment of genetic immunodeficiencies, acquired immunodeficiencies, or for the induction of immune tolerance of the organism to self or non-self gene products, cells or tissues, or for the prevention or treatment of autoimmune diseases.08-28-2008
20100092438Bacteria Mediated Gene Silencing - Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium or BTP. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating viral diseases and disorders. The bacterium or BTP includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells.04-15-2010
20130171116OPTICALLY SENSITIVE CELL NETWORK - A neural network is disclosed. The neural network comprises a plurality of optogenetically modified neural cells being three-dimensionally distributed in a hydrogel medium and being disconnected from any solid support having a shear modulus above 1 GPa.07-04-2013
20120164118COCAL VESICULOVIRUS ENVELOPE PSEUDOTYPED RETROVIRAL VECTORS - Provided herein are Cocal vesiculovirus envelope pseudotyped retroviral vectors that exhibit high titers, broad species and cell-type tropism, and improved serum stability. Disclosed Cocal vesiculovirus envelope pseudotyped retroviral vectors may be suitably employed for gene therapy applications and, in particular, for the ex vivo and in vivo delivery of a gene of interest to a wide variety of target cells.06-28-2012
20100247498IN VITRO MICRO-ORGANS, AND USES RELATED THERETO - A method of delivering a gene product to a recipient, the method comprises (a) providing a micro-organ explant expressing at least one recombinant gene product, the micro-organ explant comprising a population of cells, the micro-organ explant maintaining a microarchitecture and a three dimensional structure of an organ from which it is obtained and at the same time having dimensions selected so as to allow diffusion of adequate nutrients and gases to cells in the micro-organ explant and diffusion of cellular waste out of the micro-organ explant so as to minimize cellular toxicity and concomitant death due to insufficient nutrition and accumulation of the to waste in the micro-organ explant, at least some of the cells of the population of cells of the micro-organ explant expressing at least one recombinant gene product; and (b) implanting the micro-organ explant in the recipient.09-30-2010
20100247496NEURONAL VIABILITY FACTOR AND USE THEREOF - The present disclosure concerns a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected in the group comprising (i) a polypeptide comprising an amino acid sequence selected in the group comprising the amino acid sequence of the long isoform in 09-30-2010
20100247497VECTOR PARTICLES FOR TARGETNG CD34+ CELLS - The present invention relates to a vector particle for transferring biological material into cells, wherein said vector particle comprises at least: —a first protein which comprises the transmembrane and extracellular domains of the feline endogenous RD114 virus envelope glycoprotein, and —a second protein which comprises a ligand of the c-Kit receptor.09-30-2010
20120128643GENE VECTOR - A gene vector for use in gene therapy comprising at least one miRNA sequence target operably linked to a nucleotide sequence having a corresponding miRNA in a hematopoietic progenitor cell (HSPC) or hematopoietic stem cell (HSC) which prevents or reduces expression of the nucleotide sequence in a HSPC or HSC but not in a differentiated cell.05-24-2012
20110182868HUMAN LYSOSOMAL PROTEINS FROM PLANT CELL CULTURE - A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. More particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vectors and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). The invention further provides for compositions and methods for the treatment of lysosomal storage diseases.07-28-2011
20120315255Hepatocyte Based Insulin Gene Therapy For Diabetes - A method and vectors for controlling blood glucose levels in a mammal are disclosed. In one embodiment, the method comprises the steps of: treating the hepatocyte cells of a patient with a first, second or third vector, wherein the first vector comprises a promoter enhancer, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase and an albumin 3′UTR and lacks an HGH intron, wherein the second vector comprises an HGH intron, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase site and an albumin 3′UTR and lacks a promoter enhancer, wherein the third vector comprises an HGH intron, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase site, an albumin 3′UTR and a promoter enhancer and observing the patient's insulin levels, wherein the patient's insulin levels are controlled.12-13-2012
20120315257METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS - Cells present in adipose tissue are used to treat patients, including patients with PVD and related diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit.12-13-2012
20120315256USE OF TRANSFORMING GROWTH FACTOR - BETA 1 (TGF-B1) INHIBITOR PEPTIDES FOR THE TREATMENT OF CORNEAL FIBROSIS AND/OR HAZE - The invention refers to the use of transforming growth factor-beta 1 (TGF-β1) inhibitor peptides or polynucleotides encoding said peptides for the prevention and/or treatment of corneal fibrosis and/or corneal haze.12-13-2012
20120213752ISOLATED STROMAL CELLS AND METHODS OF USING THE SAME - Isolated stromal cells, containers comprising isolated stromal cells transfected with exogenous DNA, and methods of treating patients suffering from diseases characterized by a bone cartilage or lung defect are disclosed. The methods comprise obtaining a bone marrow sample from a donor, isolating stromal cells from the sample, and administering the isolated stromal cells to the patient.08-23-2012
20120213751NOVEL STEM CELLS, NUCLEOTIDE SEQUENCES AND PROTEINS THEREFROM - The present invention provides novel stem cells, nucleotide sequences and proteins therefrom. More specifically, the present invention provides Pax7+/Myf5− stem cells and methods for identifying and isolating them. Also provided is a MEGF10 nucleotide sequence and protein.08-23-2012
20120134971ENGINEERED BIOLOGICAL PACEMAKERS - Biological pacemakers engineered to intrinsically generate rhythmic excitations are disclosed. In addition, methods of producing the biological pacemakers are disclosed. Methods of treating or preventing arrhythmia and heart disease associated with a defective pacemakers are also disclosed.05-31-2012
20120134970Viral Vectors Encoding Multiple Highly Homologus Non-Viral Polypeptides And The Use Of Same - The present invention relates to compositions and methods for creation of vector nucleic acid sequences (e.g., retroviral nucleic acid sequences) that comprise two or more exogenous nucleic acid sequences that encode highly homologous (e.g., identical) polypeptide sequences, yet wherein at least one of the exogenous nucleic acid sequences has been mutated using degenerate codons for purpose of reducing homology between the two or more exogenous nucleic acid sequences while maintaining the encoded polypeptide sequence. Preferred nucleic acid sequences include those encoding multi-chimeric immune receptor (CIR) genes. Specific nucleic acid sequences of such CIR genes are also disclosed.05-31-2012
20120134972Novel Polypeptides Having Endolysin Activity And Uses Thereof - The present invention provides isolated polypeptides comprising a fragment of the amino acid sequence of SEQ ID NO:1, or a variant, derivative or fusion thereof, which is capable of binding specifically to and lysing cells of 05-31-2012
20100172886Method for Promoting Wound Healing - The present invention discloses a method for treating wounds and for accelerating the healing of wounds by administering an effective amount of a pharmaceutical composition containing type VII collagen protein, mini-C7 protein, variants thereof or any combinations thereof. The pharmaceutical composition may be administered through a variety of routes including intravenous injection, topical application, or oral ingestion. The method may further include administering a genetically modified fibroblast capable of expressing type VII collagen protein, mini-C7 protein, variants thereof or small growth factors to achieve synergistic healing effect.07-08-2010
20090028835HUMAN TRANSCRIPTOME CORRESPONDING TO HUMAN OOCYTES AND USE OF SAID GENES OR THE CORRESPONDING POLYPEPTIDES TO TRANS-DIFFERENTIATE SOMATIC CELLS - The identification of 101 genes upregulated or differentially expressed by mature human oocytes is provided herein. These genes and the corresponding gene products will facilitate a greater understanding of oogenesis, folliculogenesis, fertilization, and embryonic development. In addition these genes and the corresponding gene products can be used to effect dedifferentiation and/or transdifferentiation of desired somatic cells. The resultant dedifferentiated cells and somatic cells derived therefrom can be used in cell therapies such as in the treatment of cancer, autoimmunity, and other diseases wherein specific types of cells such as hematopoietic cells may be depleted because of the underlying disease or the treatment of the disease.01-29-2009
20120251510AGENTS FOR PROMOTING TISSUE REGENERATION BY RECRUITING BONE MARROW MESENCHYMAL STEM CELLS AND/OR PLURIPOTENT STEM CELLS INTO BLOOD - It was revealed that the intravenous administration of HMGB-1 and S100A8 promoted the healing of skin ulcer by recruiting bone marrow-derived cells to the site of skin ulcer. Furthermore, when HMGB-1 was intravenously administered to cerebral infarction model mice after creation of cerebral infarction, bone marrow-derived cells expressing nerve cell markers were detected in their brain. A marked cerebral infarct-reducing effect was observed in mice intravenously administered with HMGB-1 as compared to the control. The post-cerebral infarction survival rate was increased in the intravenous HMGB-1 administration group. The involvement of bone marrow pluripotent stem cells in the process of bone fracture healing was assessed using mice, and the result demonstrated that bone marrow-derived cells distant from the damaged site migrated to the bone fracture site to repair the damaged tissue.10-04-2012
20120076764METHODS AND PHARMACEUTICAL COMPOSITIONS FOR HEALING WOUNDS - A pharmaceutical composition and method for inducing or accelerating a healing process of a skin wound are described. The pharmaceutical composition contains, as an active ingredient, a therapeutically effective amount of at least one agent for modulating PKC production and/or activation, and a pharmaceutically acceptable carrier. The method is effected by administering the composition to a wound.03-29-2012
20120076763COMBINATION ANTI-HIV VECTORS, TARGETING VECTORS, AND METHODS OF USE - Recombinant lentiviral vectors containing at least: a lentiviral backbone comprising essential lentiviral sequences for integration into a target cell genome; a nucleic acid encoding a CCR5 RNAi; and an expression control element that regulates expression of the nucleic acid encoding the CCR5 RNAi element, are provided by this invention. In an alternative aspect, the vector also contains polynucleotides encoding TRIMS alpha and HIV TAR decoy sequences along with gene expression regulation elements such as promoters operatively linked to the polynucleotides. The vectors are combined with packaging plasmid and envelope plasmids and optionally conjugated to cell-specific targeting antibodies. Diagnostic and therapeutic methods for using the compositions are further provided herein.03-29-2012
20120076762INDUCED PLURIPOTENT STEM CELL GENERATION USING TWO FACTORS AND P53 INACTIVATION - Methods and compositions are provided for, inter alia, the generation of induced pluripotent stem cells. Induced pluripotent stem cells may be generated by reprogramming and inhibition of p53. Further, useful intermediates for the generation of induced pluripotent stem cells are also provided.03-29-2012
20100047217DIFFERENTIATED ANUCLEATED CELLS AND METHOD FOR PREPARING THE SAME - Provided herein are methods for preparing differentiated cells, and the cells prepared by such methods.02-25-2010
20100047216COMPOSITIONS OF LATE PASSAGE MESENCHYMAL STEM CELLS (MSCS) - The present invention provides methods and compositions relating to the use of late passage mesenchymal stem cells (MSCs) for treatment of cardiac disorders. Such late passage MSCs may be administered to the myocardium of a subject for induction of native cardiomyoctye proliferation and repair of cardiac tissue. Additionally, the late passage MSCs may be genetically engineered to express a gene encoding a physiologically active protein of interest and/or may be incorporated with small molecules for delivery to adjacent target cells through gap junctions. The late passage MSCs of the invention may be used to provide biological pacemaker activity and/or provide a bypass bridge in the heart of a subject afflicted with a cardiac rhythm disorder. The biological pacemaker activity and/or bypass bridge may be provided to the subject either alone or in tandem with an electronic pacemaker.02-25-2010
20100272698YEASTS - A yeast cell is provided comprising an artificial nucleic acid construct incorporating a gene associated with yeast cell wall integrity operatively linked to a promoter responsive to conditions characteristic of the digestive tract. Also provided is a method comprising administering to the digestive tract of the subject a yeast cell comprising an artificial nucleic acid construct comprising a gene associated with yeast cell wall integrity, operatively linked to a promoter responsive to conditions characteristic of the digestive tract, wherein the yeast cell further comprises an amount of an agent of interest encapsulated within said yeast cell.10-28-2010
20100272697PANCREATIC ISLET CELLS COMPOSITION AND METHODS - A composition comprising islet cells and an extracellular matrix component as well as methods of transplanting same are described. Retroperitoneal and subcutaneous islet cells transplants maintain their viability and increased insulin production for prolonged periods of time.10-28-2010
20100196336MODIFIED DENDRITIC CELLS HAVING ENHANCED SURVIVAL AND IMMUNOGENICITY AND RELATED COMPOSITIONS AND METHODS - Modified antigen presenting cells provided herein have improved lifespan and immunogenicity compared to unmodified antigen presenting cells, and are useful for immunotherapy. The modified antigen presenting cells express an altered protein kinase, referred to herein as “Akt.” The altered Akt associates with the cell membrane with greater frequency than unaltered Akt, and is referred to herein as “membrane-targeted Akt.”08-05-2010
20090081172THERAPEUTIC AND DIAGNOSTIC CLONED MHC-UNRESTRICTED RECEPTOR SPECIFIC FOR THE MUC1 TUMOR ASSOCIATED ANTIGEN - The invention provides an isolated nucleic acid encoding a receptor, other than an immunoglobulin, wherein the receptor binds to a MUC1 tumor antigen independently of an major histocompatibility complex (MHC). The invention provides a method of activating a signaling pathway and/or killing a cancer cell using a receptor that is similar to or is a T cell receptor03-26-2009
20090060889Ii-RNAi involved Ii suppression in cancer immunotherapy - Provided are compositions and methods involving the inhibition of Ii expression in cells for the purpose of altering antigen presentation pathways. Human Ii-RNAi constructs that effectively inhibit Ii expression in human cancer cells have been generated. The combination of different Ii-RNAi constructs that target different positions of Ii mRNA has a synergistic effect on Ii inhibition. Furthermore, specific promoters for driving Ii-RNAi expression are critical for the activity of Ii-RNAi in different types of cells. Active Ii-RNAi sequences were cloned into plasmids in which Ii-RNAi sequences are driven by either a CMV or an EF-1α promoter. Compositions and methods are disclosed for inhibiting Ii and treating cancer. Provided are siRNAs and expression constructs comprising DNA sequences which encode siRNAs effective to inhibit Ii expression, cells containing such DNA constructs or siRNAs, and methods for use of the same.03-05-2009
20090060888Regulated transcription of targeted genes and other biological events - Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the ζ chain of the T cell receptor (TCR)-CD3 complex thereby leading to signaling and transcription of a reporter gene, (2) the homodimerization of the cytoplasmic tail of the Fas receptor thereby leading to cell-specific apoptosis (programmed cell death) and (3) the heterodimerization of a DNA-binding domain (Gal4) and a transcription-activation domain (VP16) thereby leading to direct transcription of a reporter gene.03-05-2009
20120263692Engineered Xenogeneic Cells for Repair of Biological Tissue - A transplant system and method including at least one cell from a xenogeneic donor to be transplanted into a host. The at least one cell is adapted to include a gene that causes expression of a protein that suppresses or prevents an immune response of the host to the at least one cell.10-18-2012
20120263689ADIPOSE-DERIVED INDUCED PLURIPOTENT STEM CELLS - Methods and compositions for generating adipose-derived induced pluripotent stem cells for humans and animals and their use are provided.10-18-2012
20090123441Engineered Dendritic Cells and Uses for the Treatment of Cancer - This invention provides the field of therapeutics. Most specifically present invention provides methods of generating in vitro engineered dendritic cells conditionally expressing interleukin-12 (IL-12) under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals including human.05-14-2009
20130017179Lineage-Restricted Neuronal Precursors - A cell population has been identified and isolated that can differentiate into multiple neuronal phenotypes, but cannot differentiate into glial phenotypes. This mammalian CNS neuron-restricted cell expresses highly polysialated or embryonic neural cell adhesion molecule (E-NCAM) and is morphologically distinct from neuroepithelial stem cells (NEP cells) and spinal glial progenitors derived from embryonic day 10.5 spinal cord. Methods for isolating these cells and uses thereof are also disclosed.01-17-2013
20120082650METHODS FOR TREATING PARKINSON'S DISEASE AND OTHER DISORDERS OF DOPAMINERGIC NEURONS OF THE BRAIN - A specific clinical protocol for use toward therapy of defective, diseased and damaged neurons in the mammalian brain, of particular usefulness for treatment of neurodegenerative conditions such as Parkinson's disease. The protocol is practiced by directly delivering a definite concentration of a nerve growth factor via delivery of the protein, an expression vector operably encoding the nerve growth factor, or grafting a donor cell containing such an expression vector into the substantia nigra and preferably also the striatum. The method stimulates growth of targeted neurons, and reversal of functional deficits associated with the neurodegenerative disease being treated.04-05-2012
20120263688RUMC PEPTIDES WITH ANTIMICROBIAL ACTIVITY - The present invention relates to the RumC1, RumC2 and RumC3 peptides with antimicrobial activity, and also to the genes encoding these peptides and isolated from 10-18-2012
20120263693Methods for Treating Progressive Multifocal Leukoencephalopathy (PML) - The present invention relates generally to the treatment of PML by infusion of activated and expanded autologous lymphocytes.10-18-2012
20100322909TH1-ASSOCIATED MICRORNAS AND THEIR USE FOR TUMOR IMMUNOTHERAPY - Described herein is the identification of miRNAs (miRs) that are up-regulated in Th1 cells compared to Th2 cells (referred to herein as Th1-associated miRs). In particular, the miR-17-92 gene cluster was found to exhibit significantly greater expression in Th1 cells. Over-expression of miR-17-92 in T cells promotes the Th1 phenotype. Thus, the use of Th1-associated miRs for cancer immunotherapy is described. Provided herein are isolated T cells containing a heterologous nucleic acid molecule encoding a Th1-associated miR, such as the miR17-92 gene cluster, or a portion thereof. In some embodiments, the T cell is a tumor antigen (TA)-specific T cell, such as a TA-specific CTL. Further provided is a method of treating cancer in a subject by selecting a subject with cancer and administering to the subject an isolated T cell as disclosed herein. Also provided is a method of treating a subject with cancer by transfecting isolated T cells obtained from the subject with a heterologous nucleic acid molecule encoding a Th1-associated miR and administering the transfected T cells to the subject. In some embodiments of the method, the heterologous nucleic acid molecule encodes the miR-17-92 transcript or a portion thereof. In some embodiments, the isolated T cell is a TA-specific T cell, such as a CTL.12-23-2010
20080317721Method for the Treatment of Retinopathy of Prematurity and Related Retinopathic Diseases - The present invention provides a method for treating retinopathy of prematurity (ROP) and related retinopathic diseases. The method comprises administering to the retina of a mammal suffering from, or at risk of developing, retinopathy of prematurity or a related retinopathic disease an amount of cells from a vasculotrophic lineage negative hematopoietic stem cell population, effective to promote beneficial physiological revascularization of damaged areas of the retina and to ameliorate damage to the retina caused by the disease. Preferably, the mammal is a human patient. In one preferred embodiment, the lineage negative hematopoietic stem cell population is a lineage negative hematopoietic stem cell population comprising hematopoietic stem cells and endothelial progenitor cells (i.e., Lin− HSC). In another preferred embodiment, the lineage negative hematopoietic stem cell population is an isolated myeloid-like bone marrow (MLBM) cell population in which the majority of the cells are lineage negative and express CD44 antigen and CD11b antigen. As an alternative, for treatment of newborn infants, a lineage negative hematopoietic stem cell population can be isolated from umbilical cord vein blood.12-25-2008
20080299097ISOLATED POPULATION OF RAPIDLY PROLIFERATING MARROW STROMAL CELLS FOR ENHANCED IN VIVO ENGRAFTMENT - Multipotent stromal cells “MSCs” have been described as consisting of at least two populations of cells, rapidly self-renewing stem cells (RS-MSCs), and larger, slowly replicating cells (mMSCs). The present invention provides methods for enhancing engraftment of MSCs in vivo by administering an enriched fraction of RS-MSCs that express certain cell surface markers.12-04-2008
20080299095Nup98-Hox Fusions for Expansion of Hemopoietic Stem Cells - Nucleic acid constructs encoding homeobox-nucleoporin fusions are disclosed, compositions comprising same, and methods which provide enhanced expansion of stem cells. In particular, an isolated nucleic acid construct encoding a NUP98-HOX fusion is provided, which when introduced into hemopoietic stem cells provides enhanced expansion of these cells. Methods of expanding stem cells in vivo or ex vivo and methods of treatment using the stem cells are also described.12-04-2008
20080299094Methods and Kits for Predicting Liver Fibrosis Progression Rate in Chronic Hepatitis C Patients - Methods and kits for determining predisposition of an individual to develop fast progression rate of liver fibrosis are provided. Also provided are agents and pharmaceutical compositions useful in preventing fast progression of liver fibrosis and a method of identifying drug molecules which accelerate or induce liver fibrosis.12-04-2008
20120263691MODULAR APTAMER-REGULATED RIBOZYMES - An extensible RNA-based framework for engineering ligand-controlled gene regulatory systems, called ribozyme switches, that exhibit tunable regulation, design modularity, and target specificity is provided. These switch platforms typically contain a sensor domain, comprised of an aptamer sequence, and an actuator domain, comprised of a hammerhead ribozyme sequence. A variety of modes of standardized information transmission between these domains can be employed, and this application demonstrates a mechanism that allows for the reliable and modular assembly of functioning synthetic hammerhead ribozyme switches and regulation of ribozyme activity in response to various effectors. In some embodiments aptamer-regulated cis-acting hammerhead ribozymes are provided.10-18-2012
20120263690BIOCONTROL MICROORGANISMS - Methods, devices, and compositions described herein are directed to artificially evolving an organism for use as a biocontrol agent. Methods, devices, and compositions described herein are useful for evolving a microorganism to acquire traits not naturally associated with the microorganism. The artificial evolution process can utilize culture methods and devices designed to accommodate particular culture methods described herein. The organism can be artificially evolved for a characteristic such as ultraviolet light tolerance, chemical tolerance, thermotolerance, enhanced growth rate on a target carbon source, host specific growth, modified sporulation characteristics or modified spores.10-18-2012
20110038841Multi-Transgenic Pigs for Diabetes Treatment - The present invention provides certain animals, and in particular porcine animals, tissue and cells derived from these, which lack any expression of functional alpha 1,3 galactosyltransferase (αGT) and express one or more additional transgenes which make them suitable donors for pancreatic islet xenotransplantation. Methods of treatment and prevention of diabetes using cells derived from such animals are also provided.02-17-2011
20120328584Biological Pacemaker - Disclosed are methods and systems for modulating electrical behavior of cardiac cells. Preferred methods include administering a polynucleotide or cell-based composition that can modulate cardiac contraction to desired levels, i.e., the administered composition functions as a biological pacemaker.12-27-2012
20120328583TREATMENT OF PAIN USING PLACENTAL STEM CELLS - Provided herein are methods of treatment of an individual having pain, e.g., neuropathic pain, comprising administering to the individual a therapeutically effective amount of tissue culture plastic adherent placental stem cells (PDAC™).12-27-2012
20110044961Generation of Induced Pluripotent Stem Cells from Cord Blood - Methods and compositions for the generation and use of genetically corrected induced pluripotent stem cells are provided.02-24-2011
20120269788ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME - The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.10-25-2012
20090274669Dendritic Cells Transiently Transfected with a Membrane Homing Polypeptide and their use - The invention provides improved methods of producing dendritic cells (“DCs”) that transiently express a membrane homing peptide and optionally at least one additional antigen. These DCs have the ability to home to lymph nodes in vivo. In some embodiments, these DCs can be administered to a patient intravenously and can subsequently home to lymph nodes and stimulate an immune response. The methods and DCs of the invention are useful for the treatment of various diseases and disorders.11-05-2009
20100247499hUTC AS THERAPY FOR ALZHEIMER'S DISEASE - Methods for treating Alzheimer's disease, or the symptoms of Alzheimer's disease, are provided. Some embodiments are to methods for treatment comprising administering cells obtained from human umbilical cord tissue, or administering pharmaceutical compositions comprising such cells or prepared from such cells, such as cell derivatives. Some embodiments are to methods for treatment comprising hUTC. Pharmaceutical compositions for use in the inventive methods, as well as kits for practicing the methods are also provided.09-30-2010
20100233144METHOD FOR OPTIMIZING BLOOD CELL TRANSPLANTS - The invention relates to the use of allogenic T lymphocytes for the preparation of a composition intended to be injected into a recipient patient as a conditioning for a transplantation of haematopoietic stem cells, said allogenic T lymphocytes expressing a molecule allowing their specific destruction.09-16-2010
20110250187COMPOSITIONS AND METHODS FOR TREATING HYPOPHOSPHATASIA - The present invention provides compositions and methods for use in enzyme replacement therapy. The inventors disclose a method of producing membrane bound enzymes in an active soluble form by eliminating the glycosylphosphatidylinositol (GPI) membrane anchor. In particular the inventors disclose a soluble active form of the membrane bound enzyme TNSALP which they produced by deleting the GPI anchor single peptide sequence. They have further shown that this composition is useful for treatment of hypophosphatasia. The inventors also disclose oligo acid amino acid variants thereof which specifically target bone tissue.10-13-2011
20120321599HERPES VIRUS STRAINS - The present invention provides a herpes virus with improved oncolytic properties which comprises a gene encoding an immunomodulatory cytokine and which lacks a functional ICP34.5 gene and a functional ICP47 encoding gene.12-20-2012
20120321598VECTORS AND METHODS FOR LONG-TERM IMMUNE EVASION TO PROLONG TRANPLANT VIABILITY - A method can include making one or more compositions for altering allogeneic cells of a human donor for a human recipient by identifying at least one mismatch in an HLA protein between the human donor and the human recipient; determining a consensus conserved nucleic acid sequence among nucleic acid sequences encoding a domain having the mismatch or among domains having a plurality of mismatches; and forming at least one of the one or more compositions by constructing a virus vector for expressing a sequence targeting the consensus conserved nucleic acid sequence, which when expressed in cells functions as a negative modulator for nucleic acid encoding the domain having the mismatch or the domains having the plurality of mismatches.12-20-2012
20120087900IMMUNOTHERAPEUTIC AGENT - The present invention is directed to adoptive immunotherapy using a lymphocyte in which an antigen-specific receptor and a bioactive material gene such as an IL-2 gene or a water-soluble TGF-beta receptor gene are transferred. The bioactive material is intensively secreted to, for example, a local site of a tumor, thereby reducing systemic side effects as much as possible, and the survival time of the lymphocyte is increased, thereby further improving the effect of the adoptive immunotherapy.04-12-2012
20120100117METHOD FOR CHONDROGENIC DIFFERENTIATION OF PLURIPOTENT OR MULTIPOTENT STEM CELLS USING WNT6 - The present invention relates to methods for obtaining chondrocytes by culturing pluripotent or multipotent stem cells with a culture medium comprising Wnt6 or a derivative thereof. The inventive methods have the advantage of specifically leading to chondrogenic lineage and providing chondrocytes without differentiation towards hypertrophic chondrocytes, adipocytes or osteoblasts.04-26-2012
20120100116NEURON GENERATION, REGENERATION AND PROTECTION - The invention demonstrates that, contrary to apoptotic rabies virus G proteins, certain non-apoptotic rabies virus G proteins, such as the G protein of the CVS-NIV strain, have a neurite outgrowth promoting effect. The invention further demonstrates that this neurite outgrowth promoting effect is due to the cytoplasmic tail of said non-apoptotic rabies virus G proteins, more particularly to their PDZ-BS, which shows a single-point mutation compared to the one of apoptotic rabies virus G proteins. The invention provides means for inducing and/or stimulating neurite outgrowth, which are useful in inducing neuron differentiation, for example for the treatment of a neoplasm of the nervous system, as well as in regenerating impaired neurons, for example for the treatment of a neurodegenerative disease, disorder or condition or in the treatment of a microbial infection, or in protecting neurons from neurotoxic agents or oxidative stress.04-26-2012
20120100115REGIONALISED ENDODERM CELLS AND USES THEREOF - The present invention relates to the generation of anterior definitive endoderm (ADE) cells from embryonic stem cells and the differentiation of such cells to, for example, pancreatic or liver cells. The invention also relates to cell lines, cell culture methods, cells markers and the like and their potential uses in a variety of applications.04-26-2012
20100183573HEPATOCYTE GROWTH FACTOR RECEPTOR SPLICE VARIANTS AND METHODS OF USING SAME - Novel polypeptides that are splice variants of c-Met, the receptor for hepatocyte growth factor and polynucleotides encoding same are provided. Methods and pharmaceutical compositions which can be used to treat various disorders such as cancer, immunological-related, blood-related and skin-related disorders using the polypeptides and polynucleotides of the present invention, are also provided.07-22-2010
20080286250Implantable Biocompatible Immunoisolatory Vehicle for Delivery of Gdnf - The present invention relates to devices comprising a composition of human cells secreting a therapeutically effective amount of GDNF (Glial cell-line-derived neurotrophic factor) encapsulated in a device comprising a core and a semipermeable membrane allowing for the diffusion of GDNF protein. The human cells are from one cell line.11-20-2008
20130011373SIDE POPULATION CELLS IN CARDIAC REPAIR - It has been discovered that side-population cells induce cardiac tissue repair of infarcted myocardium. Provided herein are methods directed to treatment of cardiac injury using side-population cells.01-10-2013
20130011372INACTIVATED MICROORGANISMS CONTAINING DOUBLE -STRAND RNA MOLECULES (DSRNA), THEIR USE AS PESTICIDES AND METHODS FOR THEIR PREPARATION - The present invention relates to a new group of pesticides consisting of inactivated microorganisms containing double-strand RNA molecules (dsRNA), corresponding to receptor genes coupled with G proteins (GPCR) whose functioning is vital for phytophagous invertebrates (insects, mites and molluscs) or for infesting or in any case harmful organisms for the health of human beings and domestic animals, and to a method for the preparation of said microorganisms.01-10-2013
20110158970FUNGI TRANSFORMANT FOR MELANIN PRODUCTION AND USES THEREOF - The present invention cloned melanin biosynthesis genes encoding polyketide synthase (PKS), scytalone dehydratase (SCD) and 1.3.8-trihydroxynaphthalene reductase (THN) from the dematiaceous 06-30-2011
20110158969COMPOSITIONS AND METHODS FOR USING STROMAL CELLS TO ENHANCE TREATMENT OF CENTRAL NERVOUS SYSTEM INJURIES - The present invention provides novel methods and compositions for the treatment of injuries to the mammalian central nervous system. These methods involve administering stromal cells in combination with a blood-brain barrier permeabilizing agent in order to enhance neurorestoration, functional neurological recovery, stromal cell engraftment, and treatment of neurodegenerative diseases.06-30-2011
20130022585REGENERATION AND REPAIR OF NEURAL TISSUE USING POSTPARTUM-DERIVED CELLS - Cells derived from postpartum umbilicus and placenta are disclosed. Pharmaceutical compositions, devices and methods for the regeneration or repair of neural tissue using the postpartum-derived cells are also disclosed.01-24-2013
20080254008Lentiviral Vectors and Their Use - The present invention relates to lentiviral vectors for gene therapy, cancer treatment, producing recombinant proteins, such as antibodies and vaccines, and other therapeutic purposes. Novel lentiviral vectors are disclosed, e.g., comprising helper sequences in opposite orientations and/or minimally functional LTR sequences, which can be used to prepare high efficiency transduction vectors. Vectors are also designed to express silencing RNA and antisense polynucleotides.10-16-2008
20080248008Inhibitors of Protein Kinase a Anchoring - A PKA I anchoring disrupting molecule or AKAP mimic, wherein said molecule or mimic is a polypeptide which comprises the following amino acid sequence: X10-09-2008
20080248007B7-H5, A Costimulatory Polypeptide - B7-HS costimulatory polypeptides, nucleic acids encoding such polypeptides, and methods for using the polypeptides and nucleic acids to enhance a T cell response are provided herein.10-09-2008
20080226613Prognosis, diagnosis and treatment of bone marrow derived stem cell associated cancer - The present invention is based on the unexpected discovery that the loss of cells in inflamed tissue during chronic inflammation leads to the influx and long-term re-population of the tissue with bone marrow derived stem cells, and that it is these stem cells that are the primary source of metaplasia and cancer. Accordingly, the invention relates to various methods, reagents and kits for prognosing, diagnosing, staging, monitoring, preventing and treating cancers, particularly cancers associated with chronic inflammation.09-18-2008
20080226612Compositions of Cells Enriched for Combinations of Various Stem and Progenitor Cell Populations, Methods of Use Thereof and Methods of Private Banking Thereof - The present disclosure covers compositions and method for the preparation and use of mixtures of adult stem/progenitor cell populations recovered and enriched from specific tissues with very limited attempts for their purification. Such mixtures of cell populations have improved therapeutic effectiveness in the treatment of certain diseases and tissue regeneration treatments over their more purified counterpart cell populations. Such mixtures of cell populations can be cryopreserved for future clinical use.09-18-2008
20080226611Gene Therapy Using TGF-beta - The subject invention is related to a cell-mediated gene therapy treatment for orthopedic disease using a member belonging to the transforming growth factor-β (TGF-β) superfamily. TGF-β gene therapy as a new treatment method for degenerative arthritis is demonstrated. After transfection of TGF-β cDNA expression vectors into fibroblasts (NIH 3T3-TGF-β1), the cells were injected into rabbit achilles tendon and knee joints with artificially-made cartilage defects. Intratendinous injections were performed to determine the optimal concentration for in vivo expression. Partially defected cartilage model was made to simulate degenerative arthritis of the knee joint. The partial cartilage defect treated with the cell-mediated gene therapy procedure was covered by newly formed hyaline cartilage which indicates that the cells survived and stimulated matrix formation in this area. Completely denuded cartilage areas were covered by fibrous collagen.09-18-2008
20080226610Compositions and Methods for Elimination of Unwanted Cells - Disclosed are compositions comprising a recombinant nucleic acid vector including a nucleotide sequence encoding a syncytium-inducing polypeptide expressible on a eukaryotic cell surface, and a host cell containing the recombinant vector and expressing the syncytium inducing polypeptide on its cell surface, the vectors and resultant host cells expressing the syncytium inducing polypeptide being useful for selective elimination of unwanted cells.09-18-2008
20130171115CELL-MEDIATED GENE THERAPY FOR CANCER USING MESENCHYMAL STEM CELLS EXPRESSING A SUICIDE GENE - The invention provides cell-mediated gene therapy for cancer using mesenchymal stem cells (MSC) expressing a suicide gene. The MSC are administered to a subject having a tumor, the MSC are allowed to migrate to the tumor site, and then the subject is administered with a prodrug. Expression of the suicide gene by the MSC at the tumor site converts the prodrug to a drug that is lethal to cells of the tumor. The impact of the tumor on the subject's health can thereby be reduced or eliminated. The MSC of this invention may be optimized for use as an off-the-shelf product by using an immortalized MSC line, and selecting MSC with immunological characteristics to forestall a graft-versus-host response.07-04-2013
20110274671HUMAN PROGENITOR T-CELLS - Human progenitor T cells that are able to successfully engraft a murine thymus and differentiate into mature human T and NK cells are described The human progenitor T cells have the phenotype CD34+CD7+CD1a−CD5− or CD34+CD7+CD1a−CD5+ and are derived from human hematopoietic stem cells, embryonic stem cells and induced pluripotent stem cells b\ coculture with cells expressing a Notch receptor ligand (OP9-DL1 or OP9-DL4) Such cells are useful in a variety of applications including immune reconstitution, the treatment of immunodeficiencies and as carriers for genes used in gene therapy.11-10-2011
20110274670MESENCHYMAL STEM CELLS WHICH EXPRESS HUMAN HEPATIC GROWTH FACTOR,MANUFACTURING METHOD THEREOF, AND USE THEREOF AS THERAPEUTIC AGENT FOR LIVER DISEASES - The present invention relates to adult stem cells and a manufacturing method thereof. More specifically, the present invention relates to a recombinant expression vector containing a human hepatic growth factor (hHGF) gene, mesenchymal stem cells which are transformed thereby and express the hHGF, a manufacturing method of the mesenchymal stem cells, conditioned media (CM) which is obtained from the transformed cells and proliferates hepatocytes, a culture method of the mesenchymal stem cells producing the same, and the use of the transformed mesenchymal stem cells and their culture media as an agent for preventing and treating liver diseases. The manufacturing method of the mesenchymal stem cells comprises the steps of: isolating and culturing umbilical cord blood-derived mesenchymal stem cells; transforming the mesenchymal stem cells with the recombinant expression vector; and selecting the mesenchymal stem cells. The mesenchymal stem cells, which produce the hHGF in the present invention effectively, proliferate hepatocytes, suppress apoptosis and effectively suppress liver cirrhosis. Therefore, the mesenchymal stem cell can be widely used in preventing and treating various liver diseases.11-10-2011
20110274669THERAPEUTIC RETROVIRAL VECTORS FOR GENE THERAPY - Retroviral gene therapy vectors that are optimized for erythroid specific expression and treatment of hemoglobinopathic conditions are disclosed.11-10-2011
20130142764METHODS AND COMPOSITIONS FOR TREATING BRAIN DISEASES - The present disclosure provides targeting peptides and vectors containing a sequence that encodes targeting peptides that deliver agents to the brain.06-06-2013
20130177538HUMAN LYSOSOMAL PROTEINS FROM PLANT CELL CULTURE - A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. More particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vectors and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). The invention further provides for compositions and methods for the treatment of lysosomal storage diseases.07-11-2013
20130177539Compositions and methods to control insect pests - Methods and compositions are provided which employ a silencing element that, when ingested by a pest, such as a Coleopteran plant pest or a 07-11-2013
20090202503SEQUENCE OF NUCLEOTIDES AND PEPTIDES GSE 24.2 OF DYSKERIN, WHICH CAN INDUCE TELOMERASE ACTIVITY, METHOD FOR OBTAINING SAME, THERAPEUTIC COMPOSITIONS AND APPLICATIONS THEREOF - This invention relates to a compound that induces or activates telomerase activity based on the nucleotide sequence of the GSE 24.2 fragment of dyskerin or the protein or peptide sequence encoded by said nucleotide sequence. Another part of the invention relates to vectors that comprise said sequence and cells transformed thereby, and pharmaceutical compositions that contain all these elements. These compositions may be used in the treatment of diseases from the following group: ageing or acceleration of ageing, neurodegenerative diseases and dyskeratosis congenita.08-13-2009
20120251509CELL-BASED ANTI-CANCER COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - Isolated pluralities of T cells which recognize at least one epitope of a mucosally restricted antigen and pharmaceutical compositions comprising the same are disclosed. Methods of making a plurality of T cells that recognize at least one epitope of a mucosally restricted antigen are also disclosed. Methods of treating an individual who has been diagnosed with cancer of a mucosal tissue or preventing such cancer in an individual at elevated risk are disclosed as are nucleic acid molecules that comprise a nucleotide sequence that encode proteins that recognize at least one epitope of a mucosally restricted antigen and T cells comprising such nucleic acid molecules.10-04-2012
20080213235Adipose Tissue Stem Cells, Perivascular Cells and Pericytes - The present invention provides methods for growing and inducing perivascular cell differentiation of adipose tissue-derived stromal cells. The invention further provides methods for administering such adipose tissue-derived cells to a subject. The cells of the invention are useful for treating diseases, disorders, conditions, and injuries requiring new or enhanced angiogenesis, vascular remodeling, drug delivery, and tissue engineering.09-04-2008
20090246182METHOD FOR CULTURING CELLS DERIVED FROM THE ADIPOSE TISSUE AND USES THEREOF - The invention concerns a method for culturing cells derived from the adipose tissue and in particular the stromal vascular fraction (SVF) to induce formation of cardiomyocytes, the use of the cells obtained by said culture method to reconstitute an ischemized cardiac zone, in particular following an infarction, as well as a pharmaceutical composition containing said cells. The method for obtaining cardiac cells comprises at least the following steps: a) selecting cardiomyogenic cells from the stromal vascular fraction (SVF); b) culturing the cells selected at step a) in a liquid medium optimized for expanding ex vivo the cardiomyogenic cells; c) maintaining and expanding said cells by successive passes in the liquid medium; and d) obtaining cardiac cells.10-01-2009
20110268714CD34 Stem Cell-Related Methods and Compositions - This invention provides novel stem cell-based methods for treating a number of conditions. These methods employ CD3411-03-2011
20130095085METHOD FOR PRODUCING HEMATOPOIETIC STEM CELLS - An expanding agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful as a therapy for various hematopoietic diseases and useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy is provided.04-18-2013
20130101565USE OF CARBONIC ANHYDRASE II FOR PRODUCING A DRUG - The present invention falls within the field of biomedicine. Specifically, the present invention relates to the use of carbonic anhydrase II for the manufacture of a medicament for the prevention and/or treatment of the damage caused by ischemia, ischemia followed by reperfusion or toxins, acute failure or rejection of a transplanted organ, preferably the kidney. In a preferred embodiment, the toxin is cisplatin.04-25-2013
20130101566PROBIOTIC COMPOSITION FOR USE IN THE TREATMENT OF BOWEL INFLAMMATION - The present disclosure is directed to compositions comprising 04-25-2013
20130115199T-CELL RECEPTOR AND NUCLEIC ACID ENCODING THE RECEPTOR - A polypeptide comprising a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 5 of Sequence Listing or a polypeptide consisting of an amino acid sequence having deletion, addition, insertion or substitution of one to several amino acid residues in the sequence, the polypeptide being capable of constituting an HLA-A24-restricted, MAGE-A405-09-2013
20130129693ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME - The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of reversing anticoagulation, stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.05-23-2013
20110212070METHODS OF DIFFERENTIATING AND PROTECTING CELLS BY MODULATING THE P38/MEF2 PATHWAY - The present invention provides a method of differentiating progenitor cells to produce a population containing protected neuronal cells. A method of the invention includes the steps of contacting the progenitor cells with a differentiating agent; and introducing into the progenitor cells a nucleic acid molecule encoding a MEF2 polypeptide or an active fragment thereof, thereby differentiating the progenitor cells to produce a population containing protected neuronal cells. In one embodiment, the MEF2 polypeptide is human MEF2C or an active fragment thereof.09-01-2011
20080199443Bone Morphogenetic Variants, Compositions and Methods of Treatment - Human cartilage-derived morphogenetic protein variant polypeptides and isolated nucleic acids are provided. Also provided are vectors, host cells, and recombinant methods for producing human cartilage-derived morphogenetic protein variants polypeptides. Therapeutic methods useful for treating musculoskeletal disorders and joint repair with such variants are also provided.08-21-2008
20080199442Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors - The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.08-21-2008
20080213232Radial Glial Cells Promote Nerve Regeneration and Functional Recovery Following Spinal Cord Injury - An enriched population of radial glial cells has been isolated. These cells are nestin09-04-2008
20100047218REVERSIBLE IMMORTALIZATION - A gene complex for reversibly immortalizing cells contains an immortalizing gene region, which possesses at least a resistance gene, an immortalizing gene and, preferably, a suicide gene, and also two sequences which flank the gene region and which function as recognition sites for homologous intramolecular recombination, and at least one promoter located upstream of the gene region. A gene complex for immunomodulating cells contains a first immunomodulating gene region, whose expression inhibits the function of MHC I molecules, a second immunomodulating gene region, whose expression leads to the inactivation of natural killer cells, and a resistance gene. A method for obtaining cells involves preparing organ-related cells which are immortalized by transferring the first gene complex and immunomodulated by transferring the second gene complex. After the immortalized cells have been expanded, the immortalization is reversed.02-25-2010
20110250188LCMV-GP-VSV-Pseudotyped Vectors and Tumor-Infiltrating Virus-Producing Cells for the Therapy of Tumors - The invention relates to recombinant VSV viruses and viral vectors which produce a glycoprotein GP of the lymphocyte choriomeningitis virus (LCMV) instead of the G protein of the VSV, to virus producing cells which produce LCMV-GP-pseudotyped VSV virions, and to the use of said vectors and cells in the therapy of solid tumors, especially brain tumors.10-13-2011
20120276073TREATMENT OF NERVE INJURIES - This invention relates to treatment of nerve injuries and regeneration of nerves and nerve function in the acutely and chronically lesioned central and peripheral nervous system. The invention provides a pharmaceutical composition comprising histone, e.g., H1. It was surprisingly shown that histones, in particular histone H1, can be used for the preparation of a pharmaceutical composition for treatment and/or prevention of acute and chronic injuries to the central and peripheral nervous system, for promoting growth and/or regrowth of nerves and enhancing formation of synapses and synaptic plasticity, and for neuroprotection.11-01-2012
20120276072CONSTRUCTS FOR EXPRESSING LYSOSOMAL POLYPEPTIDES - Provided are isolated nucleic acids for expressing lysosomal polypeptides such as lysosomal acid α-glucosidase (GAA) and vectors comprising the same. The invention provides an isolated nucleic acid encoding a chimeric polypeptide comprising a secretory signal sequence operably linked to a lysosomal polypeptide. The invention also provides an isolated nucleic acid comprising a coding region encoding a GAA and a GAA 3′ untranslated region (UTR), wherein the GAA 3′ UTR comprises a deletion therein. The invention further provides an isolated nucleic acid comprising a coding region encoding a GAA and a 3′ UTR wherein the 3′ UTR is less than about 200 nucleotides in length and comprises a segment that is heterologous to the GAA coding region. Also provided are methods of making and using delivery vectors encoding lysosomal polypeptides to produce the lysosomal polypeptide to treat subjects afflicted with a deficiency in the lysosomal polypeptide.11-01-2012
20120276071Anti-HIV Group I Introns and Uses Thereof in Treating HIV Infections - Described is a unique class of antiviral molecule that can be applied to control and eliminate HIV infection in patients using myeloablation therapies and replenishment with transformed bone marrow stem cells programmed to express the antiviral molecule. These anti-viral molecules target the HIV genome in a highly conserved domain, and when expressed in cells prior to infection will cause the cell to die upon infection with HIV. Cell death insures no proliferation of new virus. Reconstituting the immune system with cells expressing these antivirals prevents re-establishment of HIV infection from reservoirs in the re-established lymphocyte and macrophage populations. Over time, reservoirs will be depleted entirely, effectively eliminating the virus. In effect, this new type of antiviral can be used to cure HIV infections.11-01-2012
20130149290Engineered Dendritic Cells and Uses for the Treatment of Cancer - This invention provides the field of therapeutics. Most specifically present invention provides methods of generating in vitro engineered dendritic cells conditionally expressing interleukin-12 (IL-12) under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals including human.06-13-2013
20130149289T CELL RECEPTOR MUTANTS - A T cell receptor (TCR) having the property of binding to EVDPIGHLY HLA-A1 complex and comprising a specified wild type TCR which has specific mutations in the TCR alpha variable domain and/or the TCR beta variable domain to increase affinity. Such TCRs are useful for adoptive therapy.06-13-2013
20100297089METHOD FOR PROMOTING THE SELF-RENEWAL OF ADULT STEM CELLS USING MESENCHYMAL STROMAL CELLS - The present invention relates to a composition for promoting the self-renewal of adult stem cells, comprising β-catenin or notch ligand-overexpressed mesenchymal stromal cells. Further, the present invention relates to a method for promoting the self-renewal of adult stem cells by co-culturing adult stem cells with the mesenchymal stromal cells. Furthermore, the present invention relates to β-catenin or notch ligand-overexpressed mesenchymal stromal cells for promoting the self-renewal of adult stem cells.11-25-2010
20120258084PROGENITOR CELLS AND USES THEREOF - Methods for preparing progenitor cells are described where epithelial cells are induced to undergo epithelial-mesenchymal transition as a result of exposure to an inducing agent or introduction of a gene therein that induces epithelial-mesenchymal transition. Progenitor cells resulting therefrom have use in cell-based therapies, among other utilities.10-11-2012
20100316616Use of FZC18-Containing Collagen 18 Polypeptides for the Treatment, Diagnosis and Outcome Prediction of Diseases - The present invention relates to a polypeptide comprising at least 13 consecutive amino acids selected from the amino acid sequence as set forth in SEQ ID NO: 1 or a variant thereof comprising at least 70% identity over said 13 consecutive amino acids, wherein said polypeptide or variant thereof interacts with Wnt3a and can be used for the treatment of diseases associated with increased beta-catenin pathway activity. The present invention also relates to a method for detecting the presence of a disease associated with fibrogenesis and to a method for assessing the severity and/or predicting the outcome of cancer.12-16-2010
20100316615Antisense Oligonucleotides Against VR1 - Antisense oligodeoxynucleotides against VR1, corresponding nucleotide constructs, cells containing said nucleotide constructs, pharmaceutical and diagnostic substances, uses thereof in pain therapy, and methods for diagnosing symptoms related to VR1 and for identifying pain-modulating substances.12-16-2010
20120282229NON-VIRAL DELIVERY OF TRANSCRIPTION FACTORS THAT REPROGRAM HUMAN SOMATIC CELLS INTO A STEM CELL-LIKE STATE - Disclosed herein are cellular compositions, stable continuous cell cultures, reporter cell lines, pharmaceutical preparations, cell penetrable pluripotent stem cells transcription factors and methods related thereto, related to reprogrammed somatic cells.11-08-2012
20120282231HUMAN LYSOSOMAL PROTEINS FROM PLANT CELL CULTURE - A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. More particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vectors and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). The invention further provides for compositions and methods for the treatment of lysosomal storage diseases.11-08-2012
20120282230METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF GENETIC AND RETINAL DISEASE - A process of detecting the presence of or susceptibility to a disease involving the Frizzled-4 receptor is provided. The inventive method determines the presence or absence of one or more mutations in Frizzled-4 alone or in conjunction with other proteins such as Norrin and LRP5. The presence of a mutation predicts the presence of a disease or susceptibility to a disease. The inventive process further provides correction or prevention of a disease by administration of frizzled-4 to a subject to alter or maintain a physiological function.11-08-2012
20110311499Secretion System and Methods for its Use - The present invention provides reagents and methods for inhibiting bacterial infection and abnormal cell growth, as well as for selection cloning of nucleic acid inserts.12-22-2011
20110311498GENERATION OF PATIENT-SPECIFIC DIFFERENTIATED CELL TYPES BY EPIGENETIC INDUCTION - Disclosure of a mammalian cytoplasmic donor cell line. Disclosure of a patient specific cell line. Disclosure of a method to obtain a mammalian cytoplasmic donor cell line by fusing a differentiated mammalian cell and a functionally enucleated mammalian embryonic cell line. Disclosure of a method to obtain a patient specific cell line of a cell type similar to a mammalian cytoplasmic donor cell line by functionally enucleating the mammalian cytoplasmic donor cell line and fusing the functionally enucleated mammalian cytoplasmic donor cell line with a differentiated cell obtained from the patient. A method of treatment administering the patient-specific cell line to the patient.12-22-2011
20090142312Methods for Promoting Wound Healing and Muscle Regeneration with the Cell Signaling Protein Nell1 - The present invention provides methods for promoting wound healing and treating muscle atrophy in a mammal in need. The method comprises administering to the mammal a Nell1 protein or a Nell1 nucleic acid molecule.06-04-2009
20110318316CHINESE HAMSTER APOPTOSIS-RELATED GENES - Provided is an isolated polypeptide comprising a 12-29-2011
20120003194IN VITRO MICRO-ORGANS, AND USES RELATED THERETO - Micro-organ cultures which include isolated populations of cells having specific characteristics are described. Salient features of the subject micro-organ cultures include the ability to be maintained in culture for relatively long periods of time, as well as the preservation of an organ microarchitecture which facilitates, for example, cell-cell and cell-matrix interactions analogous to those occurring in the source organ. The micro-organ cultures of the invention can be used in methods for delivering gene products to recipient subjects, for identifying cell proliferative and cell differentiating agents, and identification and isolation of progenitor and stem cells. In addition, the micro-organ cultures of the present invention can be used in methods for identifying inhibitors of cell proliferation, cell differentiation and viral infectivity. In other embodiments, the micro-organ cultures can be used for transplantation.01-05-2012
20080311090Methods for inhibition of proliferative disease, including hepatocellular carcinoma - The present invention is related to a method for modulating expression of protein kinase C-alpha associated with proliferative diseases. The invention further relates to a screening method utilizing the association between transcription factors (MZF-1 and Elk-1) and their DNA binding element (PKC-.alpha. promoter) to identify novel anticancer agents.12-18-2008
20120020940ANTIMICROBIAL PEPTIDES - The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well as a host cell comprising the nucleic acid molecule or the vector. The present invention also relates to a method for producing the peptide of the invention, a composition as well as to the peptide or peptidomimetic of the invention for use in treating infectious diseases.01-26-2012
20120020939MHC-less cells - The present disclosure relates to compositions, methods, systems, computer-implemented methods, and computer program products thereof that relate to biological cells for delivery of at least one therapeutic agent to a biological tissue or subject.01-26-2012
20120020938MHC- less cells - The present disclosure relates to compositions, methods, systems, computer-implemented methods, and computer program products thereof that relate to biological cells for delivery of at least one therapeutic agent to a biological tissue or subject.01-26-2012
20130195819T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE - The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a cancer antigen, e.g., a renal cell carcinoma antigen, wherein the TCR recognizes the cancer antigen in a major histocompatibility complex (MHC)-independent manner. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials.08-01-2013
20130195818METHOD OF PRODUCING MYELOID BLOOD CELLS - An object of the present invention is to provide a method of producing a myeloid blood cell possessing a proliferative capability. According to the present invention, provided is a method of producing a myeloid blood cell possessing a proliferative capability, including forcedly expressing (A) a cMYC gene, and (B) at least one gene selected from the group consisting of a BMI1 gene, an EZH2 gene, an MDM2 gene, an MDM4 gene, and an HIF1A gene in a myeloid blood cell.08-01-2013
20130195817METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND VASCULOGENESIS - Disclosed herein are methods and compositions for stimulating angiogenesis, using cells descended from marrow adherent stromal cells that have been transfected with sequences encoding a Notch intracellular domain. Applications of these methods and compositions include treatment of ischemic disorders such as stroke.08-01-2013
20130195816COMPOSITIONS TO EFFECT NEURONAL GROWTH - Compositions containing neurogenic agents for inhibition of neuron death and inducing proliferation of neural cells are disclosed.08-01-2013
20130195815METHOD FOR LABELING INSULIN-SECRETING PANCREATIC BETA CELLS AND OBTAINING PURIFIED INSULIN-SECRETING PANCREATIC B-CELLS AND AN INSULIN REPORTED - A method for labeling insulin-secreting pancreatic β-cells in human islets by using a genetically-encoded preproinsulin fluorescent protein reporter which targets an insulin fusion protein to correct insulin vesicles. The reporter system comprising an insulin and fluorescent protein construct provides real time tracking of secretory granules in live cells and allows for the accurate measuring of the level of secretion. The labeled cells are sorted by fluorescence-activated cell sorting to obtain purified insulin-secreting pancreatic β-cell pools from human islets. The β-cell pools are suitable for transplantation into the pancreas of diabetics in order to treat diabetes.08-01-2013
20120039859Method of Diminishing The Symptoms of Neurodegenerative Disease - A method of diminishing the symptoms of neurodegenerative disease in a patient is disclosed. In one embodiment, the method comprises the steps of: (a) identifying a patient with a neurodegenerative disease, (b) producing a cell culture, wherein the cell culture comprises cells with induced antioxidant response element (ARE) mediated transcription, and (c) transplanting at least a portion of the cell culture into the brain of the patient, wherein symptoms of neurodegenerative disease are diminished.02-16-2012
20120039858METHODS AND COMPOSITIONS FOR INHIBITING PROPAGATION OF VIRUSES USING RECOMBINANT TETHERIN CONSTRUCTS - The present invention provides chimeric protein constructs having anti-viral activity, compositions and methods of using them, and nucleic acids encoding them. The chimeric proteins include an extracellular domain of a Tetherin protein fused to the transmembrane domain, and optionally cytoplasmic tail, of a different protein. The chimeric proteins have normal anti-viral tethering activity but are resistant to inhibition by anti-Tetherins. Ex vivo methods of gene therapy are also provided.02-16-2012
20120058090Alimentary Protein-Based Scaffolds (APS) for Wound Healing, Regenerative Medicine and Drug Discovery - The invention provides engineered biomaterials derived from plant products. The engineered biomaterials are useful for biomedical applications. The engineered biomaterials are able to support the growth of animal cells.03-08-2012
20130202569Transgenic Ungulates Expressing CTLA4-IG and Uses Thereof - The present invention provides ungulates, including pigs, expressing CTLA4-Ig, as well as tissue, organs, cells and cell lines derived from such animals. Such animals, tissues, organs and cells can be used in research and medical therapy, including xenotransplanation. In addition, methods are provided to prepare organs, tissues and cells expressing the CTLA4-Ig for use in xenotransplantation, and nucleic acid constructs and vectors useful therein.08-08-2013
20120076761Cloned ungulate embryos and animals, use of cells, tissues and organs thereof for transplantation therapies including Parkinson's disease - Methods and cell lines for cloning ungulate embryos and offspring, in particular bovines and porcines, are provided. The resultant fetuses, embryos or offspring are especially useful for the expression of desired heterologous DNAs, and may be used as a source of cells or tissue for transplantation therapy for the treatment of diseases such as Parkinson's disease.03-29-2012
20130095084METHODS AND COMPOSITIONS FOR MODULATING PERIPHERAL IMMUNE FUNCTION - Disclosed herein are cell preparations useful for modulating various peripheral immune functions, methods for making said cell preparations, and methods for their use.04-18-2013
20120087901Engineered Mesenchymal Stem Cells and Methods of Using Same to Treat Tumors - This invention provides a method for treating a subject afflicted with a tumor using genetically modified mesenchymal stem cells, wherein each genetically modified mesenchymal stem cell contains an exogenous nucleic acid comprising (i) a cytotoxic protein-encoding region operably linked to (ii) a promoter or promoter/enhancer combination, whereby the cytotoxic protein is selectively expressed when the genetically modified mesenchymal stem cells come into proximity with the tumor's stromal tissue. This invention further provides genetically modified mesenchymal stem cells for use in this method.04-12-2012
20120093790HLA HOMOZYGOUS CELLS AND METHODS OF USE THEREOF - The present invention provides methods of generating a mammalian cell that is homozygous at a locus of interest, as well as cells made by the method. The present invention further provides methods of using the cells.04-19-2012
20120093789Methods of Modulating Smooth Muscle Cell Proliferation and Differentiation - The present disclosure provides methods of inducing smooth muscle cell differentiation. The present disclosure provides genetically modified cells comprising exogenous miR-143 and/or miR-145 nucleic acids; and artificial tissues comprising the genetically modified cells. The present disclosure provides methods and compositions for reducing pathological angiogenesis. The present disclosure provides methods of inducing therapeutic angiogenesis. The present disclosure provides methods, compositions, and devices for inhibiting vascular smooth muscle cell proliferation.04-19-2012
20120093788PROTEASE FOR WOUND CONDITIONING AND SKIN CARE - We have identified by molecular cloning a protease which originates from the larvae of 04-19-2012
20120093787METHODS AND COMPOSITIONS FOR INHIBITING VIRAL ENTRY INTO CELLS - Disclosed herein are methods and compositions for inhibiting viral entry into cells.04-19-2012
20120093786TREATMENT OF LIMB ISCHEMIA - The present invention uses neural stem cells in the manufacture of a medicament for the treatment of a patient suffering peripheral arterial disease. The invention is particularly suited for treating limb ischemia or Buerger's disease.04-19-2012
20120093785HUMAN ARTIFICIAL CHROMOSOME (HAC) VECTOR - The present invention relates to a human artificial chromosome (HAC) vector and a method for producing the same. The present invention further relates to a method for introducing foreign DNA using a human artificial chromosome vector and a method for producing a cell which expresses foreign DNA. Furthermore, the present invention relates to a method for producing a protein.04-19-2012
20130209426METHOD FOR GENOME MODIFICATION - The present disclosure includes methods for manipulation of the genome, to products obtained or obtainable from such methods, and uses of these products.08-15-2013
20130209427HAIR FOLLICLE NEOGENESIS - This invention provides a skin substitute comprising epithelial cells and modified mesenchymal cells, wherein the modified mesenchymal cells have decreased TSC1/TSC2 function, increased mTORCI function, and/or decreased mTORC2 function compared to wild type mesenchymal cells, and methods for using the same. This invention also provides a method for transplanting cells capable of inducing hair follicles, comprising subdermally or intradermally delivering to a patient modified mesenchymal cells, wherein the modified mesenchymal cells have decreased TSC1/TSC2 function, increased mTORCI function, and/or decreased mTORC2 function compared to wild type mesenchymal cells.08-15-2013
20130209428METHOD OF INDUCING DIFFERENTIATION OF BONE MARROW STROMAL CELLS TO NEURAL PRECURSOR CELLS, NEURAL PRECURSOR CELLS, AND USES THEREOF - There is provided a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of a Notch gene. Specifically, the invention provides a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells in vitro, which method comprises introducing a Notch gene and/or a Notch signaling related gene into the cells, wherein the finally obtained differentiated cells are the result of cell division of the bone marrow stromal cells into which the Notch gene and/or Notch signaling related gene have been introduced. The invention also provides a method of inducing further differentiation of the differentiation-induced neural cells to dopaminergic neurons or acetylcholinergic neurons. The invention yet further provides a treatment method for neurodegenerative and skeletal muscle degenerative diseases which employs neural precursor cells, neural cells or skeletal muscle cells produced by the method of the invention.08-15-2013

Patent applications in class Eukaryotic cell